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ABSTRACT 
 
There is increasing evidence that psychological stress and associated mood disorders are linked with, 
and can adversely affect the course of inflammatory bowel disease (IBD).  Stress is perceived to be 
relieved by smokers, and this, like a lack of knowledge about its adverse effects, and nicotine 
dependence, could contribute to continued smoking by patients with Crohn’s disease (CD).  Stress 
has previously been shown to influence disease course in patients with inactive ulcerative colitis (UC) 
but its influence in acute severe UC is not known. Emerging trial evidence supports the suggestion 
that psychologically-orientated therapy may ameliorate IBD-associated mood disorders, but there is 
no strong data yet to indicate that stress management has a beneficial effect on the activity or course 
of IBD. In addition gut-focussed hypnotherapy has been successfully used in the setting of functional 
bowel disorders.  
The 4 main hypotheses tested in thesis are: 
1. In patients with IBD:  (1) poor knowledge of the effects of smoking on their disease and/or (2) high 
nicotine dependence explain the higher prevalence of smoking in CD than UC 
2. Anxiety, depression and stress are more common and worsen outcome in patients with acute 
severe UC. 
3. Stress management in the form of psychotherapy given by a counsellor has a beneficial effect on 
the activity and course of IBD. 
4. Gut-focussed hypnotherapy reduces the relapse rate in patients with UC. 
 
 The major findings are as follows: 
1. Despite more patients with CD being smokers, they were better informed about the effects of 
smoking on their own disease than UC patients. Nicotine dependence was no higher in patients with 
CD than UC. In IBD patients as a whole, nicotine dependence was lower than in smokers’ clinic 
clients and comparable to that of the general population, suggesting that most IBD patients could be 
weaned off smoking successfully in the IBD clinic. 
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2. Perceived stress levels are greater in patients with ASUC than in those in remission and anxiety 
scores are highest in patients newly presenting with UC, but neither stress nor anxiety influenced 
disease outcome. 
3. In IBD patients with psychosocial stress, IBD-focussed counselling may improve not only patients’ 
psychological well-being and stress resolution but also the activity and course of their IBD  
4. Gut-focussed hypnotherapy does not have a major clinically useful effect in preventing relapse or 
altering psychological status in patients with ulcerative colitis who are withdrawing from treatment with 
thiopurines.   
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CHAPTER 1: INTRODUCTION 
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This thesis focuses on the role of psychological factors and their management in IBD. The 
Introduction will firstly provide a brief overview of IBD including its pathogenesis and in particular the 
role of smoking in IBD; it will then discuss psychological stress and mood disorders, and finally the 
role of psychological treatments in IBD. 
1.1 INFLAMMATORY BOWEL DISEASE 
Crohn’s disease (CD) and ulcerative colitis (UC) are chronic, relapsing and remitting inflammatory 
diseases of the gastrointestinal tract. The clinical manifestations of CD and UC are highly variable, 
with significant diversity in the phenotypes of the diseases. This diversity is manifested by differences 
in the location and distribution of the diseases, their natural history and disease outcomes 
1.1.1 Crohn’s disease 
CD is characterised by chronic transmural intestinal inflammation affecting any part of the GI tract and 
often in discontinuation to form skip lesions (1, 2). The Montreal classification defines the age of 
onset, site and behaviour of disease (3).  Behaviour has been divided into 3 categories; inflammatory 
disease (without the presence of strictures or fistulae), stricturing and penetrating disease (3) 
1.1.2 Ulcerative colitis 
The inflammation in UC, in contrast to CD, only involves the mucosa with disease confined to the 
colon, although rarely there may be a backwash ileitis. UC usually starts in the rectum and may 
extend proximally, with approximately 40-50% of patients exhibiting disease confined to the rectum or 
sigmoid colon, whereas 25-35% of patients will have a phenotype characterised by extensive disease 
(total colitis) (4) 
1.2 AETIOLOGY 
The pathogenesis of inflammatory bowel disease (IBD) is only partially understood, with the 
involvement of a number of genetic and environmental factors.  The role for environmental factors is 
supported by recent trends in IBD epidemiology.  
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1.2.1 Genetic factors 
Approximately 30% of IBD-related genetic loci are shared between CD and UC.  Analyses of the 
function of the genes and genetic loci implicated in IBD show several pathways that are crucial for 
intestinal homeostasis, including barrier function, epithelial restitution, microbial defence, innate 
immune regulation, reactive oxygen species (ROS) generation, autophagy, regulation of adaptive 
immunity, endoplasmic reticulum (ER) stress and metabolic pathways associated with cellular 
homeostasis (5) (see Fig 1). 
The first IBD-related gene mutations to be identified were three relatively common causal coding 
variants in NOD 2 (nucleotide-binding oligomerization domain-containing protein 2), otherwise known 
as CARD 1 (caspase recruitment domain-containing protein 15) (6). In addition, the autophagy genes 
ATG16L1 (autophagy-related 16-like 1) (7) and IRGM (immunity-related GTpase M) (8) have been 
shown to be risk factors for Crohn's disease. Within the innate immune response, these 
polymorphisms in NOD2 and the two autophagy-related genes implicate defects in the recognition 
and handling of intracellular bacteria contributing to the immunopathogenesis of IBD (further 
discussed in section 1.2.2.1). 
 
Current genome-wide association scans (GWAS) are typically powered to characterize variants of 
>1% frequency and do not include the contributions from rare variants (<1% frequency). GWAS have 
revealed many genetic risk factors for both Crohn’s disease and ulcerative colitis (Figure 1).  IL-10RA 
(Interleukin 10 receptor alpha subunit) polymorphisms have been associated with the development of 
early-onset IBD (9).  Re-sequencing studies in IBD have shown both known and new variants of 
CARD9, NOD2 and IL-23R, with independent effects on disease risk.  The IL-23R variants were 
protective, supporting previous findings of a common protective IL-23R allele.  In addition, T helper 17 
(TH17) cells generated ex vivo from subjects with a variant IL-23R allele (R381Q) show decreased 
production of the pro-inflammatory cytokine IL-17A in response to IL-23 stimulation, emphasizing the 
importance of IL-23-related pathways in human IBD (10). 
 
Despite the discovery of these new genetic susceptibility loci with GWAS, the identified IBD markers 
account for only about 20% of the heritable risk (11). 
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Figure 1 A model for IBD pathways based on GWAS 
Intestinal homeostasis involves the coordinated actions of epithelial, innate and adaptive immune 
cells. Barrier permeability permits microbial incursion, which is detected by the innate immune system, 
which then orchestrates appropriate tolerogenic, inflammatory and restitutive responses in part by 
releasing extracellular mediators that recruit other cellular components, including adaptive immune 
cells. Genetic variants, the microbiota and immune factors affect the balance of these signals. Text 
colour indicates whether the genes are linked to risk loci associated with Crohn’s disease (CD; black), 
ulcerative colitis (UC; blue) or both (red). Asterisk denotes corresponding coding mutations; cis-eQTL 
effects are underlined. G, goblet cell; P, Paneth cell. 
 
 
Adapted by permission from Macmillan Publishers Ltd: Nature; 474 (7351): 307-317, copyright 2011 
(5). 
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1.2.2 Environmental factors 
1.2.2.1 Gut microflora 
The intestinal immune system defends against pathogens and entry into the mucosa of excessive 
intestinal microbes and at the same time maintains a state of immune tolerance to resident intestinal 
microbes. Disruption of this homeostasis has been shown in animal models to cause intestinal 
inflammation and is thought to predispose humans to IBD (12, 13).  In transgenic murine models of 
CD, animals kept under germ-free conditions do not develop inflammation until bacteria are 
introduced (14). 
 
The diversion of the faecal stream induces clinical improvement in CD which recurs after restoration 
of bowel continuity or infusion of luminal contents into the bypassed ileum (15, 16); these 
observations suggest that luminal contents provide a stimulus for intestinal inflammation.  
 
Polymorphisms in patients with IBD (in the genes that regulate microbial recognition and innate 
immune pathways (e.g. NOD2), genes that control autophagy (e.g., ATG16L1, IRGM), and genes in 
the interleukin-23 pathway) indicate the important roles of host-microbe interactions in regulating 
intestinal immune homeostasis (12, 13). These NOD 2/CARD 15 polymorphisms have been shown to 
cause defective nuclear factor kappa-B activation resulting in inefficient epithelial clearance of 
invasive bacteria and defective defensin production (17). 
 
In addition, IBD patients exhibit loss of immunologic tolerance to commensal bacteria (18) and 
alterations in the composition of commensal enteric bacteria including increased Escherichia coli, 
enterococci, and bacteroides and reduction in bifidobacterium and lactobacillus species (19). 
 
Furthermore, the selective therapeutic manipulation of the enteric bacterial population by antibiotics 
and probiotics has shown benefit in IBD.  In CD, antibiotics including metronidazole (20), ciprofloxacin 
(21), or in combination (22) have been used in the treatment of active disease and also in the 
prevention of post operative relapse (23).  In pouchitis, metronidazole (24) and ciprofloxacin (25) have 
been shown to be effective.  The probiotic E. coli Nissle has been shown to be as effective as low-
dose 5-ASA in preventing relapse of ulcerative colitis (26).  In combination, the probiotic VSL 3 
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(lactobacillus, bifidobacterium and S.salivarium species) prevented relapse of chronic pouchitis after 
induction of remission by antibiotics (27). 
1.2.2.2 Diet  
Nutrition has an important role in both the supportive and therapeutic management of IBD. In active 
CD enteral feeding is an effective primary therapy for patients who can tolerate it (28). In contrast, low 
fibre, high sugar, high animal fat diets have been proposed as a risk factor for the development of IBD 
(29, 30). Whilst there are many reports of the possible associations between diet and IBD, there is, as 
yet, no definitive evidence that diet contributes to the pathogenesis of IBD. 
1.2.2.3 Appendectomy 
A protective effect of appendectomy in UC has been shown in a meta-analysis of 17 case-control 
studies with an odds ratio of 0.31 (95% CI 0.26 – 0.37) (31). There is a suggestion that it is the 
appendicitis, and not the appendectomy which is associated with the reduction in the risk of UC (32). 
These studies suggest that alterations in mucosal immune responses leading to appendicitis or 
resulting from appendectomy may negatively affect the pathogenesis of UC. In addition, in some 
studies appendectomy decreased the risk of colectomy and immunosuppressant use in UC, whilst in 
CD it was associated with more ileal disease and increased risk of stricture but a lower risk of perianal 
fistula (33, 34). 
1.2.2.4 The oral contraceptive pill 
In a meta-analysis, which included the results of nine studies, the pooled relative risk (adjusted for 
smoking) associated with oral contraceptive use was 1.44 (1.12, 1.86) for CD and 1.29 (0.94, 1.77) for 
UC (35). These results suggest a modest association between the use of oral contraceptives and the 
development of CD and UC, also confirmed in a more recent meta-analysis (36). 
1.3 SMOKING IN IBD 
Smoking has been implicated as a risk factor for developing Crohn’s disease (CD) and worsens its 
outcome (37, 38). Conversely, the onset of ulcerative colitis (UC) may be triggered by smoking 
cessation and nicotine patches are themselves effective in patients with active disease (39).   
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1.3.1 Effect of smoking on the risk of developing IBD 
The risk of developing CD in active and passive smokers is shown below in Table 1.1. Of note, 
children who commence smoking aged less than 10 years have the greatest risk for developing CD. 
Smoking is protective against the development of UC (40-43). 
Table 1.1 The effect of active and passive smoking on the risk of developing IBD (40-43). 
 ODDS RATIO 95% CI 
CROHN’S DISEASE 
LIFETIME RISK 2 1.65-2.47 
PASSIVE CHILDHOOD 2.04 1.28-3.31 
SMOKE CHILDHOOD AGE < 10YRS 3.65 1.44-11.2 
SMOKE CHILDHOOD AGE < 15YRS 3.06 1.79-5.38 
 
ULCERATIVE COLITIS 
SMOKERS VS NON-SMOKERS 0.41 0.34-0.48 
 
1.3.2 Prevalence of smoking in IBD 
The prevalence of smoking at the time of diagnosis in patients with CD has been reported to be 33-
55% (37, 38, 44-47) and in UC 9-28% (44, 46, 47) (Table 1.2). 
1.3.3 Effect of smoking and cessation on IBD phenotype and course 
In CD, active smoking is associated with disease location; most studies report a higher prevalence of 
ileal disease and lower prevalence of colonic disease in smokers (37, 45, 48). Furthermore, smokers 
are more likely to develop stricturing and penetrating disease, higher relapse rates, increased steroid 
and immunosuppression use (49-52). In addition CD smokers are likely to need more surgery with 
higher rates of post operative relapse (51).  Successful cessation of smoking has been shown to be 
beneficial in CD with lower relapse rates, steroid and immunosuppression use (53) 
In contrast, in patients with UC, smoking has been reported to delay the onset and reduce the need 
for hospitalisation, oral steroids, colectomy, and is associated with less proximal extension of distal 
colitis (54-58). 
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Table 1.2 Prevalence of smoking in IBD patients: at diagnosis and current 
STUDY SMOKING 
STATUS 
CROHN’S DISEASE ULCERATIVE COLITIS 
 
At diagnosis Current At diagnosis Current 
Linberg 1992 (45) Smoker 51% - - - 
Ex-smoker 17% - - - 
Never Smoked 42% - - - 
Cosnes 1996 (38) Smoker 55% - - - 
Ex-smoker + 
never smoked 
45% - - - 
Cosnes 1999 (50) Smoker - 49% - - 
Ex-smoker - 17% - - 
Never Smoked - 42% - - 
Cosnes 2004 (41)] Ever smokers 
(smokers & ex) 
- 61%  
(Crohn’s 
colitis) 
- 42% 
Non smokers - 39% -- 58% 
Lakatos 2004 (44)  Smoker 51% - 14% - 
Ex-smoker 6 % - 18% - 
Never smoker 43% - 67% - 
Requeiro 2005 (46) Smoker 33% - 9% - 
Ex-smoker - - - - 
Never smoked - - - - 
Aldous 2007 (37) Smoker 44% - - - 
Ex-smoker 13% -  - 
Never Smoked 43% -  - 
Van der Heide 2009 
(47) 
Smoker 52% 26% 28% 10% 
Ex-smoker 12.6% 41% 30% 48% 
Never Smoked 35.3% 33% 43% 42% 
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1.3.4 Mechanisms of the effects of smoking 
 
The mechanisms responsible for the effect of smoking in CD or UC are still unclear. Smoking affects 
both systemic and mucosal immunity and alters a wide range of both adaptive immune functions.  
Tobacco smoke contains hundreds of substances, including nicotine and carbon monoxide, which act 
on different targets: mucus layer, cytokine production, macrophage function, and the 
microvasculature.  These effects may be modulated by gender, genes, disease location and activity, 
cigarette dose, and nicotine concentration (59). Nicotine may be beneficial by increasing mucin 
synthesis, decreasing IL-8 expression, and reducing tumour necrosis factor alpha (TNFα) production 
through its action on the nicotinic acetylcholine receptor. Carbon monoxide has been shown to reduce 
lipopolysaccaride-mediated secretion of TNFα, increase interleukin -10 (IL-10) and induce heme 
oxygenase 1, which provides  protection against oxidative stress (60, 61). 
In CD, increased carbon monoxide may amplify the impairment in vasodilatation capacity in the 
chronically inflamed microvessel, resulting in ischaemia, and perpetuating ulceration and fibrosis. A 
defect in bacterial clearance or macrophage deficiency may also have a detrimental role. As 
mentioned above, genetic predisposition may influence the effects of smoking on CD. In a recent 
study, use of micro-array analysis of the colonic mucosa in CD smokers compared to CD never 
smokers, revealed a number of genes (RNF138, MT2A, and STEAP3) to be expressed differently in 
the inflamed colons of CD smokers (62). Cigarette smoke extract has also been shown to delay 
TNFα-induced NOD2 mRNA expression and was associated with abnormal NOD2/receptor 
interacting serine-threonine kinase 2 (RIPK2) interaction (63). 
1.3.5 Nicotine dependence 
Nicotine dependence is a maladaptive pattern of tobacco use that leads to significant impairment or 
distress, as defined by the DSM-IV (Diagnostic and Statistical Manual-IV) classification. Nicotine 
dependence resembles other drug dependence disorders, featuring a pattern of repeated self-
administration, tolerance, withdrawal, and compulsive drug-taking behaviours. In the setting of clinical 
research, several scales have been developed to facilitate measurement of the presence and severity 
of nicotine dependence, the most commonly used being the six item Fagerström Test for Nicotine 
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Dependence (FTND) (discussed further in chapter 3) (64). Successful smoking cessation is inversely 
related to nicotine dependence (65). 
Cigarettes are thought to be addictive because they provide a flexible, easy and attractive way of 
ingesting nicotine. The mechanisms of nicotine addiction involve 3 processes: firstly, nicotine reward 
via nicotinic acetylcholine receptors in the ventral tegmental area of the midbrain stimulates nucleus 
accumbens to release dopamine; secondly, nicotine hunger in which the mechanisms of nicotine 
addiction motivational pathways are altered creating the ‘need to smoke’; and finally, nicotine 
withdrawal leading to adverse mood and depression (64). 
In the United Kingdom (UK), about two thirds of smokers declare that they want to stop smoking and 
just over a half of smokers had made a serious attempt in the last 5 years (66). However, only a small 
proportion of smokers attempting to stop currently use smoking cessation medications (23%) or 
attend a specialist cessation service (7%) (66).  
1.3.6 Smoking and stress 
Although smoking has been implicated to affect the course of CD adversely, patients often use 
smoking as means to relieve psychological stress (67). As stress has been shown to worsen the 
course of IBD (see below), this is a conflicting situation for patients.  In a recent study, an impulsive 
sensation seeking personality was suggested to be associated CD current smokers (68). 
Conceivably, therefore, psychological interventions may have a role in achieving smoking cessation in 
patients with IBD. 
1.3.7 Awareness of the effects of smoking in IBD patients  
In a study assessing the knowledge of both doctors (general practitioners) and patients of the adverse 
effects of smoking in CD, only 2 out of 51 general practitioners and 13 out of 102 patients were aware 
of the association (69), although this study was carried out early (1996) in our understanding of the 
effects of smoking in CD.  In a subsequent study published in 2003, in which 312 CD patients 
completed a self-administered questionnaire about the effects of smoking on health and their disease, 
only 9.5% recognized that smoking increases risk the of development of CD and 12% of re-operation 
in CD (70). 
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1.4 THE ROLE OF PSYCHOLOGICAL STRESS IN IBD 
Since this thesis focuses on the role of psychological factors and their management in IBD, the 
remainder of this introduction will discuss these in the context of IBD.  
Chronic psychological stress is associated with adverse effects on health (71-73). CD and UC 
historically were classified as psychosomatic disorders with early studies reporting a close association 
between IBD and psychiatric diagnoses. Recent well-designed studies have confirmed the anecdotal 
suggestion that psychological stress can trigger relapse in IBD. Here these topics are outlined before 
reviewing the evidence assessing psychotherapy and related modalities as therapeutic options in 
patients with IBD.  
1.4.1 Stress  
Stress can be defined as a threat or perceived threat to an organism’s homeostasis.  The initial 
stimulus (stressor) evokes a reaction in the brain (stress perception) that activates physiological fight-
or-flight systems in the body (the stress response) (74). The duration and intensity of the stressor are 
the key determinants of the immune response to stress.  Acute stress, such as narrowly avoiding a 
road traffic accident, lasts for minutes to a few hours, and causes physiological changes that enable 
survival, including immune enhancement. Chronic stress such as bereavement lasts for several hours 
per day, for weeks or months and leads to immunosuppression. Allostasis (the process of returning to 
stable homeostasis) requires a rapid physiological response to stress that is terminated once the 
stressor has abated (73).  
Stressors. In animal studies, Selye showed that if an organism is severely damaged the resulting 
physiological and hormonal responses were the same regardless of the mechanism of the insult (75, 
76).  Selye proposed that the response to stress was dependent on the significance and chronicity of 
the stressor, suggesting that while stress may enhance function, a concept he termed eustress, 
persistent stress that cannot be resolved through adaptation leads to anxiety or withdrawal behaviour 
(distress) (77).  
Stress perception. Psychologists challenged Selye’s direct application of his results in experimental 
animals to man, arguing that in order for a psychosocial situation to be stressful, it must be appraised 
as such (78) and that this primary appraisal is influenced by personality and prior experience in 
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managing similar stressors (79). The term coping describes the thoughts and behaviours used to 
manage the internal and external demands of situations that are perceived as taxing (80). Coping 
theory states that an individual’s resilience to stress depends both on their coping resources and the 
strategies they employ when stressed. Commonly quoted categories of coping behaviour, which are 
not mutually exclusive, include problem-solving, emotion-oriented, avoidance-oriented and supportant 
(81). 
Physiological Stress Response. Multiple neural circuits are activated in order to meet the 
physiological demands of stress. In brief, stressful stimuli are relayed from the sensory cortices and 
ascending brainstem pathways carrying visceral and sensory stimuli to the amygdala, hypothalamus, 
and peri-aquaductal grey (limbic system) (82).  
Once a situation has been appraised as stressful, neurons of the paraventricular nucleus (PVN) of the 
hypothalamus release corticotrophin-releasing hormone (CRH). CRH, by binding to the CRH1 
receptor (CRHr1) activates nuclei of the autonomic nervous system (ANS) in the medulla, leading to 
the classic ‘fight or flight’ response mediated through the release of noradrenaline from end efferents 
and adrenaline from the adrenal medulla. CRHr1 stimulation also leads to activation of the 
hypothalamo-pituitary-adrenal (HPA) axis. CRH and vasopressin (AVP) are secreted into the portal 
vessel and in turn stimulate the anterior pituitary to produce pro-opiomelanocortin (POMC) which is 
processed to melanocortin, opioids and corticotrophin (ACTH) (83). ACTH, through its systemic action 
on the adrenal cortex leads to the release of cortisol. In the early, rapid phase of the stress response, 
cortisol binds to its high affinity, mineralocorticoid receptor (MR) in the limbic region of the brain, up-
regulating the expression of genes encoding proteins that maintain the stress response, and 
behavioural vigilance. As serum cortisol levels peak, the low affinity glucocorticoid receptor (GR) is 
activated, which leads to adaptation. In order to return to normal homeostasis, the hypothalamus, at 
the same time as releasing CRH, releases two recently described proteins Urocortin II and III, which 
act on CRH receptor 2 (CRH-r2) (84). In animal models, intracerebroventricular administration of 
urocortin, in contrast to CRH which mimics the initial behavioural, autonomic and endocrine response 
to stress, has anxiolytic properties.   
The key neurohumoral mediators of the stress response, including cortisol, adrenaline and 
noradrenaline, are biphasic in their actions, prolonged stress leading to immunosuppression (74).  
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Allostatic load refers to the physiological costs of chronic exposure to these mediators and is 
detrimental to health. It is increased by multiple exposures to different forms of stress, an inability to 
habituate to a repeated single stressor, and or an ineffectively terminated stress response. Inter-
individual differences in psychological resilience have significant effects on the kinetics and peak 
levels of circulating stress mediators; importantly, they account for why some individuals generate 
stress responses long after the stressor has abated (73, 74). 
How stress impacts on the gut is slowly being unravelled, and forms part of the new research field, 
psychoneuroimmunology, the study of the influence of cognition and emotion on neuroimmune 
functions (85). 
1.4.2 Psychoneuroimmunology of IBD 
The enteric nervous system (ENS) contains 100 million neurones and regulates the motility, exocrine 
and endocrine functions, and the microcirculation of the GI tract. It communicates via efferent and 
afferent neurones of the sympathetic and parasympathetic nervous system ANS (the ‘brain-gut’ axis); 
unlike the other nervous systems in the body it can work without central input from the brain (the 
‘brain-in-the-gut’). It is now increasingly recognised that the HPA, ANS and ENS can interact directly 
with the immune system systemically and in the gut wall. Nerve fibres of the ANS form close 
associations with immunoregulatory cells in gut mucosa, mucosa-associated lymphoid tissue, lymph 
glands, bone marrow, thymus and spleen, and these cells are known to carry receptors for several 
neurotransmitters of the ANS, and HPA systems (72) (Figure 1.2). 
Experimental stress studies involving the gut in animal models. 
 Much of what is known about the physiological effects of stress on the gut is extrapolated from rodent 
models. Standard models of acute stress induce physiological stress in a variety of ways: restraint, in 
which an animal is wrapped up and its movements restricted (restraint stress); extremes in 
temperature (cold stress); swimming to avoid drowning (forced swim stress); and pain (inescapable 
foot shock stress).  
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Figure 1.2 Psychoneuroimmunological pathways in IBD.  Stress, via the limbic system, stimulates the 
HPA (1) and the autonomic nervous system (2) leading to the production of CRF, ACTH and then 
cortisol and the catecholamines.  Noradrenaline is also released directly into the gut mucosa from 
sympathetic nerve endings of the ENS (3).  In addition, mast cells lying close to enteric nerve endings 
degranulate releasing tryptase, histamine and other mediators (4).  These neuromediators through 
poorly characterized mechanism, including activation of lymphocytes, stimulate epithelial chloride 
secretion and mucus production, increase epithelial permeability (both paracellullar, and transcellular 
across specialized M cells).  Subsequent ingress of luminal bacteria into the mucosa triggers further 
immune and inflammatory events involving dendritic cells, macrophages and other cell types. 
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Acute stress promotes diarrhoea through increased intestinal chloride ion and water secretion (86), 
mucin production (87, 88), and by stimulating intestinal motility (87, 89). Acute stress also leads to 
alterations in nociception, increasing visceral sensitivity to distension stimuli (90), and is detrimental to 
the integrity of the intestinal barrier. It modulates tight junction protein expression increasing 
paracellular permeability to luminal bacteria (91-93). Regulation of gut permeability in response to 
acute stress is complex: cholinergic innervation (94), mast cell degranulation (91), and CRF (95) have 
all been shown to increase permeability. As well as having effects on intestinal epithelial cells, stress 
can directly modulate the faecal flora, which, as indicated earlier, is now recognised as playing a 
central role in the pathogenesis of IBD (12).  In rodent models catecholamines have been implicated 
not only in increasing the numbers of E.coli but also their invasive potential (96, 97). 
Perhaps more applicable to the effects of chronic psychological stress in man are the water 
avoidance test, in which an animal is made anxious by placing it on a platform surrounded by water; 
novelty stress, where animals are housed in new cages alone; and maternal deprivation, an accepted 
model of depression (98).  
In experiments using water avoidance, chronic stress in rats increased colonic motility, mast cell 
dependent paracellular permeability (99, 100), and transcellular uptake of bacteria across M cells 
(101). Barrier integrity seems to be further impaired by incorporation of less mature cells as stress 
increases epithelial cell turnover and apoptosis (102). In related experiments in the skin, stress 
altered the expression of anti-microbial peptides (103), now recognized as playing a role in the 
pathogenesis of Crohn’s disease (104). Antidepressants (105), PPARγ agonists (93) and probiotics 
(106) have all been shown to improve the integrity of the intestinal barrier in chronic maternal 
deprivation stress.  
Acute and chronic stress in mouse models has profound effects on mucosal barrier function, leading 
to mucosal ingress of luminal commensals and subsequent activation of the mucosal gut immune 
system, which could theoretically worsen inflammation in IBD. 
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1.4.3 Stress in IBD  
1.4.3.1 Experimental stress in animal models of colitis 
Experimental psychological stress initiates and can reactivate inflammation in mouse models of 
colitis. Rats exposed to 4 days of restraint stress developed a more marked inflammatory response to 
the induction of colitis with trinitrobenzenesulfonic acid (TNBS) than control animals (107). 
Furthermore, restraint stress in animals that had recovered from TNBS colitis significantly lowered the 
dose of TNBS required to provoke colitis on rechallenge (108) and alone was enough to re-initiate an 
early inflammatory response (109). This susceptibility was transferable between mice by a population 
of CD4 lymphocytes, suggesting that stress primes immune cells, such that lower doses of antigen 
are required to initiate inflammation (108). The same group has shown that neonatal maternal 
separation, whilst leading to depression and increasing intestinal permeability, does not 
spontaneously cause inflammation. However, the severity of the colitis induced by dextran sulphate 
sodium was greater in adult animals that had experienced maternal separation compared to that 
occurring in un-separated litter mate controls (105). Furthermore, in subsequent experiments this 
group has shown that depression in mice reactivates experimental colitis, an effect prevented by 
desmethylimipramine (110) and mediated by inhibition of the vagal anti-inflammatory pathway acting 
through nicotinic acetylcholine receptors (111).  
1.4.3.2 Experimental stress in human IBD 
Experimental studies of the effects of psychological stress in human IBD, unlike in animals, are 
limited. Inter-individual differences in the appraisal of what constitutes stress makes them difficult to 
design and inherently they are difficult to blind. Furthermore exposing humans to severe or chronic 
stress is unethical.  
The effects of the cold pressor test, where stress is induced repeatedly for short periods over several 
days by plunging a hand into iced water have been compared in healthy volunteers and in patients 
with IBD (112). This sub-acute stress led to activation of the HPA, and of mucosal mast cells, with an 
increase in mucosal reactive oxygen metabolite (ROM) production which was more marked in IBD 
patients than controls (112), suggesting that patients with IBD maybe primed for the effects of stress. 
Using a more acute stress protocol, patients with quiescent UC asked to complete a 50 minute IQ test 
whilst being distracted by dichotomous music showed increases in rectal mucosal release of ROMs 
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and tumour necrosis factor alpha (TNFα), and in LPS-stimulated whole blood TNFα, IL-6 and natural 
killer cell count (113).  In addition, patients with UC may have abnormal autonomic function reflecting 
disturbed stress regulation and influencing relapse rate (114). 
Few studies have examined experimental stress in man. Previous work has shown that a 50 minute 
session of acute mental stress (completing an IQ test while music of different types is played into 
each ear) causes inflammatory changes in the mucosa of patients with quiescent UC (113). Patients 
with quiescent UC, in the upper tertile on the basis of their perceived stress questionnaire (PSQ) 
score, had a greater rate of subsequent relapse (115). Furthermore a negative serum p-ANCA 
increases the risk of anxiety or depression-related flares of UC (116).   
1.4.3.3 Stress as a cause of IBD 
Little evidence supports the notion that stress is a primary cause of IBD in humans. In a retrospective 
study of more than 20,000 Danish parents who had suffered the death of a child, incidence rates of 
IBD over 16 years of follow up were comparable with those of more than 200, 000 controls (117).The 
increased incidence of ulcerative colitis observed in south Israeli Bedouin Arabs when re-housed in 
city flats during the 1960’s (118) was as likely related to concurrent improvements in hygiene and/or 
dietary changes, as to stress, despite the parallels to the spontaneous colitis observed in cotton-top 
tamarinds (Saguinus oedipus) held in captivity (119).   
1.4.3.4 Clinical studies of stress and mood disorders in IBD 
 Psychological stress has long been reported anecdotally to increase disease activity in IBD (120, 
121) and patients with IBD frequently cite stress as a major determinant of relapse (122). Studies 
testing the hypothesis that psychological disorders are associated with IBD are difficult to design and 
perform (82, 120, 123-126). They require a long study period to allow a sufficient number of relapses 
to occur to test for correlation, and a high degree of patient compliance for the collection of detailed 
diary records of life events and symptoms. There are often confounding changes in medication during 
the study period.  The definition of what constitutes a stressful life-event is variable; furthermore, 
particular life events, for example bereavement, will cause differing degrees of stress in different 
individuals. Few studies in IBD, have utilised questionnaires to assess personality type or coping 
strategies to explore the influence of these factors (125, 126).  
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1.4.3.5 Psychological stress as a determinant of relapse in IBD 
Despite these limitations, a number of well-designed prospective studies conducted over several 
months, taken together demonstrate a significant association between psychological disorders and 
relapse of IBD (82, 124, 125).  Of 13 longitudinal studies of the course of IBD, 9 reported that stress, 
adverse life events and/or depression worsened disease activity while 4 reported no effect (see Table 
1.3)  (115, 121, 127-137). All but one (136) of the negative studies included a mixed IBD patient 
sample.  Studies containing mixed IBD populations are hard to interpret for two reasons.  First, stress, 
through its physiological effects on gut function (see above) may affect standard symptom scores, 
such as the Crohn’s disease activity index (CDAI), in UC and Crohn’s to differing extents, particularly 
in relation to weighting for diarrhoea and well being.  Second, it is possible, although unproven, that 
stress may affect the inflammatory process in different ways in the two forms of IBD.    
1.4.3.6 Anxiety and depression in IBD 
Psychological stress and stressful life events are well recognized risk factors for depression, and 
depression like chronic stress is characterized by activation of the HPA and hypercortisolaemia. 
Whilst all of us experience stress and stressful life events, the lifetime risk of depression in the 
general population is only 1:6 (138). Data from recent well-designed studies estimates the prevalence 
of depression in IBD at 25%-35%, double that of the healthy population (139, 140) and significantly 
greater than in other chronic inflammatory conditions, such as rheumatoid arthritis (141).  
In a systematic review of 17 mixed methodology studies, 10 studies compared the prevalence of 
depression in UC with Crohn’s disease: 6 reported that depression was more common in Crohn’s 
disease, 4 were equivocal, and none reported that depression was more common in UC (141).  
The prevalence of anxiety in IBD has been reported at 36-43%; factors associated were severe 
disease and socioeconomic deprivation (142-144). Compared to the general population, young 
patients with CD have a greater risk of developing anxiety disorders and depression and are more 
likely to receive psychotropic treatment (145).  Mood disorders seem to be more prevalent during 
symptomatic relapse of IBD in some (146, 147) if not all studies (148). 
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Table 1.3 Longitudinal studies assessing the association between adverse life events, stress and depression with disease activity in IBD 
 †
 Denotes studies showing a positive association with disease activity at inclusion and relapse. (CD denotes CD; UC, Ulcerative colitis; IBD, Inflammatory 
bowel disease; CDAI, Crohns disease activity index; CAI, Colitis activity index; TWI, Truelove and Witts index; HBI, Harvey Bradshaw Index, SCCAI, Simple 
Clinical Colitis Activity Index; SRRS denotes Social Readjustment Rating Scale; BDI, Beck Depression Inventory; PLSE, Paykel Life Events Scale; PSQ R & 
G, Perceived Stress Questionnaire (recent and general);  PERILES, Psychiatric Epidemiology Research Interview Life Events Scale; PSS, Perceived Stress 
Scale; SCL90R, Symptom checklist – 90R; BAI, Beck Anxiety Inventory; BHS, Beck Hopelessness Scale; RLC, multiple Holmes Recent Life Changes;   STAI, 
Spielberger State-Trait Anxiety Inventory; IBDQ, Inflammatory Bowel Disease Questionnaire; PHQ-9, Patient Health Questionnaire 9 items; TAS-20, Toronto 
Alexithymia Scale – 20 items; SSL-I, Social Support List – Interactions; HS, Hassles Scale; CISS, Coping Inventory for Stressful Situations; HRQL, Health 
Related Quality of Life; CQ, Coping Behaviour; SF-12, Short  Form – 12, MIBDI; Manitoba Inflammatory Bowel disease Index). 
Psychological factor Psychometric tool Diagnosis of relapse 
Patient 
Sample 
Findings Reference 
Life events 
SRRS 
BDI 
Symptom scores 
32 IBD 
(24 UC:8 CD) 
No association over 2 
years 
North et al 1991 (121) 
Life events  
PLES 
HADS 
Endoscopy
 †
 92 UC 
No association over 3 
months 
Riley et al 1990 (136)  
Life events SRE Modified DAI 
124 IBD 
(53 UC:77 CD) 
Positive association 
over 6 months  
Duffy et al 1991 (130) 
Life events  
PERILES 
PSS, SC90R  
Endoscopy 60  UC 
Positive association 
over 1 month 
Bitton et al  2003 (128) 
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Life events SRRS 
CDAI/HBI (CD) 
†
   
TWI/SCCAI (UC) 
163 IBD 
(76 UC:79 CD) 
No association over 11 
months 
Vidal et al 2006 (135) 
Perceived stress & 
coping  
HS, PSS, CISS, 
SCL-90R 
CDAI 87 CD 
Positive association 
over 1 year 
Bitton et al 2008 (127) 
Perceived stress 
PSQ – R 
PSQ – G 
Endoscopy
 †
 62 UC 
Positive association 
over 2 years 
Levenstein et al 2000 (115) 
Perceived stress  PSS 
MIBDI 
Steroid requirement 
451 IBD  
(176 UC :275 CD) 
Positive association 
over 1 year 
Bernstein et al   2009 (137)  
Depression  
BDI, BAI 
BHS, RLC 
CDAI
 †
 18 CD 
Positive association 8-
12 weeks later 
Mardini et al 2004 (131) 
Depression  
BDI, STAI, IBDQ, PSQ, 
IBDQ 
CDAI (CD) 
CAI (UC) 
60 IBD 
(13 UC:47 CD) 
Positive association 
over 18 months 
Mittermaier et al 2004 (133) 
Depression PHQ-9, TAS-20, SSL-I 
CDAI
 †
 
 
100 CD 
Less likely to  respond 
to infliximab 
Persoons et al 2005 (134) 
Depression BDI, STAI, HRQL, CQ  
Endoscopy
 †
 
CDAI 
87 CD Positive over 4 years Deter et al  2008 (129) 
Depression  
HADS, SCL-90R, SF-
12 
CDAI (CD)
 †
 
SCCAI (UC) 
59 IBD  
(27 UC:32 CD) 
No association over 1 
year 
Mickoka-Walus et al 2008  
(132) 
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1.5 ROLE OF PSYCHOLOGICAL TREATMENTS IN IBD 
Whatever the mechanisms involved prove to be, if psychological stress does have an adverse effect 
on the natural history of IBD, then measures which reduce stress should help symptoms and activity 
of IBD. However, in assessing the efficacy of psychological interventions in IBD, potential 
improvements in mood and quality of life should not be disregarded, as a holistic approach to patient 
care should aim to improve not only IBD activity but also patients’ general well-being. Unfortunately, 
appropriately controlled studies using non-pharmacological psychological interventions are difficult to 
blind and published results of heterogeneous studies are hard to interpret.  
Several studies are confounded by the inclusion of mixed IBD populations, varying baseline disease 
activity, and a reliance on symptom scores as disease activity measures.  Disease activity indices 
using stool frequency are subject to inaccuracy as well as to the effects of stress itself: endoscopic 
and laboratory indices give more reliable markers of disease activity. 
There is also considerable variation in the psychological approaches used, and how they are offered.  
Psychological approaches are inevitably difficult to standardize and to deliver in a uniform way in 
clinical trials.  Indeed, psychological therapy may be more effective if tailored to the stage of 
adjustment of individual patients to their IBD (Table 1.4) (149).  Differences between and sometimes 
within studies include the use of different combinations of psychological treatments, individual versus 
group therapy sessions, the number of sessions given, the frequency and duration of treatments, and 
the therapist involved.   
Despite the difficulties in interpreting published reports as a result of these limitations, a study of 302 
patients with IBD using the ADAPT (Assessment of the Demand for Additional Psychological 
Treatment) questionnaire, showed that a third of patients wanted psychological support (150). 
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Table 1.4  An approach to selecting the appropriate psychological treatment (adapted from Maunder 
et al (149)). Interventions are selected according to the stage of adjustment and degree of 
psychological distress associated with IBD 
 
 
STAGE OF ADJUSTMENT 
 
INTERVENTION 
 
Uncertainty about illness 
 
Education 
Peer-counselling 
 
Residual uncertainty Supportive counselling 
 
Distress  Reassess disease activity 
Relaxation and exercise 
Hypnosis 
Cognitive behavioural psychotherapy 
Antidepressants  
 
Suffering Psychiatric review 
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1.5.1 Psychotherapy 
Psychotherapy is an interpersonal relational intervention between patient and therapist that employs a 
range of techniques designed to improve coping mechanisms and thereby mental health (81).  
1.5.1.1 Psychoanalytic and psychodynamic psychotherapy 
The term psychoanalysis applies to therapeutic procedures pioneered by Freud, entailing free 
association, dream analysis and transference (151). Psychodynamic therapies, of which there are 
several sub-types, have their roots in psychoanalytic theory. The central components comprise 
interpersonal and object relations theory and focus upon the correction of deeply ingrained and 
insecure patterns of attachment, or problematic ways of relating to others (152).  Psychotherapy of 
these types has not unequivocally been shown to improve the course of IBD or patients’ psychological 
status. Disappointingly few studies have been adequately designed to assess the impact of such 
psychotherapy on the course of disease: the single study that included endoscopic assessment was 
confounded by the controls having been poorly matched with respect to psychological status (153), 
and the remainder compromised by the inclusion of mixed IBD populations, and a reliance on 
symptom scores as IBD outcome measures (Table 1.5).    
One of the earliest studies by O’Connor et al assessing the role of psychotherapy in patients with UC, 
was published in 1964 (153).  57 patients received individual psychoanalytic psychotherapy. The non-
randomized controls were matched by disease severity, sex, age of onset and use of steroids. 56 out 
of 57 patients in the therapy group had psychiatric diagnoses: schizophrenia (19 patients); 
psychoneurotic (3); personality disorders (34); in contrast, the control group had fewer psychiatric 
diagnoses, namely schizophrenia (3 patients), psychoneurosis (3) and personality disorders (14).  
Patients receiving psychotherapy had up to 104 sessions over a 2 year period. Non-validated 
symptom scores and proctoscopy were used to evaluate disease activity periodically; these appeared 
to show improvement in the therapy group over a period of 8 years although no statistical analysis 
was provided. Likewise, there seemed to be improvement in the psychological status of treated 
patients, particularly those without schizophrenia.  
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A series of publications by Jantschek et al and Deter et al, reported the somatic and psychosocial 
course of 108 patients with Crohn’s disease randomized on a 2:1 basis to an individualized 
psychodynamic psychotherapy and relaxation program carried out over a year, or to standard medical 
therapy; evaluation of outcome was undertaken at 2 years (154, 155).  Neither the number of 
relapses, defined by CDAI, nor the need for surgery differed between the intervention group and 
controls.  In addition, there were no differences in psychological status (measured using Beck’s 
depression inventory and the State-trait Anxiety Inventory) or quality of life in the two groups. In a later 
sub-analysis of these patients, psychodynamic psychotherapy was associated with a greater 
decrease in the number of in-hospital days in the year after it was started in comparison with controls 
(156), a finding confirmed by a subsequent report focusing on high healthcare utilisers (129). 
Lastly, Maunder et al explored the use of weekly supportive-expressive group psychotherapy for 20 
weeks in 21 CD and 9 UC patients. There was no change in quality of life, anxiety, depression or IBD 
symptoms over the course of treatment, although there was a reduction in maladaptive coping (157).  
1.5.1.2 Cognitive behavioural therapy 
Cognitive behavioural therapy (CBT) is aimed at correcting psychological problems (emotional, 
cognitive and behavioural) and at improving coping skills to alleviate patient’s distress. The main 
characteristics are that it is time-limited, structured and oriented towards problem-solving  (152) with a 
focus on modifying maladaptive thoughts, in the interest of improving maladaptive behaviour and 
negative emotions.  Unlike psychoanalytic and psychodynamic psychotherapy, CBT focuses on the 
here and now, rather than on past events and relationships.  CBTs in IBD which focus on stress 
reduction include progressive muscle relaxation and training in coping strategies as well as supportive 
counselling and disease education. As this treatment has multiple components, it is not possible to 
dissect out which modality is beneficial in any particular context (Table 1.6).   
In a randomized controlled trial of 80 IBD patients, Milne et al assessed whether practising stress 
management techniques would decrease activity and promote psychosocial functioning in IBD 
patients (158). The intervention group received six classes on stress management which included 
autogenics (self-directed relaxation training), personal planning skills and communication techniques. 
At 1 year, both the CDAI and IBD stress index dropped significantly from baseline in the treatment 
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group but not in the controls. However, CDAI at baseline was higher in the intervention than in the 
control group.   
In a smaller randomized controlled study, Schwarz et al compared the effectiveness of a multi-
component behavioural treatment package in 11 IBD patients, which included IBD education, 
progressive muscle relaxation, thermal biofeedback, and training in use of cognitive coping strategies, 
to symptom-monitoring in 10 controls (159). The controls actually improved more than the treated 
group with regard to symptoms and there were no differences in the psychological outcomes between 
the groups.  
In a prospective study by Mussell et al to determine whether cognitive-behavioural group therapy in 
addition to standard care is effective in reducing psychological distress, 28 IBD patients completed 12 
weekly treatment sessions, followed by a further 3 sessions at intervals of 3 months (160). The 
sessions consisted of 4 components: education about IBD given by a gastroenterologist; education 
about the role of cognition and emotions on the generation of distress; training in adaptive cognitive 
strategies for disease-related and everyday distress; and progressive muscle relaxation. At baseline 
patients were in clinical remission or had mildly active disease. Disease-related concerns fell during 
the 9 month follow-up period.  Depressive coping also decreased significantly in women but not in 
men.  However, these psychological improvements were not accompanied by any change in IBD 
activity. 
Garcia-Vega and Fernandez-Rodriguez randomly assigned 45 patients with inactive Crohn's disease 
to stress management (progressive muscle relaxation to lessen the physiological effects of stress and 
improve coping skills), self-directed stress management (personal planning skills and autogenic 
training), or as a control group, conventional medical treatment (161). The patients underwent eight 
individual sessions. The patients who received training in stress management experienced significant 
post-treatment reductions in tiredness, constipation, abdominal pain and/or distension; whilst those 
who received training in self-directed stress management experienced a significant reduction in 
tiredness and abdominal pain; no changes were observed in the control group.  Unfortunately, no 
validated symptom score, or laboratory measure, was used to assess Crohn’s disease activity. 
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Elsenbruch et al compared the effects of mind-body therapy on cellular immune and neuroendocrine 
measures, health-related quality of life and disease activity in 15 patients with inactive UC, with those 
in 15 randomly assigned standard care waiting controls. The mind-body therapy was described as a 
multi-component lifestyle modification aimed at improving psychosocial and physical well-being by 
teaching individuals to improve stress hardiness to integrate health-promoting behaviour. Intervention 
consisted of a structured 60-hour training program over 10 weeks which included stress management 
training, moderate exercise, Mediterranean diet, behavioural techniques and self-care strategies 
(162). Quality of life, perceived stress and disease activity were assessed with standard 
questionnaires. In response to therapy, patients in the intervention group showed significantly greater 
improvement in the SF-36 scale, Mental Health and the Psychological Health Sum score and IBDQ 
bowel symptoms compared to the control group.  However, no significant differences in circulating 
lymphocyte subsets or endocrine parameters were observed in response to the active intervention.  In 
a follow-up study, the same group found no discernible effect of this approach on the activity of their 
UC when patients were re-evaluated after 1 year (163).  
In another controlled study by Diaz Sibaja et al, 57 patients with IBD from the Spanish Crohn‘s 
Disease and Ulcerative Colitis Association were randomly assigned to a psychological treatment 
program, or a control group. The intervention modules included illness information, an analysis of 
factors which may influence illness and an explanation of coping strategies, problem-solving 
techniques, relaxation, social skill training, distraction, and cognitive restructuring techniques. The 
treated group showed improvements in anxiety and depression variables when compared to the 
controls, but unfortunately IBD activity was not assessed (164). 
Keefer et al determined the effect of a behavioural self-management program on incidence of flare 
within 12 months in IBD patients following behavioural intervention when compared to the natural 
history of flare incidence prior to program participation.  Using a regression model the results 
indicated that those participants in the treatment group were 57% less likely to flare in the following 12 
months (compared to 18% in the control group) (165). 
 
In a recent controlled study, by Boye et al, 58 UC and 56 CD patients who had active disease or had 
relapsed over the previous 18 months with high levels of stress but without any serious psychiatric 
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disorders, were randomised to receive either usual treatment or usual treatment plus stress 
management psychotherapy. High stress levels were defined by a perceived stress questionnaire 
(PSQ) score ≥ 60. The psychotherapy consisted of three group sessions (psycho-education, problem-
solving, relaxation) and 6-9 individual sessions based on cognitive behaviour therapy with 1-3 booster 
sessions at 6 and 12 months follow-up. Patients completed the IBDQ at baseline, 6, 12, and 18 
months. The intervention did not improve disease or reduce relapse; however, it increased the IBDQ 
score. On analysis of UC and CD separately, improvement of IBDQ was only found in the UC group 
(166). 
 
The studies described above have all focused on adults with IBD.  In a report comprising of 
adolescents, by Szigethy et al, 41 with IBD of heterogeneous type, treatment and severity, together 
with mild to moderate sub-syndromal depression were randomized to either Primary and Secondary 
Control Enhancement Therapy-Physical Illness (PASCET-PI), a technique based on cognitive 
behavioural therapy, or to standard treatment. Depression improved in the intervention group but 
there were no discernible differences in the change IBD severity between the two groups (167, 168).  
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Table 1.5 Summary of longitudinal studies examining the effect of psychoanalytic and psychodynamic psychotherapy on IBD activity and associated mood 
disorders.  † Denotes randomized controlled trials. (CD denotes Crohn’s disease; UC, Ulcerative colitis; IBD, Inflammatory bowel disease; CDAI, Crohn’s 
disease activity index; WB, Weschsler Bellevue; RT, Rorschach test; TAT, Thematic apperception test;  BDI, Beck’s depression inventory; STAI, State trait 
anxiety inventory; PSKB, Psychic and socio-communicative status (Psychischer und sozial-kummunikativer befund); HADS Hospital anxiety and depression 
scale; QOL, quality of life; QL, Quality of life questionnaire). 
Type of Intervention 
 
Patient Sample 
(follow up 
period) 
Baseline Effect  of Intervention 
(assessment method) 
Reference 
IBD activity Mood status IBD  Mood QOL 
Individual   
 (Up to 104 sessions)  
 
1. Psychoanalysis 
UC  
57 Intervention  
57 Controls 
(8 years) 
 
Mixed  
active / inactive 
Intervention 
56 psychiatric 
disorder 
Controls 
20 psychiatric 
disorder 
Possibly 
improved  
(Symptoms, 
proctoscopy)  
Improved  
(WB,RT TAT) 
Not assessed O’Connor et al 
1964 (153) 
Individual 
(26 sessions over  1 year)  
1. Short term psychodynamic 
2. Autogenic training  
CD† 
72 Intervention 
36 Controls 
(2 years) 
Mixed  
active / inactive 
_ 
 
 
No effect overall 
(CDAI);  
reduced in-
hospital days in 
subgroups  
No effect 
(BDI, STAI, 
PSKB) 
No effect 
(QL) 
Jantschek et al 
1998, Deter et al 
2007, Deter et al 
2008  
(129, 154, 156) 
Group 
(20 sessions over 20 weeks) 
1. Supportive expressive 
therapy 
IBD 
21 CD 
9 UC 
(20 weeks) 
Mixed  
active / inactive 
33% depressed 
70% anxious 
No effect 
(Symptoms) 
No effect 
(HADS) 
No effect 
(IBDQ) 
Maunder et al  
2001 (157) 
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Table 1.6 Longitudinal studies evaluating the effect of cognitive behavioural psychotherapeutic techniques in IBD. † Denotes randomized controlled studies. 
(CD denotes Crohn’s disease; UC, Ulcerative colitis; IBD, Inflammatory bowel disease; CDAI, Crohns disease activity index; CAI, Colitis activity index; HBI, 
Harvey Bradshaw Index; PCDAI, Pediatric Crohns disease activity index; CSK, Clinical score of Kozarek; QOL, Quality of life; BDI, Beck’s depression 
inventory;  STAI, State trait anxiety inventory, CES-D, Center of Epidemiological Studies – Depression scale; SCL-90 R, Symptom check list 90 revised;  
SCL-90, Symptom check list 90; PSS, Perceived stress scale;  HADS, Hospital anxiety and depression scale; CDI and CDI-P, Children’s depression 
inventory, child and parent; K-SADS, Schedule for affective disorders and schizophrenia for school age children – present and lifetime; CGAS, Children’s 
global assessment scale; PCSC, Perceived control scale for children; IBDQ, Inflammatory bowel disease questionnaire;  IBD Stress, Inflammatory bowel 
disease stress index); PSQ, Perceived stress questionnaire. 
Type of Intervention 
 
Patient Sample 
(follow up 
period) 
Baseline Effect  of Intervention 
(assessment method) 
Reference 
IBD activity Mood status IBD  Mood QOL 
Group 
(6 Sessions)  
1. Personal planning skills 
2. Communication skills 
3. Autogenic training 
IBD† 
40 Intervention  
40 Controls  
 
(1 year) 
Mixed  
active / inactive 
         _ Improved 
(CDAI) 
         _ Improved  
(IBD Stress) 
 
Milne at al 1986 
(158) 
Individual 
(12 Sessions) 
1. Progressive muscle 
relaxation 
2. Thermal biofeedback 
3. Cognitive coping strategies 
4. Education  
IBD† 
11 Intervention 
10 Controls 
 
(3 months) 
Not clear          _ 
 
(excluded major 
depression,  
bipolar disorder,  
schizophrenia) 
No effect 
(symptom 
score) 
No effect 
(BDI, STAI) 
Improvement 
(IBD Stress) 
Schwarz et al 1991 
(159) 
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Group 
(15 Sessions)  
1. Psycho-education IBD 
2. Psycho-education cognition 
and emotion 
3. Adaptive coping strategies 
4. Progressive muscle 
relaxation 
IBD 
14 CD 
14 UC 
 
(9 months) 
Mixed  
active / inactive 
         _ 
 
(excluded 
psychiatric 
disorders) 
No effect 
(CDAI, CAI) 
Improved in 
women 
(CES-D, SCL-90 
R) 
         _ Mussell et al 2003 
(160) 
Individual 
(8 Sessions)  
1. Stress management group 
     - progressive muscle 
relaxation 
     - stress management 
2. Self-directed stress 
management group 
     - personnel planning skills 
     - autogenic training 
CD† 
30 Intervention 
15 Controls 
(12 months) 
All inactive Not assessed Equivocal 
(HBI measured 
at baseline but 
not at follow up) 
Not assessed Not assessed Garcia-Vega et al 
2004 (161) 
Group 
(60 hours training) 
1. Stress management 
training 
2. Moderate exercise 
3. Mediterranean diet 
4. Behavioural techniques 
5. Self care strategies 
UC† 
15 Intervention 
15 Controls 
 
(10 weeks) 
Mixed  
active / inactive 
         _ 
 
(excluded 
psychiatric 
disorders) 
Improved  
IBDQ bowel 
symptoms at 10 
weeks but not at 
1 year (no 
change in CAI) 
No effect 
(PSS) 
Improved  
(SF-36, IBDQ) 
Elsenbruch et al 
2005 (162) 
Longhurst et al 
2007 (163) 
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Group 
(10 sessions) 
1. Illness information 
2. Coping model 
3. Problem solving strategies 
4. Social skill training 
5. Distraction 
6. Cognitive restructuring 
techniques 
IBD 
34 CD 
23 UC 
 
(12 months) 
All Inactive 18% depressed 
35% anxious 
Not assessed Improved 
(HADS, BDI, 
SCL-90)  
        _ Diaz Sibaja et al 
2007 (164) 
Individual 
(9-11 sessions) 
1. Education CBT, IBD, 
depression, problem solving 
2. Relaxation skills 
3. Cognitive therapy 
4. Coping skill 
5. Personnel planning 
IBD† 
(adolescents) 
15 CD: 7 UC 
Intervention  
14 CD:5UC  
Control 
 
(12-14 weeks) 
Mixed  
active / inactive 
All mild/ 
moderate 
subsyndromal 
depression 
No effect 
PCDAI 
CSK 
 
Improved 
(CDI and CDI-P, 
K-SADS, CGAS, 
PCSC) 
         _ Szigethy et al 2007, 
2009  
 
(167, 168) 
Individual + Group 
(9 -15 sessions) 
1.Psycho-education 
2. Problem solving 
3. Relaxation 
56 CD : 58 UC 
Intervention 
Control 
(18 months) 
Active Highly stressed 
(PSQ≥60) 
No effect - Improved 
 (IBDQ) 
Boye et al, 2011 
(166) 
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1.5.2 Social support/patient groups  
Social support and close networks with friends and family are associated with happiness (169) and 
conversely social isolation is linked with depression and poor health. Attempting to strengthen 
patients’ exogenous coping resources by manipulating their social environment is extremely difficult. 
Despite being unproven as a way of improving coping strategies and disease course, a supportive 
relationship between patients, whether in groups or as individuals, and their IBD team is likely to be 
important, as may be links with patient bodies such as the Crohn’s and Colitis Foundation of America 
(CCFA) and Crohn’s and Colitis (UK) (until recently, National Association of Colitis and Crohn’s 
disease). 
In the latter context, the effect of a one week IBD summer camp sponsored by CCFA was assessed 
in children and adolescents with IBD. The IMPACT-II questionnaire (35 questions measuring 6 quality 
of life domains) and State-Trait Anxiety Inventory were completed at the start and end of the week. 
Out of 125 individuals who consented to participate, 61 patients (47 CD, 14 UC) completed the 
questionnaires: improvements were seen in health-related quality of life, bowel symptom scores, 
social functioning and treatment intervention scores but not in anxiety scores; no formal assessments 
of IBD activity were undertaken (170).  
1.5.3 Disease-specific education 
Intrinsic to the forms of psychotherapy detailed above is disease-specific education.  Prospective 
studies designed to evaluate the clinical effect of education in IBD, in the absence of coping training, 
are disappointing: they suggest that it has little effect on psychological status or disease course, 
although it may reduce healthcare utilization and increase patient satisfaction (Table 1.7).  
There are a number of special difficulties relating to trials involving education programs. Many 
patients with IBD have complex disease; these require highly qualified staff to provide appropriate 
explanation and education. Education programs are expensive and time-consuming. What information 
patients require depends in part on the duration of their IBD, a factor often overlooked in randomly 
applied studies of the possible benefits of such programs.  
In a prospective study, Larsson et al (171) evaluated changes in anxiety in a group-based educational 
intervention for IBD patients screened for high anxiety using the HADS questionnaire. Of 135 anxious 
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patients, 49 were recruited for 8 weekly group sessions consisting of medical information about IBD 
treatment, nutrition and diet, stress and stress management, as well as coping strategies.  There was 
no significant change in the HADS-A score at 6 months in those who participated in the education 
program although participants reported they had gained better knowledge of their disease. 
Furthermore, the educational program did not improve IBD activity domains of the IBDQ.   
Kennedy et al devised and assessed a broad-based patient-centered approach to IBD self-
management (172).  635 patients, according to which of the 19 hospitals they attended, were 
allocated to intervention or control groups.  The active intervention comprised 4 components: a patient 
guidebook with both lay and evidence-based knowledge about investigation, treatment, and self-
management of IBD; a written self-management plan; a patient-centered approach to care provided 
by a trained clinician; and direct access to services. One year after initiation of the intervention, self-
managing patients had made fewer hospital appointments without an increase in the number of 
primary care visits.  Self-reported relapses were fewer in the intervention group, but were 
unfortunately not confirmed by physician assessment or investigation. There were no differences 
between the intervention and control groups in IBDQ or HADS scores at the end of the study period.   
In a further study by Waters et al, 89 patients with IBD were randomized to either formal group IBD 
education in addition to standard care or to standard care alone (173). The education program was 
provided by a nurse practitioner over 4 weeks in 3-hour sessions, consisting of general information 
about gut and immune system anatomy and physiology, the pathophysiology of IBD, current and 
future treatments. At week 8, the education group had higher knowledge scores, perceived 
knowledge ratings and patient satisfaction. They showed a non-significant trend towards better 
medication adherence and lower healthcare use, but no difference in quality of life questionnaires; 
unfortunately, no details relating to IBD disease activity were shown.  
Bregenzer et al prospectively analysed the effects of an education program in 145 IBD patients: 73 
were allocated, on the basis of their distance from home to hospital, to receive 4 group education 
sessions (each session lasting 2 hours) and the other 72 patients to the control group (174). Each 
education session was carried out by specialists (gastroenterologists, surgeons, psychologists, social 
worker and nutrition advisor). The contents of the program included pathogenesis, diagnostic 
procedures and course of IBD; medical and surgical treatment; nutrition, social problems and support; 
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and finally stress management and coping with disease. IBD activity, measured using the CDAI or 
CAI (Colitis Activity Index) after 6 or 10 months, showed no differences between the 2 groups.  The 
educational program also had no effect on depression, quality of life and, surprisingly, disease-related 
knowledge. However, subjectively most patients were very satisfied with the education program 
reporting that it improved their ability to self-manage their IBD. 
Jaghult et al prospectively investigated whether an education programme could improve health 
related quality of life in 93 IBD patients. The intervention group attended a multi-professional 
education programme while the control group received regular information. Four questionnaires were 
used for measuring health-related quality of life. No significant differences were found when 
comparing the two groups at 6 months although the multi-professional education programme was 
highly appreciated by the patients (175). 
In a further study by Oxelmark et al, 44 patients with IBD were randomized to either formal group IBD 
education sessions or to standard care alone (173). The education program consisted of 9 sessions 
over a 3 month period, provided by a physician, nurses, dieticians, surgeons; of which 4 sessions 
incorporated group therapy provided by a medical social worker and psychotherapist.  The control 
group received conventional “on demand” medical and psychosocial/psychological treatment during 
the study period.  Although the group-based intervention program was highly appreciated, there were 
no significant differences in average quality of life (IBDQ) or coping (measured using the Sense of 
Coherence scale) at month 12 (176). 
Taken together, these studies suggest that a proportion of patients with IBD benefit in relation to 
health-related quality of life and mood disorders from a cognitive behavioural approach; 
psychodynamic psychotherapy and disease-specific education alone have little if any effect. Although 
the effects of all these interventions in ameliorating IBD appear disappointing, this could reflect the 
‘one-size fits all approach’ necessary for these interventions in randomized controlled trial design, as 
well as to the difficulties with trial methodology referred to above. 
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Table 1.7 Longitudinal studies evaluating the effect of education techniques in IBD. † Denotes randomized controlled studies (CD denotes Crohn’s disease; 
UC, Ulcerative colitis; CDAI, Crohns disease activity index; CAI, Colitis activity index;  Seo AI,  Seo Activity index; HADS, Hospital anxiety and depression 
scale; QOL, Quality of life;  ADS, General depression scale; IBDQ, Inflammatory bowel disease questionnaire; SF-36, social functioning 36 questionnaire; 
GLQI, Gastrointestinal life quality index; SOC, Sense of Coherence scale. 
Type of Intervention 
(follow up period) 
Patient Sample 
 
Baseline Effect of Intervention Reference 
IBD activity Mood status IBD Mood QOL 
Group 
8 sessions x 2-3 hours 
(6 months) 
26 CD 
23 UC 
 
Mixed  
active / inactive 
          _ No change 
(symptom 
score) 
 
No effect 
(HADS) 
 
No effect 
(IBDQ,  
SF-36) 
Larsson et al 2003 
(171) 
 Individual  
 1 session 
(1 year) 
92 CD:177 UC†   
Intervention 
139 CD:226 UC  
Control 
Mixed  
active / inactive  
          _ Improved self- 
reported 
relapse,   
reduced  
hospital 
outpatient 
attendances 
No effect 
(HADS)  
 
No effect (IBDQ) Kennedy et al 2004 
(172) 
Group 
4 sessions x 3 hours 
(8 weeks) 
31 CD:14 UC†  
Intervention 
26 CD:18 UC 
Control 
Mixed  
active / inactive  
Not measured 
 
No details 
(CDAI, Seo AI) 
 
         _ No effect (IBDQ) Waters et al 2005 
(173) 
Group 
4 sessions x 2 hours 
(10 months) 
40 CD:33 UC†  
Intervention 
49 CD:23 UC  
Control 
Mixed  
active / inactive  
Depression 
scale: normal 
range 
No effect 
(CDAI, CAI) 
No effect 
(ADS) 
No effect (GLQI) Bregenzer et al 
2005 (174) 
Group 
(6months) 
93 IBD 
Intervention/ 
Controls 
Remission - - - No effect Jaghult et al 2007 
(175) 
Group 
9 sessions 
 (12 months) 
24 IBD 
Intervention 
20 IBD 
Control 
Mixed  
active / inactive 
Coping  
(SOC) 
- No effect  
(SOC) 
No effects 
(IBDQ) 
Oxelmark et al 
2007 (176) 
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1.5.4 Anti-depressants 
The effects of psychoactive drugs on disease activity in IBD have not yet been properly evaluated.  
Anti-depressants are probably the most widely used treatment for depression but they are successful 
in relieving psychological symptoms in only about 30% patients (138, 177).  
Data from a single open label study of paroxetine (20-40mg) in 8 IBD patients with major depression 
treated for 8 weeks reported improvements in depression and social disability scores but not in IBD 
activity (178).  Uncontrolled case studies which report the use of bupropion in patients with CD have 
suggested improvement in symptom scores, measured using CDAI (179, 180).  In both instances, 
controlled trials are desirable; in the latter, design and results will need to take into account the effects 
of bupropion on discontinuation of smoking. 
A preliminarily reported randomized placebo-controlled double blind trial of imipramine 10mg/day 
(titrated to a maximum dose 50mg/day if tolerated) for 8 weeks in 50 patients with mild to moderately 
active left-sided or distal UC claimed to show that the antidepressant improved both disease activity 
measured using the Powell-Tuck score and mood status measured using the Hamilton depression 
score (181). However, the study was compromised by four aspects of trial design.  First, patients were 
randomized regardless of their mood status; at baseline the depression score was higher in the 
treated patients than in the controls.  Second, the tricyclic antidepressant used may have improved 
the Powell-Tuck score through a direct anticholinergic constipating effect. Third, details of the 
sigmoidoscopic or laboratory measures of disease activity were not reported.  Lastly, the dose of 
imipramine used was low, in the range frequently used for chronic pain and irritable bowel syndrome 
(182, 183) .  
1.5.5 Exercise 
Encouraging physical exercise is moderately effective in reducing stress and depression (184).  
Recent evidence suggests that a low intensity but not severe exhaustive exercise program may 
conceivably have a beneficial effect in patients with CD. 
In an uncontrolled pilot study to evaluate the effects of regular light-intensity exercise, 12 sedentary 
patients with inactive or mildly active CD were enrolled into a thrice-weekly, half-hour walking program 
for 12 weeks. Improvements were seen in the IBD stress index, IBDQ, and Harvey Bradshaw Simple 
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Index (185). Another Canadian group prospectively compared the effects of a similar low-intensity 
walking program and of no exercise on the quality of life of 32 patients with mildly active or quiescent 
CD. Patients in the exercise but not in the sedentary group experienced improvements in IBDQ, IBD 
Stress Index and Harvey-Bradshaw index after 3 months (186). 
 
1.6 HYPNOTHERAPY 
1.6.1 Historical perspective 
Franz Anton Mesmer, a Viennese physician, described “animal magnetism” in 1775.  Mesmer 
believed that there is an invisible animal magnetic force or fluid in the atmosphere which he could 
harness, store in his body, and transmit to physically ill patients with curative effects, leading to the 
derivation of the word “mesmerism”.   
Subsequently the term “hypnosis” (from the Greek “hypnos” meaning sleep) was coined by the 
Scottish surgeon, James Braid in 1843. It was in the late nineteenth century, when two French 
physicians, Ambroise Liebeault and Hippolyte Bernheim, built the structure of modern hypnotherapy 
(based on Braid’s principle of hypnotic induction by suggestion).  Their collaborative effort became 
known as the Nancy School of Hypnotism. At the same time, the French neurologist, Jean-Martin 
Charcot whilst working at the Salpêtriere in Paris sought to demonstrate hypnosis as similar to 
hysteria. Charcot's pupils looked for physical signs in the hypnotised person to explain the hypnotic 
phenomenon. 
1.6.2 Induction of trance 
Hypnotherapy is a technique by which a practitioner induces a temporary trance-like state in patients: 
while they are in this state, the practitioner then uses suggestion (Figure 1.3). During hypnotic 
induction, participants are given a series of instructions, which, if followed, assist in achieving a trance 
state. Hypnotic procedures are intended to encourage focussed attention, inattention to surroundings, 
and absorption in the inner mental world.  With practice, some people are able to enter the desired 
state very quickly, either spontaneously or by thinking through a hypnotic procedure. Hypnotic 
procedures are generally facilitated by encouraging the participant to be non-analytical in their 
52 
 
thinking, increasing the participant's motivation and willingness to actively involve themselves with the 
procedures, and raising participant's expectancies of a positive outcome. 
Hypnotic suggestion is used to influence what a participant is thinking or feeling, and it is widely 
acknowledged that many of the interesting effects associated with hypnosis are actually brought 
about by suggestion.  Suggestions differ from everyday kinds of instructions in that a 'successful' 
response is experienced by the subject as having a quality of involuntariness or effortlessness.  One 
widely held belief is that being in a 'hypnotic state' facilitates responsiveness to suggestion. 
Suggestions are often enhanced by appropriate imagery but can also be produced by direct 
suggestion without imagery (for example, relaxation: "You are becoming more and more relaxed as 
time goes by"). 
1.6.3 Hypnotherapy in medicine 
Hypnotherapy has been used successfully for many years as a treatment for psychological disorders.  
It has also been used in a variety of medical diseases which are believed to have a psychosomatic 
component and to be worsened by stress; these include hypertension, asthma, and eczema and 
psoriasis (187-191). 
1.6.4 Hypnotherapy in functional bowel disorders 
In relation to its use to date in irritable bowel syndrome and IBD (see below), the practitioner then 
uses suggestion to induce relaxation as well as beneficial modification of the way in which the patient 
experiences the gut working (i.e. gut-focussed hypnotherapy). In gastrointestinal disease, hypnosis 
was first shown to be effective in patients with refractory IBS (192) and later in functional dyspepsia 
(193), prevention of duodenal ulceration (194) and also non-cardiac chest pain (195). 
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Figure 1.3 The trance and suggestion elements of hypnosis (adapted from Hypnosis UK 2009) 
 
 
 
 
 
 
 
 
 
 
 
1.6.5 Mechanism of action of hypnotherapy in GI disorders 
The mode of action of hypnotherapy has not been fully elucidated.  In addition to psychological 
influences (196), there is evidence that hypnotherapy can influence gastrointestinal physiology, 
including motility, visceral sensation, immune function and central pain modulation.  In patients with 
IBS, distal colonic motility has been shown to be reduced by hypnotherapy (197).  Furthermore, the 
orocaecal transit time increased during hypnotic relaxation in healthy volunteers (198).  Gut-focussed 
hypnotherapy has also been shown to normalise rectal sensitivity in patients with IBS (199) and 
modulate gastric acid secretion (200).  Several reports have addressed the effects of hypnotherapy 
on the immune system.  Two studies found that self-hypnotherapy of students antagonised decreases 
in NK cell T-cell counts induced by the stress of examinations (201, 202); changes in CD3+, CD4+, 
CD8+ lymphocyte counts before exams were also reduced by self-hypnotherapy (201-203).  In our 
unit, the effects of one session of gut-focussed hypnosis on systemic and rectal mucosal inflammatory 
responses was assessed in 17 ulcerative colitis patients with active disease; it reduced serum IL-6 
concentration by 53%, circulating NK cell numbers by 18%, and at the rectal mucosal level, release of 
Suggestion 
Suggestions are instructions 
to experience the world in a 
certain way. A “successful” 
response is where the effect 
feels like it is happening all 
by itself (involuntariness) 
Hypnotic Trance 
A hypnotic “trance” is the end 
state of a hypnotic induction. 
An induction aids the focus of 
attention and often (but not 
necessarily) contains 
suggestions for relaxation 
Hypnotic suggestion 
Hypnotic suggestions are suggestions delivered in a 
hypnotic context (after a hypnotic induction). Many 
people respond better to suggestions while in 
hypnosis but it is important to remember that it is not 
necessary to deliver a hypnotic induction for 
suggestions to be effective 
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substance P by 81%, histamine by 35% and IL-13 by 53% (204).  In addition, brain imaging 
techniques have shown that the anterior cingulated cortex plays a role in hypnotic pain modulation 
(205). 
1.6.6 Hypnotherapy in inflammatory bowel disease 
There are anecdotal reports, but limited formal data, of the benefit of hypnotherapy in patients with 
IBD (Table 1.8).  In one unblinded study of 12 patients with active UC and Crohn’s disease, after 6 
weeks of gut-focussed hypnotherapy, there was a non-significant trend to improvement in IBDQ 
scores (206).  More recently, similar findings were reported in 8 women with inactive IBD, in whom 
there was significant improvement in IBDQ scores (207). 
Furthermore, a study of 15 IBD patients with either severe disease or disease refractory to 
corticosteroids received 12 sessions of gut-focussed hypnotherapy and were followed up for a mean 
of 5 years (208). 2 of the 15 failed to respond to hypnotherapy and required surgery. Of the remaining 
13, 4 were in remission, 8 had mildly severe and 1 moderately severe disease at the end of the study; 
improvements in quality of life were seen in 12 and most patients managed to stop corticosteroids.  
These small uncontrolled reports emphasize the need for controlled studies of the efficacy of 
hypnotherapy in IBD. 
More recently, in a paediatric study of 5 CD patients and 1 UC patient with active disease, older 
children received gut-focussed hypnotherapy whilst the younger children received therapy consisting 
of relevant stories, breathing techniques and imagery. Most of these patients had severe emotional 
stress. The children received between 4 and 12 sessions for a period of up to 3 months with no 
changes in other treatment modalities: they showed resolution of clinical symptoms and a decrease in 
inflammatory markers (209). 
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Table 1.8 Case histories and longitudinal studies evaluating the effect of hypnotherapy techniques in IBD. † Denotes randomized controlled study. (CD 
denotes Crohn’s disease; UC, Ulcerative colitis; IBD, Inflammatory bowel disease; CDAI, Crohns disease activity index; IBDQ, Inflammatory bowel disease 
questionnaire). 
Type of Intervention 
 
Patient Sample 
(& follow up) 
           Baseline                    Outcome Reference 
IBD activity Mood status  IBD  QOL  
Individual 
(No of sessions-unclear) 
1. Hypnotherapy 
IBD (Adult) 
2CD  
1 UC 
(1 year, unclear) 
Active Pt 1 Anger 
Pt 2.Anger 
Pt 3.Rage          
 
 Pt 1. “cured” in few wks 
Pt 2. Needed surgery 
Pt 3. Remission at 1 yr  
         - (210) 
Individual 
(Sessions-unclear, 6 months) 
1. Hypnotherapy 
2. Exercise 
3. IBD Support 
4. Immunosuppression (6-MP) 
1 UC (Adult) 
(4 yrs) 
Active Moderate 
depression 
 No significant flares for 
4yrs 
 
         - (211) 
Individual 
(Sessions-unclear, 6 weeks) 
1.Gut focused hypnotherapy 
12 IBD 
 
Active -  -  Improvement 
(IBDQ) 
(non-significant) 
(206) 
Individual 
(7 sessions over 3 months)  
1. Gut directed hypnotherapy 
    + Audiotape (self) 
IBD (Adult) 
4 CD 
4UC 
(12 months) 
Inactive -  -  Improvement 
(IBDQ) 
(207) 
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Individual 
(12 sessions) 
1. Gut focused hypnotherapy  
IBD (Adult) 
3 CD 
12 UC 
(5.4 yrs) 
 
Active 
(on 
corticosteroids) 
-  60% stopped steroids 
4 pts remission 
8 pts mild active 
1 pt moderately active 
2 pts no response  
 Improved  
 
(208)  
Individual 
(4-12 sessions over 3 months) 
 
1. Gut focused hypnotherapy 
2. Breathing techniques, imagery 
IBD (Paediatric) 
5 CD 
1 UC 
 
(unclear) 
Active Severe 
emotional 
distress 
 Improvement clinical 
symptoms 
 
Decrease in 
inflammatory markers 
  
  
         _ (209) 
Individual 
(12 sessions over 3 months) 
1. Gut focused hypnotherapy 
2 CD (Adults) 
 
(6 months) 
Inactive (pt1) 
 Active (pt2) 
 
Depression 
Significant 
depression 
 No change 
No change 
 No change 
No change 
(212) 
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1.7 SUMMARY 
Patients suffering with IBD vary dramatically in their psychological response to the illness: despite 
significant morbidity from their IBD, many appear heroically resilient. For those who develop or 
already have associated psychological stress or other mood disturbances, management should be 
holistic and, as far as possible, individualized; a cognitive behavioral approach is currently the best-
documented option. The reasons for the apparent under-provision of psychological support to patients 
with IBD are likely to include a failure by gastroenterologists to recognize the benefits in quality of life 
which can be achieved by addressing concurrent mood disorders, a lack of proof, as yet, of the 
benefits to IBD itself of most psychological treatments and, in the UK at least, a shortage of health 
care funding.  
 
Nevertheless, it is clear that at the same time as optimizing conventional treatment of their IBD, 
physicians should look out, and even formally screen for psychological stress and mood disorders in 
their patients.  They should be ready and able to offer patients therapies directed at improving their 
psychological state, even if such approaches have not yet been shown to reduce IBD activity.  At the 
very least, physicians should ensure that they have in place routes for prompt referral of their patients 
to colleagues with expertise in the management of psychological disorders.  What remains unclear is 
which of the wide range of available interventions is most appropriate for individual patients with IBD 
who have associated psychological illness.  
In this thesis we will address the following: firstly, smoking in IBD, in particular a comparison in 
Crohn’s disease and UC of patients’ knowledge of the effects of smoking and their level of nicotine 
dependence; secondly, the prevalence of mood disorders and stress in patients with patients with 
acute severe ulcerative colitis (ASUC); thirdly, the effects of psychotherapy given by a counsellor 
specially trained in IBD on the course of IBD in outpatients; and finally, a clinical trial of hypnotherapy 
for the prevention of relapse in patients with UC. 
.   
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CHAPTER 2: HYPOTHESES 
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The following hypotheses are tested in this thesis. 
 
1)  In patients with IBD:  (1) poor knowledge of the effects of smoking on their disease and/or (2) 
high nicotine dependence explain the higher prevalence of smoking in CD than UC. 
 
2)  In acute severe UC (ASUC):  (1) anxiety, depression and stress are more common in acute 
severe ulcerative colitis (ASUC) than in patients with inactive UC; (2) anxiety, depression and 
stress are more common in patients presenting for the first time with UC; (3) anxiety, depression 
and stress worsen outcome in ASUC. 
 
3)  The natural history of IBD can be altered by psychotherapy given by a counsellor specially 
trained in the management of IBD-related psychological problems. 
 
4)  Gut-focussed hypnotherapy reduces the relapse rate in patients with inactive UC after withdrawal 
from a thiopurine. 
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CHAPTER 3: TOBACCO DEPENDENCE AND AWARENESS OF HEALTH RISKS OF SMOKING IN 
PATIENTS WITH INFLAMMATORY BOWEL DISEASE 
 61 
 
SUMMARY 
 
 It is widely believed, and reported by many smokers, that cigarette usage helps relieve 
psychological stress. 
 We hypothesised that (1) poor knowledge of the effects of smoking on their disease and/or (2) 
high nicotine dependence would explain the higher prevalence of smoking in CD than UC.  
 We therefore assessed: firstly, the prevalence of smoking; secondly, patients’ awareness of 
the effects of smoking; and finally nicotine dependence in IBD patients compared to healthy 
and disease-matched controls. 
 246 consecutive IBD outpatients completed a questionnaire on smoking habits and its effect 
on IBD.  Smokers were assessed for dependence using the Fagerstrom Test for Nicotine 
Dependence (FTND) score and their results compared to those of age, sex and ethnicity-
matched healthy and asthma controls attending a smoking cessation clinic.  
 Patients with CD were better informed about the effects of smoking on their own disease than 
UC patients but there was no association between patients’ knowledge and their smoking 
behaviour. Nicotine dependence was similar in CD and UC patients; in IBD patients as a 
whole it was lower than in smokers’ clinic clients and comparable to that of the general 
population.  Their low nicotine dependence suggests that most IBD patients could be weaned 
off smoking successfully in the IBD clinic and referral to a smoking cessation clinic offered to 
the minority who are highly dependent and others expressing interest in attending.  
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3.1 INTRODUCTION & AIMS 
As outlined in chapter 1, the association between smoking and IBD was first made more than 25 
years ago (213, 214).  Smoking has been implicated as a risk factor for developing CD and worsens 
its outcome (39, 215). Conversely, the onset of UC may be triggered by smoking cessation and 
nicotine patches are themselves effective in patients with active disease (39).   
In view of the adverse effects of smoking in CD, and on health in general, it is generally agreed that 
all patients with IBD should be advised to stop. As discussed in chapter 1, the factors influencing 
successful smoking cessation include awareness of the harmful effects of tobacco, and the severity of 
nicotine dependence (216, 217). Although smoking has been shown to affect the course of CD 
adversely, patients report the use of smoking as a way of relieving stress (67). 
 
3.2 HYPOTHESES & AIMS 
We hypothesise that: 
(1) poor knowledge of the effects of smoking on their disease and/or  
(2) high nicotine dependence would explain the higher prevalence of smoking in CD than UC.   
To test these hypotheses, we first assessed the prevalence of smoking in our IBD patients, expecting 
that it might be lower than in some earlier reports (38, 44, 45). We also assessed patients’ awareness 
of the effects of smoking on their type of IBD.  Lastly, we compared the nicotine dependence of our 
smoking IBD patients with that of the general population (66) and of people attending a smoking 
cessation clinic, speculating that high nicotine dependence in patients with CD might adversely affect 
their ability to give up smoking. 
 
3.3 METHODS  
3.3.1 Patients and methods 
331 consecutive patients with an established diagnosis of IBD (218) confirmed by conventional 
endoscopic, histological and radiological features attending our outpatient IBD clinic over 6 weeks in 
November 2008 - January 2009, were issued a questionnaire on smoking habits and its effect on IBD 
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(Appendix 1.1).  246 patients (173 CD, 73 UC) returned the completed questionnaire (response rate 
74.3%).  In the questionnaire, patients were asked their current smoking status; ex-smokers were 
asked when they stopped smoking in relation to their diagnosis and whether this was due to advice 
from their physician.  All IBD patients were asked whether smoking made their type of IBD better, 
worse or had no effect. 
Smokers were assessed for nicotine dependence using the Fagerstrom Test for Nicotine Dependence 
(FTND) (219) (Table 3.1).  FTND is a validated and widely used measure of nicotine dependence in 
patients; it is a revision of the original Fagerström Tolerance Questionnaire devised in 1978 (220). 
The FTND score ranges from 0-10 (0-2 very low, 3-4 low, 5 medium, 6-7 high, 8-10 very high 
dependence). 
To check whether smoking habits were markedly different in the 85 patients who did not complete the 
questionnaire, we assessed the prevalence of smoking in patients who did not respond using their 
case records, and when necessary by a telephone conversation with the patient. 
From our Smoking Cessation Clinic database, we firstly obtained 210 healthy controls (5 subjects for 
each smoker with IBD) and secondly 44 asthma controls (1 subject for each smoker with IBD) each 
matched for age, sex and ethnicity to one of the group of smoking IBD patients who responded to the 
questionnaire.  The smoking behaviour of IBD patients was also compared with the 2008/09 United 
Kingdom (UK) population data from the Office of National Statistics (66). 
In addition, the phenotype of the patient was documented using the Montreal classification (3) 
(Appendix 1.2)  based on the most recent conventional endoscopy (gastroscopy and 
ileocolonoscopy), histology and radiological investigations (barium follow through, MR and/or CT 
abdomen) prior to their clinic attendance.  This, together with the use of immunosuppression 
(thiopurine, methotrexate or anti-TNF therapy) and surgical intervention was related to smoking 
status.  Surgery for CD was defined as any intra-abdominal or perianal procedure, the latter including 
fistula surgery or the drainage of peri-anal sepsis.  For UC, surgery was defined as colectomy. 
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Table 3.1 The Fagerstrom Test for Nicotine Dependence (FTND) (219). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
How soon after you wake up do you smoke 
your first cigarette? 
Within 5 mins 3 
6-30 mins 2 
31-60 mins 1 
> 60mins 0 
Do you find it difficult to stop smoking in no 
smoking areas? 
Yes 1 
No 0 
Which cigarette would you hate most to give 
up? 
The first of the morning 1 
Any other 0 
How many cigarettes per day do you usually 
smoke? 
10 or less 0 
11-20 1 
21-30 2 
30 or more 3 
Do you smoke more frequently in the first 
hours after waking than during the rest of the 
day? 
No 0 
Yes 1 
Do you smoke if you are so ill that you are in 
bed most of the day? 
No 0 
Yes 1 
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3.3.2 Statistical analysis 
Differences between the IBD patients and their controls were sought in categorical data using Chi 
squared test or Fisher exact test and in continuous data using Wilcoxon signed rank (for comparing 
patients and their matched controls) or Mann Whitney U and Kruskal-Wallis tests (for comparing 
unpaired data).  Outcome measures are shown as median values (ranges).  Analysis was performed 
using GraphPad Prism (version 4.0) and SPSS (version 17.0) statistical software.  
3.3.3 Ethical Considerations 
This study was designed to assess a clinical service and did not require formal ethical approval, 
according to UK National Research Ethics Service (NRES) guidelines (221). 
 
3.4 RESULTS 
3.4.1 Smoking prevalence 
Of the 246 IBD patients completing the questionnaire, 35 of 173 (20%) with CD and 9 out of 73 (12%) 
with UC were current smokers (p=0.15).  Of the remaining 138 CD patients, 86 (50%) had never 
smoked and 52 (30%) were ex-smokers (Table 3.2).  At diagnosis, the prevalence of smoking in CD 
was 67 of 173 (39%). Of the 52 ex-smokers with CD, 20 had stopped smoking prior to being 
diagnosed.  The remaining ex-smoking 32 CD patients, with disease duration of 8.5 (1-41) years, 
stopped smoking 4 (1-35) years after their original diagnosis, 19 (59%) as a result of advice from their 
physician.  
Likewise, in UC 36 (49%) patients had never smoked, with the remaining 28 (38%) being ex-smokers 
(Table 3.2).  Of 18 of these UC ex-smokers, 10 stopped smoking 3 (1-15) years prior to their 
diagnosis.  
The prevalence of smoking in the 85 patients who did not respond to the questionnaire was lower 
than in the study population; 3 of 38 (7.9%) CD and 4 of 47 (8.5%)  UC patients who did not complete 
the questionnaire were current smokers.  Of the remaining non-responders, 10 (28%) CD and 7 
(15%) UC patients were ex-smokers. 
IBD phenotype and previous course in non smokers, ex-smokers and smokers  
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As shown in Table 3.2, the phenotype of CD differed with regards to age at diagnosis with ex-smokers 
being significantly older at diagnosis than never-smokers and smokers; this difference persisted when 
comparing the 20 ex-smokers who stopped prior to diagnosis to the 67 patients who smoked at 
diagnosis (i.e. 35 current and 32 ex-smokers who gave up after diagnosis) and the 86 never smokers.  
There were no significant differences in location and behaviour of disease including peri-anal 
involvement, in the use of immunosuppression or surgery between those patients who had never 
smoked, ex-smokers and current smokers.  In the patients with UC patients, ex-smokers were 
significantly older at diagnosis; however, smoking status was not related to the extent of disease, the
use of immunosuppression or the need for colectomy (Table 3.2). 
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Table 3.2 Demographics and smoking habits of IBD patients. 35 of 173 (20%) with CD and 9 out of 73 (12%) with UC were current smokers.  The phenotype 
of CD differed with regards to age at diagnosis with ex-smokers being older at diagnosis than never-smokers and smokers; however there were no significant 
differences in location and behaviour of disease including peri-anal involvement, in the use of immunosuppression or surgery between those patients who had 
never smoked, ex-smokers and current smokers.  In the patients with UC, ex-smokers were significantly older at diagnosis; however, smoking status was not 
related to the extent of disease, the use of immunosuppression or the need for colectomy 
P value for the differences between those patients who have never smoked, ex-smokers and current smokers calculated using the Chi squared test and 
Kruskal-Wallis.  5 ASA, 5-aminosalicylate, Anti-TNF, anti-tumour necrosis factor (infliximab, adalumimab).  * Previous surgery for UC = colectomy. 
 
 Crohn’s disease (n=173) 
 
 Ulcerative colitis (n=73)  
 Never Smoked 
(n=86) 
Ex-smokers 
(n=52) 
Current Smokers 
(n=35) 
P value Never Smoked 
(n=36) 
Ex-smokers 
(n=28) 
Current Smokers 
(n=9) 
P value 
Age at testing 
(median (range) yrs) 
34 (18-90) 46 (21-78) 36 (20-71) 0.007 36 (18-64) 50 (25-71) 35 (21-54)) 0.14 
Disease duration 
(yrs) 
12 (1-53) 10 (1-41) 10 (1-46) 0.29 6 (1-54) 6 (1-39) 7 (3-27) 0.97 
Age at diagnosis 
(yrs) 
- - - - 25 (7-61) 34 (14-66) 25 (13-49) 0.03 
Male (no of patients) 44 (51%) 22 (42%) 16 (46%) 0.59 22 (61%) 16 (57%) 6 (67%) 0.81 
Ethnicity 
   Caucasian 
    Asian 
    Afro-Caribbean 
    Oriental 
 
66 (77%) 
12 (14%) 
8   (9%) 
 
47 (90%) 
2   (4%) 
3   (6%) 
 
30 (86%) 
5   (14%) 
0 
 
0.11 
 
 
21 (58%) 
12 (33%) 
2   (6%) 
1   (3) 
 
26 (93%) 
2  (7%) 
0 
0 
 
5 (56%) 
3 (33%) 
1 (11%) 
0 
 
0.07 
Age at diagnosis 
   A1. <17 
 
24 (28%) 
 
6   (11%) 
 
5   (14%) 
 
0.0008 
 
- 
 
- 
 
- 
 
- 
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   A2. 17-40 
   A3. >40 
55 (64%) 
7   (8%) 
29 (56%) 
17 (33%) 
26 (74%) 
4   (11%) 
Location 
   L1. Ileal 
   L2. Colonic 
   L3. Ileo-colonic 
   L4. Upper GI 
 
21 (24%) 
18 (21%) 
47 (55%) 
7   (8%) 
 
17 (33%) 
6   (12%) 
29 (56%) 
2   (4%) 
 
13 (37%) 
4   (11%) 
18 (51%) 
2   (6%) 
 
0.39 
 
 
0.65 
 
- 
 
- 
 
- 
 
- 
Behaviour 
   B1. Inflammatory 
   B2. Stricturing 
   B3. Penetrating 
   P. peri-anal 
 
40 (47%) 
25 (29% 
21 (24%) 
31 (36%) 
 
21 (40%) 
16 (31%) 
15 (29%) 
12 (23%) 
 
14 (40%) 
14 (40%) 
7   (20%) 
8   (23%) 
 
0.73 
 
 
0.29 
 
- 
 
- 
 
- 
 
- 
Extent 
   Proctitis 
   Left 
   Total 
 
- 
 
- 
 
- 
 
- 
 
5   (13%) 
9   (25%) 
20 (55%) 
 
1  (3%) 
8  (28%) 
19 (67%) 
 
0 
2  (22%) 
7  (78%) 
 
0.45 
Medication 
   5 ASA 
   Steroids 
   Thiopurine /    
   Methotrexate 
   Anti-TNF 
 
46 (54%) 
6   (7%) 
49 (57%) 
 
18 (21%) 
 
23 (44%) 
2   (4%) 
23 (44%) 
 
5   (10%) 
 
14 (40%) 
2   (6%) 
16 (46%) 
 
6   (17%) 
 
0.33 
0.78 
0.28 
 
0.23 
 
27 (75%) 
2   (6%) 
15 (42%) 
 
0 
 
24  (85%) 
4    (14%) 
14   (50%) 
 
0 
 
5  (55%) 
0  (0%) 
6  (66%) 
 
1  (11%) 
 
0.27 
0.59 
0.46 
 
0.03 
Previous Surgery* 
  No of operations  
  (median (range)) 
43 (50%) 
0 (0-5) 
34 (65%) 
1 (0-3) 
20 (57%) 
1 (1-4) 
0.73 
0.38 
2  (6%) 
- 
 
4 (14%) 
- 
 
3  (33%) 
- 
0.08 
- 
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3.4.2 Knowledge of the effects of smoking 
 
Patients with CD were better informed about the effects of smoking on their own disease than were 
UC patients. 90 of the 173 (52%) CD patients knew that smoking worsens CD, whereas only 15 of the 
73 (21%) UC patients knew of the beneficial effects of smoking on their disease (p=0.03).  Knowledge 
was unrelated to smoking status in either CD or UC (p=0.82, p=0.54 respectively).  Furthermore, in 
CD there no difference in knowledge between the current smokers (19 out 35 (54%)) and the ex-
smokers (19 out of 32 (59%)), who stopped smoking after diagnosis (p=0.81). 88% CD smokers 
stated that they were interested in stopping smoking and 33% would consider attending a smoking 
cessation clinic. 
3.4.3 Smoking dependency 
 
In both CD and UC, the FTND scores were significantly lower than in healthy and asthma controls 
(p<0.0001) attending the smoking cessation clinic (Table 3.3).  Only 7 of the 35 (20%) CD patients 
were highly dependent (FTND score ≥ 6).  There was no difference in FTND dependence scores 
between CD and UC patients (p=0.16).  In CD, patients’ awareness of the adverse effects of smoking 
was no different in those highly (FTND score ≥ 6) than those less dependent (FTND score ≤ 5) 
(p=1.0).  The number of cigarettes smoked per day in CD (8 (1-20)) was lower than in healthy (20 (2-
50)), (p<0.0001) and in asthma controls (20 (2-40)) attending the smoking cessation clinic (p<0.0001).  
Similarly, the number of cigarettes smoked per day was again less in UC (5 (2-15)), than in healthy 
(20 (5-40)) and asthma controls (20 (5-35)) (p<0.004, p=0.002, respectively).   
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Table 3.3. Smoking dependence in IBD patients.  
In both CD and UC, the FTND scores were significantly lower than in healthy and asthma controls 
attending the smoking cessation clinic. The Fagerstrom test for nicotine dependence is shown (both 
median (range) and mean (standard deviation) for ease of comparison to other studies). P values for 
the differences between CD or UC patients and their corresponding healthy or asthma smoking clinic 
controls, respectively, calculated using the Wilcoxon signed rank test (2-tailed).   
 
 
Fagerstrom Test for Nicotine Dependence (FTND) score  
 
IBD patients 
 
Healthy controls 
 
Asthma Controls 
 
Crohn’s Disease (n=35) 
Median     3 (0-8) 
Mean        2.69 (2.36) 
    
       7 (2-10)    (p<0.0001)  
       6.81 (1.77) 
 
     6 (2-9)   (p<0.0001) 
      6.17 (1.87)  
 
Ulcerative Colitis (n=9) 
Median     1 (0-4) 
Mean        1.33 (1.66) 
   
       6 (2-10)    (p<0.004) 
       6.26 (1.94) 
 
      7 (4-10)       (p<0.004) 
      7.11 (2.15) 
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3.5 DISCUSSION  
 
3.5.1 Smoking Prevalence 
 
The prevalence of current smoking (20%) in our CD patients was lower than previously reported (26-
49%) (47, 50, 68, 222), but comparable to that of the general UK population (22% in 2008/9) (66).  
Similarly, the prevalence of smoking at diagnosis (39%) was towards the lower end of results from 
previous studies (33-55%) (37, 38, 44-47).  Recently, Van der Heide et al reported smoking habit in a 
cohort of 380 CD patients over a 10 year period; at diagnosis, the prevalence of smoking was 52% in 
1995  but 10 years later, only 26% of patients still smoked (47); a trend similar to the findings in our 
study.  
In our UC patients, the prevalence of current smoking was also low at 12%, comparable to figures 
reported in an early UK study (8%) (213) and the recent Dutch study (10%) (47), but much lower than 
in a very recent Greek one (25%) (68) and than in the general population (22%) (66).  
There may be several reasons for the low prevalence of current smoking seen in our patients with 
CD.  Firstly, over the last decade there has been increasing education of patients in clinics provided 
by physicians and IBD nurse specialists, in parallel with the growing evidence of the adverse effects 
of smoking in CD.  Secondly, the overall prevalence of smoking in the general population in the UK 
has fallen from about 35% in 1982, to 22% in 2008/9 (66), the latter coinciding with the smoking ban 
in public places in 2007; it is likely that societal factors influenced patients with CD as they have the 
rest of the population. 
3.5.2 Disease phenotype and course 
 
The effects of smoking on phenotype and disease progression in CD have been widely investigated 
previously (37, 41, 45, 51, 52).  Although this study was not designed to assess the influence of 
smoking status on IBD phenotype or course, we have shown that at diagnosis ex-smokers were older 
than never or current smokers, an observation which has previously been reported (37) and may 
reflect a promoting effect of smoking on the development of CD in predisposed individuals.  In our 
study, unlike in others (37, 41, 45, 51, 52), smokers with CD showed no differences from never 
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smokers with respect to disease location, behaviour or need for immunosuppression or surgery.  Our 
negative findings findings may reflect not only our study design and a type II statistical error related to 
the low prevalence of smoking in our study, but also the low cigarette consumption and nicotine 
dependence of our patients. 
In UC, smoking has been reported by some (54, 55, 57, 58), but not all authors (223) to delay the 
onset, to reduce the need for hospitalisation, oral steroids and colectomy, and to be associated with 
less proximal extension of distal colitis than occurs in non-smokers.  Apart from a delayed onset seen 
in ex-smokers, we again failed to confirm the earlier observations, possibly for the same reasons as 
for our CD patients. In addition, the delayed onset in ex-smokers may reflect the protective effect of 
smoking in those with a genetic predisposition to the development of UC. 
3.5.3 Knowledge of the effects of smoking 
 
We had hypothesised originally that low levels of knowledge about its effects on their disease would 
be one factor contributing to a high prevalence of smoking in patients with CD. Indeed, in a study 
published in 1996, only 2/51 general practitioners and 13/102 patients were aware of the adverse 
effects of smoking in CD (69), and while in a more recent report, less than 10% of 312 patients with 
CD recognised that smoking increases the risk of development of CD and 12% of re-operation (70).   
In contrast to our expectations, in our study we have shown that most patients with CD (52%), 
independent of their smoking status, are aware of the adverse effects of smoking on their disease.  
This may be a result of disease education in the clinic provided by physicians (who have become 
increasingly aware themselves of the expanding literature), wider access to the internet and education 
provided by support organisations, such as Crohn’s and Colitis UK (formerly the National Association 
of Crohn’s and Colitis).  Knowledge of its risks to health is stated by smokers to be a major motivating 
factor in discontinuing the habit (66), and may explain in part the relative low prevalence of smoking in 
our CD population.  Indeed, in our study more smokers (88%) with CD were interested in stopping 
smoking than in the general population (67%) (66).   
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3.5.4 Nicotine dependence 
 
This is the first study to compare nicotine dependence in IBD patients with that in controls attending a 
smoking cessation clinic.  We had expected that high levels of nicotine dependence would be found in 
smokers with IBD, especially those with CD who were aware of its adverse effects on their disease. In 
fact, low nicotine dependence was seen in both our CD and UC patients compared to healthy and 
disease controls attending a smoking cessation clinic.  FTND scores in our IBD patients were in 
keeping with those of smokers in the general population, who in a large recent English study had a 
mean FTND of 3.1 (67), and in a recent study across 13 countries, had FTND scores of 2.8-4.6 (224). 
Similarly, a Canadian study reported low nicotine dependence (FTND<3) in 24%, moderate (FTND 3-
5) in 43% and high in 33% of patients with CD, a profile of dependence resembling that of the USA 
population (222). Very recently, mean FTND scores in Greek patients with CD were 4.46 (±0.47, SE) 
and with UC 2.93 (±0.42), but no control data were quoted (68). 
 
3.5.5 Limitations 
 
We do not have data on our patients’ education level and cannot therefore draw any conclusions 
about the relation between this factor and their knowledge about smoking and Crohns, or nicotine 
dependence. Furthermore, our interrogation of patients about their knowledge of its effects on IBD 
was limited. 
 
The socioeconomic status of patients was not assessed in this study, which may be useful tool to 
further assess nicotine dependence and smoking cessation in IBD patients.  The probability of 
abstinence of smoking after receiving cognitive behavioural therapy and nicotine patches in smokers 
has been shown to be greater in those with a higher socioeconomic status (225). In addition, smokers 
with higher income have been reported more likely to intend to quit smoking (226).  
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3.6 CONCLUSIONS 
 
This study of IBD patients’ smoking habits demonstrates that a smaller proportion of CD patients 
continue to smoke than has been reported previously.  However, contrary to our hypothesis, patients 
with CD who smoke, do so despite recognising the detrimental effects of smoking on their disease.  
This is not explained by nicotine dependence which in our IBD patients is lower than in smokers’ clinic 
clients and comparable to that of the general population.   
Why patients who know the risks incurred by smoking, and who are not highly nicotine dependent 
continue to smoke is unclear. One speculative explanation might be that psychological stress 
contributes to their smoking habit (67), but unfortunately we did not assess this, or other mood 
characteristics, in this study. The level of interest in smoking cessation in our patients with IBD is high.  
Their knowledge about the risks to health of smoking and their low nicotine dependence suggests that 
most IBD patients could be helped to stop smoking successfully in the IBD clinic without specialist 
treatment. It would seem sensible to recommend smoking cessation to all patients, and consider a 
referral to a smoking cessation clinic to those highly dependent or expressing interest in this 
approach.
 75 
 
CHAPTER 4: ANXIETY AND PSYCHOLOGICAL STRESS IN ACUTE SEVERE ULCERATIVE 
COLITIS: PREVALENCE AND EFFECT ON OUTCOME 
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SUMMARY 
 
 There is increasing evidence that psychological stress and associated mood disorders are 
linked with, and adversely affect the course of IBD. In this study we assessed whether stress 
anxiety and depression are more common in, and worsen outcome in acute severe ulcerative 
colitis (ASUC). 
 39 patients with ASUC requiring hospital admission and intravenous (iv) hydrocortisone with a 
Baron’s sigmoidoscopic score ≥2, completed questionnaires to assess anxiety (Hospital 
Anxiety & Depression Score (HADS-A and HADS-D)) and stress levels (Perceived Stress 
Questionnaire). Outcomes were assessed using the Travis criteria (day 3) and colectomy 
rates at day 70, in relation to upper and lower tertiles of the anxiety, depression and stress 
scores. 
 Although stress and depression scores were similar, anxiety levels were higher in the 11 
newly presenting ASUC patients. 
 Patients with ASUC had higher stress and depression levels than 27 patients with inactive UC 
but there was no difference in anxiety scores. There was no difference in those responding to 
iv hydrocortisone (by Travis criteria) or in day 70 colectomy rates between patients who were 
highly anxious or highly stressed compared to those less anxious or stressed. 
 
 Perceived stress levels are greater in patients with ASUC than in those in remission and 
anxiety scores are highest in patients newly presenting with UC, but neither stress, anxiety 
nor depression influence disease outcome. 
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4.1 INTRODUCTION 
UC is characterised by periods of relapse and remission, about 50% of patients having a relapse in 
any year (227). Severe exacerbations of UC are classically manifest as six or more bloody stools per 
day, with one or more of: temperature greater >37.8
o
C, heart rate>90 bpm, haemoglobin <10.5g/dl or 
an erythrocyte sedimentation rate (ESR) >30mm/h (228). 
Patients with severe attacks need admission to hospital, where the mainstay of treatment is 
intravenous steroids. Seventy percent of patients treated with intravenous steroids have a clinical 
response (229), while the remainder need second line treatment; options include ciclosporine, 
infliximab and surgery. The Travis score (24 hour stool frequency and serum C-reactive protein 
concentration) measured on the third day of intravenous steroid treatment has a central prognostic 
role: there is an 85% chance of the patient needing colectomy (or second-line drug treatment) if the 
number of stools passed daily exceeds 8, or the number of stools passed daily is between 3 -8 
together with a serum CRP is >45 mg/L (230).  
As indicated in chapter 1, there is increasing evidence that psychological stress and associated mood 
disorders are linked with, and adversely affect the course of IBD.   
 
4.2 HYPOTHESES 
In this study we hypothesised that:  
1) anxiety, depression and stress are more common in acute severe ulcerative colitis (ASUC) than in 
patients with inactive UC 
2) anxiety, depression and stress are more common in patients presenting for the first time with UC 
3) anxiety, depression and stress worsen outcome in ASUC in that they will make patients less likely 
to respond to steroids and hence more likely to need second line medical therapy or colectomy. 
 
4.3 METHODS 
Study design: 
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This was a 4-centre (Barts and the Royal London NHS Trust, University College Hospitals NHS 
Foundation, Guy’s and St Thomas’ NHS Foundation Trust and West Middlesex University Hospital 
NHS Trust) prospective study, during the period Jan 2008 – April 2010.  
There were 3 studies, one to assess the association between patients’ psychological state and 
disease activity, one to assess its association with a new diagnosis of UC, and one to assess its 
impact on disease outcome in ASUC: 
Study 1: ASUC vs Inactive UC (cross sectional). 
Study 2: New diagnosis ASUC vs ASUC in those previously diagnosed with UC (cross sectional). 
Study 3: Outcome of patients with ASUC (longitudinal). 
4.3.1 ASUC patients 
Inclusion criteria: 
Inpatients (aged 16-75) with existing UC or first presentation of UC, diagnosed by standard clinical, 
radiological and pathological criteria (218), suffering an acute severe flare of their colitis.  ASUC was 
defined by patients with a stool frequency > 8 on the day of presentation requiring hospital admission 
and iv hydrocortisone with a Baron’s sigmoidoscopic score ≥ 2 (231).  The Baron’s sigmoidoscopic 
score, as shown in Table 4.1, incorporates a range between 0-3: a score of < 2 represents inactive 
colitis whilst scores of ≥ 2 indicate active disease. 
Exclusion criteria: 
Patients were excluded if their stool culture or clostridium difficile toxin was positive.  
Clinical intervention 
Patients were treated with intravenous steroids in the conventional manner (hydrocortisone 100mg 
qds iv) with their gastroenterologist overseeing their care in the standard way: the attending 
physicians were unaware of the stress and mood score results.  All patients were given prophylactic 
sc low molecular weight heparin. Written informed consent was obtained. 
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Table 4.1 Baron’s sigmoidoscopic score for assessment of UC (231). 
Score Mucosal Appearance 
 
0 Normal 
 
1 Loss of vascular pattern (oedema) but no bleeding 
 
2 Friable, bleeding to light touch 
 
3 Ulcerated and or spontaneously haemorrhagic 
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Clinical assessment of disease and activity: 
Data on disease duration and extent, duration of current relapse, maintenance therapy, Baron 
sigmoidoscopic score (231), daily stool frequency, C-reactive protein (CRP) and p-ANCA was 
recorded. 
Measurements of anxiety and stress – psychometric questionnaires: 
Within 24 hours of admission each participant completed questionnaires to assess stress levels using 
the Perceived Stress Questionnaire (Recent, R-PSQ, General, G-PSQ) (115) and also anxiety and 
depression (Hospital Anxiety & Depression Score (HADS-A and -D)) (232). 
The perceived stress questionnaire is a validated questionnaire, devised by Susan Levenstein et al 
(233), to measure psychological stress.  It consists of two identical 30 question questionnaires: 
recent, in which the statements used apply to the last month, and general, in which used statements 
apply to the last two years (Appendix 1.3). The score for both recent and general stress levels were 
stated as the PSQ index ranging from 0 (non-stressed) to 0.99 (highly stressed).  In a study of 
outpatients with quiescent UC, those in the upper tertile on the basis of their general perceived stress 
questionnaire (G-PSQ) score, had a greater rate of subsequent relapse (115). 
The widely used HADS questionnaire consists of a 14 question validated questionnaire, developed to 
measure anxiety and depression in the hospital setting (Appendix 1.4) (232, 234).  The anxiety and 
depressive subscales are also valid measures of severity of the emotional disorder.   Each item is 
answered by the patient on a four point (0–3) response category so the possible scores range from 0 
to 21 for anxiety and 0 to 21 for depression.  A score of 0 to 7 is regarded as being in the normal 
range, a score of 11 or higher indicating probable presence of the mood disorder and a score of 8 to 
10 being just suggestive of the presence of the respective state (235). 
4.3.2 Inactive UC patients 
Inclusion criteria: 
Outpatients with UC (aged 16-75) diagnosed by standard clinical, radiological and pathological 
criteria, with inactive disease. Inactive disease was defined as patients in clinical remission for >3 
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months together with a Baron’s sigmoidoscopic score of < 2 (Table 4.1)  (231) and a Simple Clinical 
Colitis Activity Index (SCCAI) of < 3 (Table 4.2) (236). The Simple Clinical Colitis Activity Index, 
consisting of scores for five clinical criteria (Table 4.2), has been validated as a  measure of clinical 
activity; a score of < 3 represents clinical remission (236). It has been shown to have a highly 
significant correlation with the Powell-Tuck Index (r=0.959, p<0.0001) which also incorporates 
sigmoidoscopy (236, 237).  
Exclusion criteria: 
Patients were excluded if there was a change in UC medication in the previous 3 months or if they 
were currently using topical therapy (5-ASA or steroid).  
4.3.2 Outcome measures 
4.3.2.1 Study 1: ASUC vs Inactive UC  
The psychometric scores (HADS-A & D and PSQ-R & G) of the ASUC patients were compared to 
those of the 27 outpatients with inactive UC. 
4.3.2.2 Study 2: ASUC (new diagnosis vs previously diagnosed) 
The psychometric scores (HADS-A & D and PSQ-R & G) of the newly diagnosed ASUC patients were 
compared to those with ASUC previously diagnosed. 
4.3.2.3 Study 3: ASUC (clinical outcomes) 
Clinical response was assessed after 3 days of intravenous steroids. Non-responders were defined as 
those patients whose bowel frequency was >8/day or CRP>45 mg/L, according to the Travis’ criteria 
[3]. Use of second line medical therapy (ciclosporine/infliximab) and colectomy rate at day 70 was 
recorded  
Using a similar design to that of Levenstein et  al (115), we compared clinical outcomes, using the 
Travis criteria (day 3) and colectomy rates at day 70, between patients with  anxiety, depression and 
stress scores in the upper and lower tertiles.  
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Table 4.2 The Simple Clinical Colitis Activity Index 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Symptom Score 
Bowel Frequency (day) 
  1-3 
  4-6 
  7-9 
  >9 
 
0 
1 
2 
3 
Bowel frequency (night) 
  1-3 
  4-6 
 
1 
2 
Urgency of defaecation 
  Hurry 
  Immediately 
  Incontinence 
 
1 
2 
3 
Blood in stool 
  Trace 
  Occasionally frank 
  Usually frank 
 
1 
2 
3 
General well being 
  Very well 
  Slightly below par 
  Poor 
  Very poor 
Terrible 
 
0 
1 
2 
3 
4 
Extracolonic features 1 per manifestation 
Total Score  
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4.3.3 Statistics 
The study population was divided into three tertiles on the basis of their Perceived Stress 
Questionnaire (PSQ-R &G) results.  The proportions of patients who responded to intravenous steroid 
therapy in the most ‘stressed’ upper tertile was compared with the response rate in the lower tertile 
and analysed by chi-squared analysis. Similar analyses were undertaken for the HADS-A and HADS-
D questionnaires. 
We calculated that a sample size of 69 patients (23 in the low-stress tertile and 23 in the high-stress 
tertile, with the middle tertile being excluded in this analysis) would enable us to detect a clinically 
important difference of 40% (estimating an 80% response rate in the low-stress group and 40% in the 
highly stressed group) in the response rate to intravenous steroids, with power 80% and P=0.05 
(238). 
Differences between the ASUC patients according to psychological tertiles and between their inactive 
UC controls were sought in categorical data using Chi squared test or Fisher exact test and in 
continuous data using Mann Whitney U test. All P values were 2-tailed.  Outcome measures are 
shown as median values (ranges).  Analysis was performed using GraphPad Prism (version 5.0, San 
Diego, California) and SPSS (version 17.0) statistical software. 
4.3.4 Ethical considerations 
This study received formal ethical approval from the UK National Research Ethics Service (reference 
no: 08/H0703/23). 
 
4.4 RESULTS 
Studies 1-3: Patients recruited  
39 ASUC patients (aged 28 (18-74) yrs (median (range)); disease duration 10 (0-240) months) and 27 
patients with inactive disease (aged 36 (22-65) yrs (median (range)); disease duration 121 (22-370) 
months) were recruited (Table 4.3). 
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Table 4.3 Baseline demographics of ASUC and inactive UC patients.  There was no significant 
difference in age, gender nor disease extent between those with ASUC compared to those with 
inactive UC.  Those in the ASUC group had a shorter disease duration, higher Baron’s 
sigmoidoscopic score and CRP (mg/L) compared to those with inactive disease. 
 
 ASUC  
(n=39)  
Inactive UC  
(n=27)  
P value  
Age  28 (18-74)  36 (22-65)  0.09  
Male  23 (59%)  16 (59%)  1.0  
Disease extent  
 
   Proctitis 
 
 
 
0 (0%) 
 
 
0 (0%) 
 
 
0.58 
   Left  12 (31%)  6 (22%)   
 
 
   Extensive  27 (69%)  21 (78%)  
Disease duration (months)  10 (0-240)  121 (22-370)  <0.0001  
Baron’s Score  2 (2-3)  1 (0-1)  <0.0001  
CRP (mg/l)  64 (6-248)  <5 (1.1-11.7)  <0.0001  
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4.4.1 Stress, Anxiety and Depression 
 
Study 1: ASUC vs Inactive UC 
Patients with ASUC had higher stress levels (R-PSQ Index 0.52 (0.18-0.94) (median (range)), G-PSQ 
0.48 (0.10-0.93)) and higher depression scores (HADS-D 6 (0-17)) than patients with inactive UC (R-
PSQ 0.36 (0.12-03.66), p= 0.001, G-PSQ 0.38 (0.18-0.76), p=0.046, HADS-D 3 (0-9) p=0.046 
respectively) [Figures 4.1 and 4.2] but there was no difference in anxiety scores between the 2 groups 
(HADS-A: 10 (0-21), 8.0 (0-15), p=0.18, respectively) [Figure 4.2].  
 
In patients with ASUC, there was a positive correlation between stress and both anxiety scores (R-
PSQ, r2=0.27, p=0.001; G-PSQ, r2= 0.14, p=0.02)) [Figure 4.3(i)] and depression scores (R-PSQ, 
r2=0.29, p=0.0004; G-PSQ, r2= 0.11, p=0.036)) [Figure 4.3(ii)].  The positive correlation between 
stress and anxiety (R-PSQ, r2=0.33, p=0.002; G-PSQ, r2= 0.30, p=0.004)) [Figure 4.3(iii)] was also 
seen in the inactive UC patients in this group but there was no correlation with depression (R-PSQ, 
r2=0.01, p=0.71; G-PSQ, r2= 0.05, p=0.29)) [Figure 4.3(iv)]. 
 
Study 2: Previously diagnosed vs new diagnosis UC 
Although stress and depression scores were similar, anxiety levels were higher in the 11 newly 
presenting ASUC patients (12 (3-18)) (median(range)) than in those previously diagnosed (9 (0-21), 
p=0.049) [Fig 4.4].  
 86 
 
 
Figure 4.1 Study 1: Stress levels in ASUC compared to inactive UC.  Patients with ASUC had higher 
stress levels than in patients with inactive UC.  Median values shown. 
 
General PSQ
p=0.046
ASUC Inactive UC
0.0
0.2
0.4
0.6
0.8
1.0
P
S
Q
 I
n
d
e
x
Recent PSQ
p=0.001
ASUC Inactive UC
0.0
0.2
0.4
0.6
0.8
1.0
P
S
Q
 I
n
d
e
x
 
 
 
 
Figure 4.2 Study 1: Anxiety and depression levels in ASUC compared to inactive UC.  Patients with 
ASUC had similar anxiety scores but higher levels of depression than patients with inactive UC. 
Median values shown. 
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Figure 4.3(i) Correlation of (A) recent stress and (B) general stress with anxiety in ASUC.  In patients 
with ASUC, there was a positive correlation between stress and anxiety.  
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Figure 4.3(ii) Correlation of (A) recent stress and (B) general stress with depression in ASUC. In 
patients with ASUC, there was a positive correlation between stress and depression. 
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Figure 4.3(iii) Correlation of (A) recent stress and (B) general stress with anxiety in inactive UC 
patients.  In patients with inactive UC, there was a positive correlation between stress and anxiety. 
0 5 10 15 20
0.0
0.2
0.4
0.6
0.8
1.0
r2=0.33
Anxiety
R
e
c
e
n
t 
P
S
Q
0 5 10 15 20
0.0
0.2
0.4
0.6
0.8
1.0
r2=0.30
Anxiety
G
e
n
e
ra
l 
P
S
Q
 
Figure 4.3(iv) Correlation of (A) recent stress and (B) general stress with depression in inactive UC 
patients. In patients with inactive UC, there was no correlation between stress and depression. 
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Figure 4.4 Perceived stress, anxiety and depression scores in newly diagnosed ASUC compared to 
previously diagnosed UC. Although stress and depression scores were similar, anxiety levels were 
higher in the newly presenting ASUC patients than in those UC patients previously diagnosed. 
Median values shown. 
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4.4.2 Study 3: Clinical outcomes 
 
Overall clinical outcome 
16/39 (41%) patients did not respond to iv hydrocortisone by Travis criteria (day 3). 11/39 (28%) 
commenced on 2
nd
 line medical therapy and 9/39 (23%) needed colectomy by day 70. All patients had 
were given 2
nd
 line medical therapy prior to colectomy. Overall colectomy rates for the ASUC group 
independent of their psychological state at baseline is shown in Figure 4.5. 
ASUC outcome according to psychological state 
There was no significant difference in those responding to iv hydrocortisone (by Travis criteria) or in 
day 70 colectomy rates (Fig 4.6) between patients who were highly (upper tertile) anxious (Travis 
response 8/13, colectomy rate 2/13), highly (upper tertile) depressed (Travis response 6/13, 
colectomy rate 3/12) or highly (upper tertile) stressed (R-PSQ: Travis response 8/12, colectomy rate 
6/13; G-PSQ Travis response 5/13, colectomy rate 4/13) compared to those less (lower tertile) 
anxious (5/13 (p=1.0), 3/13 (p=1.0), respectively), depressed (lower tertile) (Travis response 7/13 
(p=1.0), 1/13 (p=0.59) or stressed (lower tertile) (R-PSQ, 5/13 (p=0.44), 1/13 (p=0.08); G-PSQ 5/12 
(p=1.0), 1/13 (p=0.32), respectively) (n=12 represents incomplete questionnaire completion by one 
individual). 
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Figure 4.5 Kaplan Meier survival curve to colectomy in patients with ASUC (n=39). At day 70, 9/39 
(23%) of the ASUC patients needed colectomy (day 70).   
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Figure 4.6  Kaplan Meier survival curves to colectomy in patients with ASUC according to upper and 
lower tertiles of stress, anxiety and depression.  There was no difference in colectomy rates at day 70 
between patients who were highly (upper tertile) stressed, anxious or depressed stressed compared 
to those less so (lower tertile). 
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4.5 DISCUSSION 
 
In recent years, there has been increasing recognition by doctors and patients that psychological 
distress and depression are common in, and can worsen the course of IBD (see Chapter 1).  
Study 1: ASUC vs Inactive UC 
This study has shown that perceived stress levels and depression scores are greater in patients 
admitted with ASUC than in those in remission. It may be as a result of hospital admission that these 
patients appeared to be more stressed and depressed than those with inactive disease.  However it 
could also be argued that it was the effect of being more stressed and depressed that caused severe 
active disease. Furthermore, anxiety was associated with perceived stress (in both inactive and active 
disease), whereas depression was associated with perceived stress in patients admitted with active 
disease (ASUC group). Although we did not study this, in a separate cross sectional survey of mood 
disturbances from our unit, anxiety and depression were significantly more common in patients with 
IBD than in healthy controls (239).   
Study 2: Previously diagnosed vs new diagnosis UC 
Our results in study 2 show that although stress scores were similar, anxiety levels were higher in the 
newly presenting ASUC patients than those with longstanding disease; this is a perhaps not 
unsurprising consequence of ‘fear of the unknown’.  As discussed in chapter 1, Maunder and Esplen 
(see Table 1.4) (149) suggest that the process of normal adjustment to IBD depends on the 
interaction of a triad of illness uncertainty, loss and change, and suffering.  They suggest that 
maladaptive coping leads to anxiety and depression and propose a step-wise escalation of 
psychological interventions appropriate for each stage of adjustment. 
Study 3: Clinical outcomes 
As far as we are aware, study 3 (longitudinal) is the first study to assess clinical outcome in patients 
admitted with ASUC according to psychological status. Our study design was based on a that of a 
previous study by Levenstein et al, in which patients with quiescent UC, in the upper tertile on the 
basis of their perceived stress questionnaire (PSQ R or G) score, had a greater rate of subsequent 
relapse (115).  
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We found that neither stress nor mood significantly influence outcome of acute severe UC.  There 
was no difference in those responding to iv hydrocortisone (by Travis criteria) or in day 70 colectomy 
rates between patients who were highly anxious, depressed or highly stressed compared to those 
minimally anxious, depressed or stressed. Although there was no significant difference in day 70 
colectomy rates (Fig 4.6) between patients who were highly (upper tertile) stressed (RPSQ) to those 
who were less stressed (lower tertile) there was a trend to a higher proportion of those highly stressed 
needing colectomy.  This failure to reach statistical significance may reflect a type 2 error due to the 
small numbers of patients recruited in study 3 (longitudinal study), despite attempted recruitment over 
2 years at four IBD centres.  
4.5.1Limitations 
 
There are a number of limitations to this study. Firstly, to further assess the effect of hospital 
admission on stress and mood in IBD, it would have been useful to compare the stress and mood in 
ASUC patients with a further control group, for example, general gastroenterology in-patients, which 
was not assessed in this study. 
We acknowledge the small numbers of patients recruited in study 3 (longitudinal study); this could 
have been increased by the incorporation of further centres and a longer recruitment period, which 
was not feasible in the study.  Lastly, this study did not assess patients’ personality, resilience nor the 
coping strategies they employ (81, 127). 
 
In summary, clinicians should consider providing a more holistic approach, screening their admitted 
IBD patients for stress and related mood disorders. There is some evidence that cognitive behavioural 
therapy of various types, antidepressants, and possibly exercise, can improve IBD-associated mood 
disorders (see Chapter 1).  Because of the difficulties inherent in undertaking appropriately targeted 
and blinded studies, good data about the effects on IBD of interventions aimed to ameliorate stress 
and its associated mood disorders are limited. As a next step, we would suggest conducting 
appropriately designed clinical trials to evaluate the effects of stress management and other 
psychologically-orientated therapies in patients with ASUC, assessing not only patients’ psychological 
well-being and stress resolution but also the impact on the course of their colitis itself. 
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4.6 CONCLUSION  
Perceived stress and depression levels are greater in patients with ASUC than in those in remission 
and anxiety scores are highest in patients newly presenting with UC. Although further controlled 
studies are needed to assess whether psychological interventions can influence outcome in acute 
severe UC, psychological support should be available for patients with ASUC, particularly those newly 
presenting to help them cope with their disease. 
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CHAPTER 5:  DOES PSYCHOLOGICAL COUNSELLING ALTER THE NATURAL HISTORY OF 
INFLAMMATORY BOWEL DISEASE? 
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SUMMARY 
 
 There is increasing evidence that psychological stress can increase mucosal inflammation 
and worsen the course of inflammatory bowel disease (IBD).  To assess whether 
psychotherapy by a counsellor specially trained in management of IBD can influence the 
course of disease, a case controlled study was designed to compare the course of IBD in 24 
patients (13 ulcerative colitis; 11 Crohn’s), during the year before (year 1) and the year after 
referral (year 2) for supportive outpatient psychotherapy to an IBD counsellor, to that of 24 
IBD controls. 
 Patients were referred for counselling because of disease-related stress, work problems, 
concerns about surgery and bereavement.  
 In the year after starting counselling (year 2), patients had significantly fewer relapses and 
outpatient attendances than in the year before referral (year 1); furthermore, steroid usage 
and relapse-related use of other IBD medications was lower during psychotherapy. Patients 
also informally reported improvements in their well-being and perception of stress 
 There were no differences in any of these measures between years 1 and 2 in the control 
group. 
 The findings suggest that IBD-focussed counselling may improve not only psychological well-
being, but also the course of IBD in individuals with psychosocial stress.  
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5.1 INTRODUCTION 
As discussed in chapter 1 psychological stress has long been anecdotally reported as adversely 
affecting disease activity in IBD, and there have been substantial recent advances in both proving this 
relationship and in elucidating the mechanisms by which it occurs (82, 124, 125).  To date there have 
been very few reports, however, of the effects of attempts to ameliorate stress on disease course in 
patients with IBD.  
 
5.2 HYPOTHESIS AND AIMS 
We hypothesised that the natural history of IBD could be altered by psychotherapy given by a 
counsellor specially trained in the management of IBD-related psychological problems.   
To do this, comparisons were made of the course of IBD in the year before and the year after patients 
with psychological symptoms started supportive psychotherapy, with that of a case-matched group of 
patients with IBD not receiving psychotherapy, and with that of a number of patients who were 
referred for psychotherapy but failed to attend. 
 
5.3 METHODS 
5.3.1 Patient group 
Using retrospective case note review, the course of IBD was assessed during the year before (year 1) 
and after referral (year 2) of patients with an established diagnosis of IBD (218), confirmed by 
conventional endoscopic, histological and radiological features referred for supportive outpatient 
psychotherapy to an IBD counsellor (Meg Corser (MC)) between 2000-2007 at Barts and The London 
NHS Trust. 34 patients were referred for outpatient supportive therapy. Of these, 24 patients had 
psychotherapy sessions (Table 5.1) and 10 failed to attend. Of the 10 patients who failed to attend 
after referral for counselling, the clinical course of 6 was evaluated; the remaining 4 patients who 
failed to attend could not be evaluated: 2 were lost to follow up from the IBD clinic within a few weeks 
of referral and 2 were referred within 6 months of their diagnosis of IBD, so that data for the year prior 
to referral (year 1) was not obtainable.   Each year about 2000 IBD patients attend the outpatient the 
 98 
 
specialist outpatient clinic at this tertiary centre.  Patients referred for psychotherapy had 
psychological difficulties related to their IBD or had suffered recent major life events, which were 
raised by them in discussion with the physician in the outpatient clinic, and were open to the idea of 
psychological counselling.  None of the patients had received IBD-focussed counselling previously. 
5.3.2 Controls 
From our IBD database, we obtained 24 control patients each matched to one of the group of 
counselled patients for age, sex, diagnosis, disease duration, medication at baseline and for relapse 
rate in year 1 (Table 5.1).  None had problems for which they requested psychological support.  
Details of their disease course in year 2 were subsequently obtained by case note review. 
In addition, the course of disease before referral (year 1) and after referral (year 2) was assessed in 
the 6 evaluable patients who were referred for psychotherapy but failed to attend (see above). 
5.3.3 Outcome measures 
The outcome measures assessed in years 1 and 2 were: the number of relapses documented in the 
notes by the physician, numbers of outpatient attendances, numbers of hospital admissions, numbers 
of courses of steroids, and relapse-related use of other IBD medication, i.e. an increase in 5-
aminosalicylate dosage or introduction of antibiotics, immunosuppression (thiopurine or 
methotrexate), or anti-TNF therapy. Relapse was defined by the physician’s global assessment: in UC 
as the presence of diarrhoea and rectal bleeding with a step-up in their IBD medication; and for CD as 
the presence of abdominal pain and/or diarrhoea also with a step up in their IBD medication.  
5.3.4 Psychotherapy 
All psychotherapy sessions were carried out by the same counsellor (MC).  She had had previous 
experience in relationship and bereavement counselling and had undergone a training programme 
organised by Crohn’s and Colitis UK in 1997-8 at St Mark’s Hospital, London, UK.  This programme 
included training in both IBD itself and aspects of counselling and psychotherapy relating to IBD.  
Each patient was provided with a verbal working contract which adhered to the British Association of 
Counselling and Psychotherapy regulations, with no ceiling set for the number of sessions he/she 
received.  Sessions were person-centered and used both cognitive behavioural therapy and solution 
focused-therapy, to provide continuous psychological support to deal with IBD-related and external 
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events.  The counsellor aimed to enable the patient to seek internal resources to develop resilience; 
she made no special recommendations about smoking cessation.  Patients’ psychological response 
to therapy was assessed by the counsellor, as part of the chart review process, using a visual 
analogue scale 0-6 (0 denotes poor, 6 excellent response to counselling), consisting of: commitment 
to the sessions; resolution of stress-related difficulties; and overall psychological well-being. 
5.3.5 Statistical analysis 
Statistical analyses were undertaken Graphpad Prism (Version 5, San Diego California) software. 
Comparison between the counselled patients and their controls at baseline was made using 
Wilcoxon’s signed ranks test, Fisher exact test and chi squared test for continuous and discrete 
variables respectively.  Outcome measures are shown as median values (ranges), and comparisons 
between year 1 and 2 within and between the case-matched groups were made using Wilcoxon’s 
signed ranks test.  All analyses were two-tailed and p-values were considered significant if less than 
0.05. 
5.3.6 Ethical Considerations 
This study was designed to assess the value of our clinical counselling service and thus did not 
require formal ethical approval, according to UK National Research Ethics Service (NRES) guidelines 
(221). 
 
5.4 RESULTS 
5.4.1 Reasons for referral 
34 patients were referred for counselling at least a year after diagnosis of IBD.  Of these, 24 
underwent counselling. The reasons for referral were disease-related stress (14 patients), work 
problems (3), concerns about surgery (5) and bereavement (2).  The patients received 6 (1-13) 1 hour 
counselling sessions during year 2.  15 patients completed their counselling during year 2, while 9 
continued for up to a further 5 years. 
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5.4.2 Demographics 
There were no significant differences between the 24 counselled patients and their matched controls 
in terms of age, sex, IBD type, disease duration or medication at baseline (Table 5.1).  In addition, 19 
of the 24 controls were matched identically to 19 of the 24 counselled patients in terms of the number 
of relapses in year 1.  However, there were more smokers in the counselled group (7 CD, 3UC) than 
control group (3 CD) (p=0.049) at baseline.  
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Table 5.1 Baseline demographics of patients in counselled group and matched controls. There were 
no significant differences between the groups for any of the baseline variables except for smoking 
(p=0.049 Fisher exact test). 
Characteristic Counselled patients 
(n=24) 
Control patients  
(n=24) 
Age (median (range)) yrs 38 (18-67) 37 (20-64) 
Male 11 (46%) 11 (46%) 
Smoker 10 (42%) 3 (12.5%) 
Duration of disease (median (range)) yrs 5 (1-40) 4 (1-33) 
Ulcerative Colitis 13 13 
Extensive 9 (69%) 9 (69%) 
Left-sided 4 (31%) 4 (31%) 
Crohn’s disease 11 11 
Location Ileal 1 (9%) 1 (9%) 
 Ileocolonic 6 (54%) 6 (54%) 
 Colonic 4 (36%) 4 (36%) 
Behaviour Inflammatory 5 (45%) 3 (28%) 
 Stricturing 4 (36%) 4 (36%) 
 Penetrating 2 (18%) 4 (36%) 
+ Perianal 1 (9%) 3 (28%) 
Medication   
5-aminosalicylate 18 (75%) 20 (83%) 
Immunosuppressant (azathioprine/methotrexate) 13 (54%) 12 (50%) 
Steroids (oral) 5 (21%) 6 (25%) 
Infliximab 1 (4%) 1 (4%) 
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5.4.3 Clinical outcomes 
As shown in Table 5.2 and Fig 5.1, in the year after starting it (year 2), counselled patients had fewer 
relapses (0 (0-2)) and outpatient attendances (3.5 (1-10)) than in the year before referral (year 1) (2 
(0-5), P=0.0008; and 6.5 (1-17), P=0.0006, respectively).  There were no significant differences in 
these variables between years 1 and 2 in the control group (Table 5.2 and Figures 5.1 and 5.2), and 
the differences between the changes seen in each variable in the two groups were statistically 
significant (P=0.006 and P=0.03 respectively).  The numbers of hospital admissions did not change 
between year 1 and 2 in either group (Figure 5.3). However, steroid usage (1 course (0-4) in year 1, 0 
(0-2) in year 2, P=0.005) (Figure 5.4) and relapse-related use of other IBD medications (5 
ASA/antibiotics) declined during psychotherapy (1 drug (0-5) in year 1, 0 (0-2) in year 2, P=0.002) but 
did not change in the control group (p=0.01 and P=0.0006 for differences from counselled group).  No 
patients in the counselled group were commenced on an immunomodulator or anti-TNF therapy in 
either year 1 or 2.  In the control group, there was no significant overall change in the use of 
immunomodulator or anti-TNF between year 1 and 2.  Furthermore, sub-analysis of the key outcome 
measures when limited to the 19 subject pairs that were well matched in year 1 on all variables, 
including relapse rates, confirmed the results obtained for the complete set of 24 patient-pairs (data 
not shown).  
In the 6 evaluable patients who were referred for counselling but did not attend any sessions, there 
were no differences in the numbers of relapse (2 (0-3)) and outpatient attendances (5.5 (2-9)) in the 
year before referral (year 1) compared with those in the year after (year 2) (1.5 (1-3), p=0.75 and 5.5 
(3-10), p=0.75, respectively) (Figures 5.1 and 5.2).  Similarly, there were no differences in steroid use 
(Figure 5.3) or hospital admissions (Figure 5.4). 
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Table 5.2   Effects of counselling on IBD activity.  In the year after starting it (year 2), counselled 
patients had fewer relapses and outpatient attendances than in the year before referral. There were 
no significant differences in these variables between years 1 and 2 in the control group.  Steroid 
usage and relapse-related use of other IBD medications (5 ASA/antibiotics) declined during 
psychotherapy 1 but did not change in the control group.  The numbers of hospital admissions did not 
change between year 1 and 2 in either group. Median values are shown (range). 
 
Outcome variable 
 
Counselled patients (n=24) 
 
Control patients (n=24) 
Changes in 
counselled 
vs control 
pts’ results 
Year 1 Year 2  P value
†
 Year 1 Year 2  P value
††
 P value
†††
 
No of relapses* 2 (0-5)* 0 (0-2) 0.0008 1 (0-3)* 2 (0-2) 0.64 0.0006 
No of out-patient 
attendances 
6.5 (1-17) 3.5 (1-10) 0.0006 5 (2-9) 5 (2-11) 0.99 0.03 
Courses of steroids 1 (0-4) 0 (0-2) 0.005 1 (0-3) 1 (0-2) 0.62 0.01 
Changes in 
5ASA/antibiotics 
1 (0-5) 0 (0-2) 0.002 0 (0-2) 0 (0-2) 0.81 0.0006 
Changes in 
Immunosuppression 
0 (0-0) 0 (0-0) - 0 (0-2) 0 (0-2) 0.57 - 
New infliximab 0 (0-0) 0 (0-0) - 0 (0-1) 0 (0-3) 0.50 - 
No of hospital of 
admissions 
0 (0-2) 0 (0-2) 0.33 0 (0-2) 0 (0-1) 0.43 0.21 
 
†
 P value for the difference between year 1 and year 2 for counselled group (Wilcoxon signed rank 
test). 
††
 P value for the difference between year 1 and year 2 for control group (Wilcoxon signed rank 
test). 
††† 
P value for differences between changes in variables for counselled versus control groups 
(Wilcoxon signed rank test) 
* The number of relapses in year 1 in the counselled group (prior to intervention) was not significantly 
different to that of the control group in year 1, p = 0.08 (Wilcoxon signed rank test), 
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Figure 5.1 Relapse rates in years 1 and 2 in the three patient groups, counselled patients (n=24), 
case-matched controls (n=24) and patients who were referred for counselling but failed to attend 
(n=6). In the year after starting it (year 2), counselled patients had fewer relapses than in the year 
before referral. There were no significant differences in the control or referred but failed to attend 
groups.  Individual data points are shown; the horizontal lines indicate median values. 
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Figure 5.2 Outpatient attendances in years 1 and 2 in the three patient groups, counselled patients 
(n=24), case-matched controls (n=24) and patients who were referred for counselling but failed to 
attend (n=6).  In the year after starting it (year 2), counselled patients had fewer outpatient 
attendances than in the year before referral. There were no significant differences in the control or 
referred but failed to attend groups.  Individual data points are shown; the horizontal lines indicate 
median values. 
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Figure 5.3 Hospital admissions in years 1 and 2 in the three patient groups, counselled patients 
(n=24), case-matched controls (n=24 and patients who were referred for counselling but failed to 
attend (n=6). The numbers of hospital admissions did not change between year 1 and 2 in any of the 
groups. Individual data points are shown; the horizontal lines indicate median values. 
 
 
 
Figure 5.4 Steroid use in years 1 and 2 in the three patient groups, counselled patients (n=24), case-
matched controls (n=24) and patients who were referred for counselling but failed to attend (n=6).  In 
the year after starting it (year 2), counselled patients had fewer steroid courses than in the year before 
referral. There were no significant differences in the control or referred but failed to attend groups.  
Individual data points are shown; the horizontal lines indicate median values. 
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Duration of counselling  
The effect of duration of counselling on IBD course was also assessed.  The 12 patients who had 
therapy for < 6 months had a tendency towards improvement in relapse rates between year 1 (1.5 (0-
5)) and year 2 (0.5 (0-2)) (p=0.07) ; the changes in their outcome variables were all still statistically 
significant when compared with those of their matched controls (year 1: 1 (0-3); year 2: 1 (0-4))  
(p=0.03 for changes in counselled vs control patients’ results ).  In patients receiving counselling for > 
6 months, there was a significant reduction in the relapse rate between years 1 (2 (0-5)) and year 2 (0 
(0-1)) (p=0.002), and the differences between the changes seen in them and their matched controls 
(year 1: 1.5 (0-4); year 2: 2 (0-3))   was also significant (p=0.004). 
Effect of smoking cessation 
Of the 10 smokers in the counselled group, 4 stopped in year 2 (3CD, 1 UC), compared to 1 out of the 
3 patients with CD in the control group.  Sub–analysis of the data without the 3 CD smokers in the 
counselled group who stopped, and their matched controls, did not influence the results found after 
psychotherapy; the counselled patients had fewer relapses (0 (0-2)) and outpatient attendances (4 (0-
9)) than in the year before referral (year 1) (2 (0-5), P=0.0009; and 7(1-17), P=0.0001, respectively).  
There were no significant differences in these variables between years 1 and 2 in the control group 
(relapses year 1 (2 (0-4)), year 2 (2 (0-4)) (p=0.70), outpatient attendances year 1 (6 (2-9)), year 2 (5 
(2-11)) (p=0.84)), and the differences between the changes seen in each variable in the two groups 
were statistically significant (P=0.001 and P=0.001 respectively).   
5.4.4 Counsellor assessment 
The counsellor’s assessment of the 20 patients who attended >1 session showed that patients were 
committed to the sessions (median score 4 (4-6)).  Counselling was felt to help solve stress-related 
difficulties (4 (3-5)) and patients were scored 4 (3-6) overall in psychological well-being after the 
counselling sessions.  Patients also informally reported improvements in their well-being and 
perception of stress level.  The 4 patients who attended only the first counselling session felt that 
counselling was unlikely to be of benefit to them, but continued to be followed up in the IBD clinic.  
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5.5 DISCUSSION 
 
As discussed in chapter 1, in recent years, there has been increasing recognition by doctors as well 
as patients that psychological stress and other psychological disorders such as depression can 
worsen the course of IBD (82, 124, 125, 136). 
Interestingly the baseline demographics revealed more smokers in the counselled group compared to 
their matched controls in keeping with the suggestion that IBD patients who are more stressed are 
more likely to be smokers. 
This study has shown that counselling in patients identified to have psychological difficulties related to 
their IBD or to recent major life events, benefited them both in relation to the activity of their IBD and 
to their psychological well being.  The improvement in IBD activity associated with psychotherapy was 
demonstrated by reductions in relapse rates, in use of steroids and other medications, and in 
outpatient attendances in the counselled compared to the control patient group.  Two of our patients 
had counselling because of recent bereavement; this is of interest in relation to the use in two 
previous studies reporting a positive association between IBD activity and life events of 
questionnaires (Holmes Recent Life Change and Psychiatric Epidemiology Research Interview Life 
Events Scales) which incorporate bereavement as a major factor in life event scores (128, 131). 
5.5.1 Limitations 
 
There are a number of limitations to this study, the first being that it is a retrospective case-note 
review.  We acknowledge that the study size is small, and that the numbers counselled represent a 
small proportion of patients seen in the IBD clinic when viewed in relation to the findings of the 
ADAPT study discussed in chapter 1 (150).  The psychological support service in our IBD service has 
limited capacity: our one part-time counsellor (MC) can see only a limited number of referrals.  
Patients seen in the IBD clinic can also gain access to psychological support through their general 
practitioners, but we have no figures for the numbers of patients given counselling outside the hospital 
setting.  There was no formal assessment of the psychological state of the counselled patients 
beyond the therapist’s overall judgment.  The tiny minority of very disturbed patients are normally 
referred to a psychiatrist rather than our counsellor: the apparently disproportionately low number of 
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patients referred to the counsellor in relation to the ADAPT findings (150) does not imply that the 
counselled patients in the present study were particularly distressed individuals. 
There was no objective documentation of IBD activity in this study, for example using colonoscopy, 
blood tests (C-reactive protein) and/or faecal calprotectin given that disease activity may improve as a 
result of the direct effect of stress reduction on bowel frequency rather than through its effects on 
mucosal inflammation. 
To decrease the possibility that the results in the counselled patients could have been explained by 
regression to the mean, we compared them with both individual case-matched controls who did not 
have psychological difficulties leading to referral for counselling (Tables 5.1 and 5.2), and with a small 
number of patients referred for counselling but who did not attend (Figure 5.1): in both these control 
groups, disease activity variables were unaltered in year 2.  The relapse rate in year 1 showed a non-
significant trend to being higher in the counselled patients than in the controls, suggesting that the 
counselled patients may have been sicker; however sub-analysis of the 19 patient-pairs in whom all 
variables were matched in year 1 revealed no differences in the outcome measures between the two 
groups.  Re-analysis of the data after removal of the patients who stopped smoking in year 2 did not 
alter our results, so that smoking cessation in the patients with CD, whether or not a consequence of 
psychotherapy, did not account for its beneficial effects. 
It is conceivable that counselling may have improved the course of patients’ IBD by increasing their 
adherence to medication (240), but we were unable to collect data about treatment adherence. Lastly, 
this study gives no indication of the mechanisms by which counselling works, whether directly through 
psychoneuroimmunological pathways (82, 124, 125), or indirectly, for example by improving drug 
adherence.  
 
5.6 CONCLUSIONS 
 
This retrospective study of IBD patients with psychosocial stress demonstrates that IBD-focussed 
counselling may improve not only patients’ psychological well-being and stress resolution but also the 
activity of their IBD, as indicated by reductions in relapse rate, use of steroids and other medications, 
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and outpatient attendances during the year after it was started.  These findings suggest that 
counselling could also reduce healthcare utilisation and costs in patients with IBD complicated by 
psychological stress. 
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CHAPTER 6: HYPNOTHERAPY FOR THE PREVENTION OF RELAPSE IN ULCERATIVE 
COLITIS: A MULTI-CENTRE, RANDOMISED, SINGLE-BLIND, CONTROLLED CLINICAL TRIAL 
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SUMMARY 
 
 There are anecdotal reports of the use of hypnotherapy in IBD and we hypothesised that it 
could be used for the maintenance of remission in UC. 
 A multi-centre, randomised, single-blind, controlled trial was conducted to compare relapse 
rates in patients with quiescent UC treated either with gut-focussed hypnotherapy (GFH) or 
control educational sessions (CES) after withdrawal from a thiopurine. Patients with inactive 
UC treated for ≥1 year with azathioprine or mercaptopurine were asked to stop it. Patients 
were randomised 2:1 to receive GFH or CES over 13 weeks. The primary outcome was 
relapse rate at week 52. Psychological status and quality of life were assessed at weeks 0 
and 13 and at relapse using the HADS, perceived stress (PSQ) and IBDQ questionnaires. 16 
patients were randomised to GFH and 10 to CES.  
 At week 52, there was no difference in relapse rates between those patients who had 
received GFH and the CES-treated patients.  At week 13, GFH did not alter psychological or 
quality of life scores in patients still in remission.  
 This trial did not suggest that gut-focussed hypnotherapy has a major effect in preventing 
relapse or altering psychological status in patients with UC withdrawing from thiopurines.   
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6.1 INTRODUCTION  
 
As indicated in chapter 1, hypnotherapy can be defined as the intentional induction of a trance-like 
state without the loss of will or consciousness. It has been used successfully for many years as a 
treatment for psychological disorders.  It has also been used in a variety of medical disorders 
including irritable bowel syndrome, which are believed to have a psychosomatic component and to be 
worsened by psychological stress. 
 
6.2 AIMS  
 
We hypothesized, because of existing anecdotal data in IBD, that by reducing the systemic and/or 
mucosal response to psychological stress or by other pathways, hypnotherapy would reduce the 
relapse rate in patients with inactive UC. To test this hypothesis we selected a population of patients 
with UC who are at substantial risk of relapse. Many patients with UC need to take a thiopurine, 
azathioprine or mercaptopurine (MP), in addition to a 5ASA, to keep their disease in remission: in 
these, withdrawal of the drug has been associated with a relapse rate at 1 year of 60% (241).  
Therefore, to test whether hypnotherapy has a clinically useful prophylactic role, we conducted a 
multi-centre, randomised, single-blind, controlled trial to compare relapse rates in patients with 
quiescent UC treated either with gut-focussed hypnotherapy (GFH) or control educational sessions 
(CES) after withdrawal from a thiopurine. 
 
6.3 METHODS 
6.3.1 Patients 
Patients for recruitment were sought from 6 centres in London, UK (Barts and the London NHS Trust, 
University College London Hospitals NHS Trust, Guy’s and St Thomas’ Hospitals NHS Trust, Imperial 
Healthcare NHS Trust, West Middlesex University Hospital NHS Trust and North-West London NHS 
Trust (St.Marks Hospital)) during the period October 2007 – April 2010.  
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6.3.2 Inclusion criteria  
UC was confirmed by standard clinical, radiological, endoscopic and/or histological criteria. Patients 
aged 16-75 years with inactive UC who had been treated with azathioprine or mercaptopurine for a 
minimum of 1 year were considered for inclusion.  Inactive disease was defined by a Simple Colitis 
Activity Index (SCCAI) score <3 (236) and Baron’s sigmoidoscopic score <2 (231).  Patients were 
required to be in clinical remission for at least 3 months prior to recruitment and on unaltered 
maintenance therapy (including 5ASA) for at least 4 months. 
6.3.3 Exclusion criteria 
Exclusion criteria were: use of prednisolone orally or topically, or of topical 5ASA in the preceding 3 
months, antibiotics, warfarin, anti-diarrhoeal drugs, NSAIDs, aspirin at a dose of greater than 75 
mg/day, herbal remedies; alcohol or drug abuse; pregnancy or breast feeding; female of child-bearing 
age not taking adequate contraception; participation in another drug trial in the previous three months; 
serious liver, renal, cardiac, respiratory, endocrine, neurological or psychiatric illness.  Patients were 
also excluded if they already used relaxation techniques. 
6.3.4 Protocol 
 
An overview of the study protocol is shown in Figure 6.1.  The study was registered with 
ClinicalTrials.gov (Ref: NCT00553163).  At recruitment patients were asked to stop taking 
azathioprine or mercaptopurine.  Patients underwent separately arranged sessions with the therapist 
(MS) and for clinical assessment (MW), including sigmoidoscopy, which precluded them from meeting 
each other, for example in waiting rooms, to compare treatments.  
Patients were randomized on a 2:1 basis to gut-focused hypnotherapy (GFH) or control educational 
sessions (CES) at each participating site using a computer-generated code.  The interventions took 
place over the first 13 week after randomization.  Patients were subsequently assessed every 3 
months by the clinician until 1 year or relapse, if earlier. 
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Figure 6.1 Study protocol: Hypnotherapy for the prevention  of relapse in UC. UC, ulcerative colitis, 
GFH, gut focused hypnotherapy, CES, Control education sessions, HADS, Hospital Anxiety and 
Depression score, PSQ, Perceived Stress, MHLC, Multidimensional Health Locus of Control, STAI, 
State Trait Anxiety Inventory, TGN, thioguanine nucleotide levels, SHSS, Stanford Hypnotisability 
Susceptibility Score. 
 
Protocol 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
Inactive UC 
Stop thiopurine 
Randomisation 2:1 
CES (n=10) 
Completion 
Completion 
Week 0 Week 13 Week 52 
Intervention Follow up 
GFH (n=16) 
Questionnaires 
IBDQ 
HADS 
PSQ 
MHLC 
STAI 
Laboratory 
TGN 
pANCA 
Calprotectin 
Questionnaires* 
IBDQ 
HADS 
PSQ 
STAI 
Hypnotisability 
SHSS 
 115 
 
6.3.5 Thiopurine withdrawal 
 It was decided to use patients withdrawing from use of a thiopurine for this trial for several practical 
and ethical reasons.  At the time of this study design, there was good data about relapse rates on 
azathioprine withdrawal (241) and therefore a base for power calculations (see below).  Thiopurines, 
while effective therapy, carry a substantial risk of side-effects (e.g. bone marrow suppression, liver 
damage, infection, lymphoma) and require regular blood checks, so that patients and doctors would 
welcome their discontinuation if feasible.  If hypnotherapy proved effective, it would be a safe 
alternative to azathioprine or mercaptopurine. 
6.3.6 Interventions 
Gut-focussed hypnotherapy (GFH) 
 All sessions were performed by the same medically qualified hypnotherapist (MS), who was not 
involved in undertaking the end-point assessments.  Subjects first underwent a preliminary 20 min 
interview with the therapist to establish rapport and to ask about their conceptualisation of UC.  
Subjects were then given instruction about relaxation techniques.  They were instructed on how 
hypnosis may influence gut function.
  
Hypnosis was induced by eye closure, followed by progressive
 
muscular relaxation and standard deepening techniques.   
Session one was spent familiarising
 
the patient with the process. In subsequent sessions, abdominally 
focused
 
suggestions were introduced, centred around reducing inflammation and normalising colonic 
motility and sensitivity using both patient-centred imagery and conditioning techniques.  More direct 
suggestions
 
about reduction of pain and improvement of health were made
 
on a repetitive basis at 
each session.  Patients were informed that the effects of hypnosis are not necessarily immediate. The 
emphasis was on the patient developing control over their gut rather than being controlled by their 
gut.  This was part of promoting an internal locus of control (242), which is known to be important for 
successful outcome with biofeedback (243) and self management of diabetes (244).  Subjects were 
seen at 6 face-to-face visits in the 13 week treatment period (weeks 1, 2, 3, 5, 9 and 13).  Subjects 
also received
 
a CD with instructions for self-hypnosis and were encouraged to practise
 
at home on at 
least a daily basis; they received a phone call at weekly intervals from the therapist to monitor 
progress and compliance.  After the end of the initial 13 week period, patients were asked to continue 
to practise self-hypnosis, and were phoned monthly by the therapist. 
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Control educational sessions (CES) 
The control interventions were undertaken by the same therapist (MS) who undertook the 
hypnotherapy sessions.  Subjects first underwent a preliminary 20 min interview with the therapist to 
establish rapport and to ask about their knowledge of UC.   
Subjects were seen at 4-weekly intervals (a total of 4 face-to-face visits in the 13 week treatment, at 
weeks 1, 5, 9 and 13), and received a phone call at weekly intervals from the therapist to monitor 
progress and field questions.  After the end of the initial 13 week period, patients were phoned 
monthly by the therapist. No attempt was
 
made to offer any form of relaxation techniques to these 
patients.
  
 
The content of the educational sessions was standardised, to cover the following:  (a) what is the 
nature and prognosis of UC?; (b) what is the cause of UC?; (c) what are the implications of UC for 
family life (covering inheritance risk, sexual function, pregnancy and childbirth) ?; (d) the medical and 
surgical treatment of UC (see Appendix 2). 
6.3.7 Outcome measures 
Primary end-point:  The proportion of patients suffering a relapse at 1 year. Relapse was defined 
symptomatically by SCCAI >2, recorded from a diary card completed daily by each patient, and 
confirmed sigmoidoscopically (Baron score >1).   
Secondary end-points: 
i) Psychological status:  To assess whether GFH improved patients’ mood they were asked to 
complete the Hospital Anxiety Depression Score (HADS), Perceived Stress Questionnaire (PSQ) 
(115) and State Trait  Anxiety Inventory (form Y) (STAI) at entry and week 13. Furthermore, to assess 
the relation between disease activity and mood, subjects also completed these questionnaires at 
relapse. 
The STAI Form Y is also a validated questionnaire for measuring anxiety in adults. It differentiates 
between the temporary condition of “state anxiety” and the more general and long-standing quality of 
“trait anxiety”. It comprises two twenty item scales (for copyright reasons only part, STAI Y-1, is shown 
in Appendix 1.5) with a range of scores between 20-80; higher scores indicating greater anxiety (245). 
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In addition, patients were asked to complete the multidimensional health locus of control 
questionnaire (form C) (MHLC) (246) at entry (Appendix 1.6).  The MHLC is an 18 item, area-specific 
measure of expectancies regarding locus of control developed for prediction of health-related 
behaviour. An internal locus of control (score range 6-36) is known to be important for successful 
outcome with biofeedback (243) and self-management of diabetes (244). 
The Stanford Hypnotic Susceptibility Scale (247) was carried out after the final intervention to ensure 
no differences between the 2 groups.  This scale measures how easily a person can be hypnotized; 
and results range from 0 (not susceptible) to 12 (highly susceptible) (summary of scale in Appendix 
1.7). 
Other tests measured at baseline included the measurement of thioguanine nucleotide (TGNs) 
concentrations to assess adherence to thiopurines, and faecal calprotectin (248) to confirm inactive 
disease. In addition, pANCA was also measured at baseline; a negative pANCA has been shown to 
increase the risk of anxiety- or depression-related flare of UC (116). 
ii) Quality of life: Patients were asked to complete the Inflammatory Bowel Disease Questionnaire 
(IBDQ) at recruitment, at week 13 and at relapse (249). The IBDQ is a validated and reliable tool to 
measure of health-related quality of life in adult patients with IBD. The questionnaire consists of 32 
questions scored in four domains: bowel symptoms, emotional health, systemic systems and social 
function. 
iii) Faecal calprotectin: This was used to confirm inactive disease at baseline (248). This was 
undertaken by myself, with samples run in duplicate, using PhiCAL enzyme linked immunoassay 
(Firefly Scientific, UK).  
6.3.8 Blinding 
All psychometric and laboratory results were withheld from the clinical assessor and hypnotherapist 
until the trial was complete so as to maintain blinding. The clinical assessor (MW) was also blind to 
each patient’s treatment arm. 
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6.3.9 Statistical analysis 
The primary parameter was relapse rate at 12 months. With azathioprine withdrawal the 12 month 
relapse rate was reported as 60% at the time this study was devised (241).  The minimum clinically 
useful difference in relapse rate at 12 months with hypnotherapy compared to control was considered 
to be 35%.  At a power of 80%, using 2:1 randomisation, we calculated that we would need 60 
patients in total (40 patients for GFH and 20 for CES) to detect a 35% absolute difference between 
groups at p<0.05. Assuming a 10% drop-out rate we intended to recruit 66 patients in all. 
Time-to-relapse curves were calculated using the
 
Kaplan–Meier method, and statistical significance
 
determined using the log rank test.  Differences between the IBD patients and their controls were 
sought in categorical data using Chi squared test or Fisher exact test and in continuous data using 
Wilcoxon signed rank (for comparing paired data) or Mann Whitney U (for comparing unpaired data).  
All P values were 2-tailed.  Outcome measures are shown as median values (ranges).   
Data was analysed on an intention-to-treat basis. Analysis was performed using GraphPad Prism 
(version 4.0) and SPSS (version 17.0) statistical software.  
6.3.10 Ethical Considerations 
This study received formal ethical approval from the UK National Research Ethics Service (reference 
no: 07/H0705/60). 
 
6.4 RESULTS  
6.4.1 Recruitment 
21190 IBD patient visits were screened at 426 clinics over 30 months producing 321 patients with UC 
on a thiopurine: 292 declined enrolment or did not meet inclusion criteria. Of 29 potential participants, 
1 was excluded for active UC and 2 for protocol violations at baseline. Thus, 16 patients were 
randomised to GFH and 10 to CES (Figure 6.2). 
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Figure 6.2 CONSORT (250) diagram of recruitment:  Hypnotherapy for the prevention of relapse in 
UC. IBD, denotes inflammatory bowel disease, UC, ulcerative colitis 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
426 IBD clinics screened 
 
21190 IBD patient-visits 
 
29 UC patients assessed 
 
28 UC patients recruited 
 
2 excluded  (immediate 
protocol violations) 
 
1 excluded  
(Barons score>1) 
Reasons for exclusion 
128 clinically active disease 
52 thiopurine<1yr or dose 
change 
54 not keen on participation  
    (incl. travel and work) 
22 comorbidity/age 
32 other (incl language,  
     moving away) 
4 participation in other study  
26 UC patients included 
 
321 UC patients on 
thiopurine screened 
 
16 pts Gut focused 
hypnotherapy 
 
10 pts Control education 
sessions 
 
292 excluded 
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6.4.2 Demographics and other baseline data 
As shown in Table 6.1, the phenotype of UC differed with regards to age with those receiving CES 
being significantly older than those receiving GFH.  At baseline, there were no differences between 
treatment groups in disease extent or duration, time since last relapse, 5ASA use, duration of 
thiopurine use, faecal calprotectin, TGN levels, pANCA status nor IBDQ (Table 6.2). All but one of the 
patients were thiopurines adherent as judged by their baseline 6 TGN level. Those receiving CES 
appeared more stressed at baseline (recent PSQ) but there were no differences between in anxiety or 
depression scores (HADS and STAI) between the groups (Table 6.2). 
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Table 6.1 Demographics and other baseline data for both the Gut Focussed Hypnotherapy (GFH) and 
Control Education Session (CES) groups.  There were no differences between treatment groups in 
disease extent or duration, time since last relapse, 5ASA use, duration of thiopurine use, faecal 
calprotectin, TGN levels, pANCA status nor IBDQ. Those receiving CES appeared more stressed at 
baseline (recent PSQ) but there were no differences in anxiety or depression scores (HADS and 
STAI) between the groups. 
 
P value for the differences calculated using the Chi squared test and Mann-Whitney U test.  SCCAI, 
simple clinical colitis activity index, TGN, thioguanine nucleotide level (pmol/8 x108erythrocytes), 
MHLC, Multidimensional Health Locus of Control (Internal) Form C, R-PSQ, recent perceived stress 
questionnaire, HADS A, hospital and anxiety depression score – anxiety,  HADS D, hospital and 
anxiety depression score – depression, STAI, State Trait Anxiety Inventory, IBDQ, inflammatory 
bowel disease questionnaire . *CRP values were given values <5 by certain laboratories. 
 Hypnotherapy 
(n=16) 
Education 
(n=10) 
 
P value 
Age (median (range) yrs) 31 (22-65) 48.5 (29-63) 0.03 
Male (no of patients) 8 (50%) 7 (70%) 0.42 
Disease extent 
   Left 
   Total 
 
2 (12.5%) 
14 (87.5%) 
 
4 (40%) 
6 (60%) 
 
 
0.16 
Disease Activity           
((median (range)) 
   
   SCCAI 0 (0-2) 0.5 (0-2) 0.1 
   Baron’s score 0.5 (0-1) 1(0-1) 0.2 
Duration of thiopurine  
(months (range))  
66 (18-282) 
 
82 (12-94) 
 
0.42 
 
Maintenance 5ASA 14 (87.5%) 9 (90%) 1.0 
Time to previous flare 
(months (range))  
34 (7-117) 
 
20 (4-94) 0.47 
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TGN (median (range)) 240 (0-817) 230 (75-574) 0.96 
MHLC (median (range)) 22 (10-28) 18.5 (9-27) 0.27 
Laboratory 
  Hb 
  WBC 
  MCV 
  PLT 
  CRP 
 
13.5 (10.8-15.6) 
5.62 (4-8.1) 
94.7 (67.7-104.3) 
261 (195-860) 
<5 (1-11.7)* 
 
14.3(13.1-16.0) 
5.51 (3.7-7.1) 
92.7 (86-107.1) 
279(207-380) 
<5 (1.7-5)* 
 
0.39 
0.37 
0.50 
0.70 
0.71 
Faecal calprotectin 8.5 (<5-198) <5 (<5-210) 0.78 
pANCA +ve 4 (25%) 4 (40%) 0.66 
Psychological status 
  R-PSQ 
  G-PSQ 
  HADS – Anxiety 
  HADS – Depression 
  STAI – State 
  STAI – Trait 
 
0.30 (0.12-0.57) 
0.34 (0.24-0.58) 
7 (3-12) 
2 (1-8) 
37 (24-58) 
25.5 (28-53) 
 
0.42 (0.28-0.63) 
0.42 (0.32-0.76) 
10 (0-15) 
5.5 (0-9) 
45 (28-63) (n=9) 
47 (25-54) (n=9) 
 
0.03 
0.054 
0.15 
0.61 
0.12 
0.17 
Quality of life: IBDQ 192 (172-210) (n=15) 190.5 (149-215) 0.42 
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6.4.3 Primary outcome  
Eight of 16 (50%) GFH and 7 of 10 (70%) CES-treated patients had relapsed by week 52 (p=0.42) 
(Figure 6.3).   
6.4.4 Secondary outcomes 
 
Psychological status and quality of life. 
At week 13 following the final therapy session, neither GFH nor CES altered psychological (HADS-A, 
HADS-D, R-PSQ, and STAI) or IBDQ scores in patients still in remission (Table 6.2).  
 
At relapse, patients in both groups showed deteriorations in IBDQ (GFH: week 0, 193 (172-210) 
(n=15), relapse 133 (97-144) (n=5), p=0.002; CES: week 0, 190 (190 (149-215), relapse 148 (122-
166) (n=6), p=0.002 (Mann Whitney U)) and those given GFH had higher scores for depression (table 
6.3). 
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Figure 6.3. Kaplan Meier survival curve of UC patients remaining in remission after gut-focused 
hypnotherapy or control education sessions. Relapse was defined by SCCAI>2, Baron’s score >1. 
There was no difference in relapse rates between the groups at week 52. GFH, gut-focused 
hypnotherapy, CES, control education session.  P value was calculated using log rank test. 
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Table 6.2. Psychological status and quality of life scores between baseline and week 13 in those 
patients who remained in remission (at week 13) in both the GFH and CES groups. Neither GFH nor 
CES altered psychological (HADS-A, HADS-D, R-PSQ, and STAI) or IBDQ scores in patients still in 
remission.  R-PSQ, recent perceived stress questionnaire, HADS A, hospital and anxiety depression 
score – anxiety,  HADS D, hospital and anxiety depression score – depression, STAI, State Trait 
Anxiety Inventory, IBDQ, inflammatory bowel disease questionnaire. *P values were calculated using 
Wilcoxon signed rank test. 
 
 
Questionnaire 
 
Hypnotherapy (n=12) 
 
Education (n=9) 
 
Week 0 
 
Week 13 
 
*P value 
 
Week 0 
 
Week 13 
 
*P value 
 
R-PSQ 
 
 
0.29 (0.12-0.57) 
(n=11) 
 
0.31 (0.11-0.59) 
(n=11) 
 
0.50 
 
0.44 (0.29-0.63) 
 
0.45 (0.07-0.68) 
 
0.29 
 
HADS A 
 
7.5 (3-12) 
 
7 (4-11) 
 
0.92 
 
11 (0-15) 
 
10 (4-14) 
 
1.0 
 
HADS D 
 
2 (1-8) 
 
1.5 (0-8) 
 
0.71 
 
5 (0-7) 
 
4 (0-8) 
 
0.82 
 
STAI - STATE 
 
33 (24-48) 
(n=11) 
 
34 (21-54) 
(n=11) 
 
1.0 
 
46 (28-63) 
(n=8) 
 
39.5 (22-53) 
(n=8) 
 
0.09 
 
STAI - TRAIT 
 
36 (28-51) 
(n=11) 
 
38 (25-49) 
(n=11) 
 
0.21 
 
48.5 (25-54) 
(n=8) 
 
45.5 (28-55) 
(n=8) 
 
0.34 
 
IBDQ 
 
 
192 (172-210) 
(n=11) 
 
195 (114-212) 
(n=11) 
 
0.93 
 
188 (149-215) 
 
192 (170-212) 
 
0.23 
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Table 6.3 Psychological status and quality of life scores between baseline, week 13 (in those patients 
who remained in remission), and at relapse in both the GFH and CES groups. R-PSQ, recent 
perceived stress questionnaire, HADS A, hospital and anxiety depression score – anxiety,  HADS D, 
hospital and anxiety depression score – depression, STAI – State Trait Anxiety Inventory, IBDQ,  
inflammatory bowel disease questionnaire. *P values were calculated using Kruskal-Wallis test. 
 
 
 
 
 
 
Questionnaire 
 
Hypnotherapy (n=16) 
 
 
Education (n=10) 
 
 
Week 0 
(n=16) 
 
Week 13 
(n=12) 
 
Relapse 
(n=8) 
 
P 
value* 
 
Week 0 
(n=10) 
 
Week 13 
(n=9) 
 
Relapse 
(n=7) 
 
P 
value* 
 
R-PSQ 
 
0.30 (0.12-0.56) 
 
0.31 (0.11-0.59) 
(n=11) 
 
0.48 (0.29-0.58) 
(n=5) 
 
0.13 
 
0.42 (0.28-0.63) 
 
0.45 (0.07-0.68) 
(n=8) 
 
0.47 (0.34-0.73) 
(n=6) 
 
0.62 
 
HADS - Anxiety 
 
 
7 (3-12) 
 
 
7 (4-11) 
 
10 (2-15) 
(n=5) 
 
0.49 
 
10 (0-15) 
 
 
10 (4-14) 
 
9.5 (7-12) 
(n=6) 
 
0.95 
 
HADS - 
Depression 
 
 
2 (1-8) 
 
 
 
1.5 (0-8) 
 
7 (5-10) 
(n=5) 
 
0.03 
 
5.5 (0-9) 
 
 
4 (0-8) 
 
6 (1-10) 
(n=6) 
 
0.53 
 
IBDQ 
 
 
193 (172-210) 
(n=15) 
 
194 (114-212) 
 
 
133 (97-144) 
(n=5) 
 
0.004 
 
190 (149-215) 
 
 
192 (170-166) 
 
 
148 (122-166) 
(n=6) 
 
0.002 
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6.4.5 Compliance 
14/16 (87.5%) patients given GFH attended all the therapists’ sessions compared to all 10 of those 
receiving CES.  In addition, 14/16 (87.5%) of the GFH patients reported using self-hypnosis daily for 
the first 3 months and 10/12 (83%) did so at least weekly until week 52 or relapse.  
 
6.4.6 Susceptibility to hypnotherapy 
In 11 of the 16 patients who completed the SHSS in the GFH group, the SHSS score was (median 
(range) 8 (3-12).  There was no difference in SHSS within the GFH group in those who remained in 
remission ((11 (4.5-11) (n=5)) compared to those who relapsed ((8 (3-12) (n=6), (p=0.45)) 
6.4.7 Outcome according to pANCA, locus of control and psychological status in the GFH treated 
group 
In patients receiving GFH there was no difference in pANCA status between those who remained in 
remission (4 out 7: pANCA –ve) and those who relapsed (6 out of 7: PANCA -ve) (p=0.55, Fisher 
exact test) (Table 6.4).  
In patients receiving GFH there was no difference in baseline MHLC (Internal) scores between those 
who remained in remission (22 (10-28)) (median (range)) and those who relapsed (18.5 (9-27)).   
Furthermore, relapse in these patients was not influenced by baseline R-PSQ, HADS-A, HADS-D or 
STAI scores (Table 6.5).  
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Table 6.4 Comparison of those patients who received GFH remaining in remission compared to those 
who received GFH and relapsed according to pANCA status at baseline. pANCA –ve status did not 
predict relapse ((p=0.55) *P values were calculated using Mann Whitney U test). (In 2 patients, 
pANCA status was not checked). 
 
 GFH remission (n=7) GFH relapse (n=7) 
P ANCA -ve 4 6 
P ANCA +ve 3 1 
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Table 6.5 Comparison of those patients who received GFH remaining in remission compared to those 
who received GFH and relapsed according to psychological status at baseline. Relapse in these 
patients was not influenced by baseline R-PSQ, HADS-A, HADS-D, or STAI scores. R-PSQ, recent 
perceived stress questionnaire, HADS A, hospital and anxiety depression score – anxiety,  HADS D, 
hospital and anxiety depression score – depression, STAI – State Trait Anxiety Inventory, IBDQ, 
inflammatory bowel disease questionnaire. *n=7 in both groups as 2 patients failed to complete the 
STAI questionnaire, **P values were calculated using Mann Whitney U test. 
 
 
 
 
Questionnaire 
 
Hypnotherapy (n=16) 
Remission  
 (n=8) 
Relapse 
 (n=8) 
 
P value** 
 
R-PSQ 
 
0.27 (0.12-0.43) 
 
0.40 (0.16-0.57) 
(n=11) 
 
0.34 
0.13 
 
HADS - Anxiety 
 
 
6 (0-7) 
 
 
6 (3-12) 
 
0.60 
  
 
0.49 
 
HADS- Depression 
 
 
1 (0-6) 
 
 
 
2 (1-8) 
 
0.28 
  
 
0.03 
 
STAI - STATE 
 
 
33 (25-45) (n=7)* 
 
 
42.5 (31-48) (n=7)* 
 
  
.18 
0.004 
 
STAI -TRAIT 
 
35 (28-50) (n=7)* 
 
 
50.5 (32-51) (n=7)* 
 
 
.18 
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6.5 DISCUSSION  
 
While small uncontrolled studies have suggested that hypnotherapy could have a beneficial effect 
both on disease activity and quality of life in patients with IBD (207-209), this trial, which as far as we 
are aware is the first randomised controlled study of hypnotherapy in IBD, failed to show any 
improvement in relapse rate or psychological status in patients with UC who had discontinued 
treatment with a thiopurine.  Furthermore, we did not find any relationship between response to 
hypnotherapy and either the Stanford Hypnotisability Susceptibility Score, or psychometric 
assessments of mood and stress perception at recruitment.   
6.5.1 Trial design 
Gut-focussed hypnotherapy (GFH) 
The hypnotherapy technique we used was selected in part to mimic the type of hypnosis used in the 
previous study in our unit, since this had shown that a single session of hypnosis reduced systemic 
and rectal mucosal measures of inflammation (204).  In addition, we asked subjects to practise self-
hypnosis daily, since it has the advantage of being more practicable and cheaper than asking 
patients, who are often in full time employment, to attend the hospital on a weekly (or even daily) 
basis: we used these arguments both in relation to the trial itself and to clinical use of hypnotherapy 
should it have proved effective in this study.  There is also evidence that self-hypnosis is effective in 
children with abdominal symptoms (251). 
Control procedure (educational session, CES) 
Any form of relaxation therapy, such as breathing advice or non-gut-focussed hypnotherapy, could 
conceivably have had a beneficial effect and therefore have reduced differences in outcome between 
the GFH and control groups.  We therefore chose as our control procedure a non-emotive question 
and answer educational interview about the nature of UC, previous studies having not suggested that 
education about IBD improves its natural history, as discussed in chapter 1 (section 1.5.3) (171, 251); 
indeed, the relapse rate after thiopurine withdrawal in our control group (70%) proved to be similar at 
1 year to that reported by Hawthorne et al (241).  A more recent study, which was published after we 
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begun our trial, a third of UC patients relapsed within 12 months after withdrawal of azathioprine 
(252). 
6.5.2 Stratification for psychological state and other factors 
Recognising that the response to hypnotherapy might be influenced by their pre-treatment 
psychological state, we considered either recruiting only patients with pre-existing psychological or 
stress-related ‘vulnerability’, or stratifying at recruitment the patients into two groups, for example on 
the basis of their Perceived Stress Questionnaire (PSQ) score and/or pANCA status, previous work 
having shown that a high PSQ is associated with an increased risk of relapse (115), and that a 
negative pANCA increases the risk of anxiety or depression-related flare of UC (116). 
However, such an approach would have produced several problems.  First, fewer patients would have 
been eligible for the study.  Second, in UC, perhaps unlike in irritable bowel syndrome, hypnotherapy 
may act more through its effects on autonomic balance and augmentation of vagal tone (204) than by 
reducing psychological stress. In the event, retrospective analysis showed no obvious relation 
between psychometric scores or pANCA and the effect of hypnotherapy on relapse rate, although this 
conclusion is of course compromised by a possible Type 2 statistical error as a result of small 
numbers of patients in each subgroup.   
6.5.3 Limitations of trial 
Difficulties in recruitment.   
The main limitation of this study, as implied above, is the small numbers of patients recruited, despite 
intensive efforts at six large IBD centres.  Although our negative results may therefore reflect a type 2 
error, they do not suggest that hypnotherapy has a very major effect in reducing the relapse rate of 
UC or improving patients’ quality of life.  
The reasons given for our inability to complete recruitment for the trial are shown in Figure 6.1: many 
highlight the difficulty in recruiting patients with inactive UC to a study involving multiple time-
consuming hospital visits. They also suggest that even if hypnotherapy had been shown to be an 
effective option, it might not be popular with the majority of potentially appropriate patients. By actually 
targeting the correct patient may make the treatment more acceptable. 
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‘Floor’ effect 
Although our failure to detect any effect of GFH on IBDQ or the psychometric scores of these patients 
with UC could also be due to a type 2 statistical error, another explanation could be a floor effect, 
since baseline scores indicated a low prevalence of psychological disturbance in the patients 
recruited (Table 6.2). 
Randomization and blinding 
 In order to maximise the potential generalisability of our results, we opted to randomize our patients 
to hypnotherapy or the educational sessions, rather than allow them to choose which arm to 
participate in.  In retrospect, it seems possible that this decision may have had an adverse effect on 
our ability to recruit patients, as well as, conceivably, on the outcome of the hypnotherapy arm.  
Conversely, the single-blind design is likely to have tilted the outcome in favour of those patients 
having hypnotherapy.   
 
6.6 CONCLUSIONS 
This trial did not suggest that gut-focussed hypnotherapy has a major effect in preventing relapse of 
altering psychological status in patients with UC withdrawing from thiopurines. Whether hypnotherapy 
would be valuable as an adjunctive therapy, for example in patients with mild-moderately active IBD, 
or whether it would benefit carefully selected patients, for example those with marked sympathetic 
overactivity (253) such as during severe flares (254) or high hypnotisability scores, merits further 
investigation. 
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CHAPTER 7: SUMMARY AND CONCLUSIONS 
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Here, I will outline the main results arising from this thesis, indicate some future directions and finally 
conclude with some unifying thoughts. 
 
Chapter 3: Tobacco dependence and awareness of health risks of smoking in patients with 
inflammatory bowel disease. 
This study of IBD patients’ smoking habits demonstrates that a smaller proportion of CD patients 
continue to smoke than has been reported previously.  However, contrary to our hypothesis, patients 
with CD who smoke do so despite recognising the detrimental effects of smoking on their disease.  
This is not explained by nicotine dependence which in our IBD patients is lower than in smokers’ clinic 
clients and comparable to that of the general population 
Unfortunately, we did not have data on our patients’ educational level and cannot therefore draw any 
conclusions about the relation between this factor and their knowledge about smoking and Crohns’; 
this could be incorporated into future studies. Furthermore, our interrogation of patients about their 
knowledge of its effects on IBD was limited, and could be done more fully in the future. 
Why patients who know the risks incurred by smoking, but who are not highly nicotine dependent 
continue to smoke is unclear. One possible explanation might be that psychological stress contributes 
to their smoking habit (67), but unfortunately we did not assess this, or other mood characteristics, in 
this study.  Again, it would be extremely useful if future studies to assess smoking in IBD, were 
designed to assess both psychological stress and mood disorders, which in turn could be potential 
targets to assist CD patients to give up smoking. 
 
Chapter 4: Anxiety and psychological stress in ASUC: prevalence and effect on outcome 
Our study showed that perceived stress levels are greater in patients with ASUC than in those in 
remission and anxiety scores are highest in patients newly presenting with UC, but neither stress nor 
anxiety appeared to influence disease outcome.  
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The next step would be to conduct appropriately designed clinical trials to evaluate the effects of 
stress management and other psychologically-orientated therapies in inpatients with ASUC, 
assessing their impact not only on patients’ psychological well-being and stress resolution but also on 
the course of their IBD itself.  For example, in a study of rheumatology inpatients and diabetic 
outpatients, a multifaceted psychiatric intervention (conducted by a psychiatric liaison nurse and/or 
using referral to a liaison psychiatrist followed by advice to the treating physician) was targeted at the 
complex medically ill (255).  The prevalence of major depression was reduced from 61% to 28% in 
the intervention group with no change in those receiving standard care (57% to 50%).  A similar study 
design could conceivably be used in patients with ASUC or indeed inpatients active Crohn’s disease.  
 
Chapter 5: Does psychological counselling alter the natural history of IBD? 
We have shown that in IBD outpatients with psychosocial stress, IBD-focussed counselling may 
improve not only patients’ psychological well-being and stress resolution but also the activity and 
course of their IBD. . 
A third of patients would like access to psychological support, though not all of these patients had a 
mood disorder (150).  As a first step to meeting their needs, gastroenterologists should consider 
routinely screening their patients during clinic visits in an effort to identify those suffering from stress 
and related mood disorders: the quality of life of these individuals may improve most with a 
psychological approach. 
A limitation of the published studies of psychological interventions as well as our own, is the poor 
characterization of the study subjects in terms of the type and severity of their psychological disorder. 
Common sense dictates that IBD patients with associated mood disorders have different needs from 
those who are distressed by their disease (adjustment disorder), and from those who cope effectively. 
Thus, the essential clinical question is what psychological intervention should be offered, when and to 
whom?  
There is a wide range of other factors likely to influence response to, and therefore choice of therapy.  
These include the patient’s perception of their stress, its severity and duration; their resilience and 
coping strategies; their mood and personality; their age and social support.  This highlights the 
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importance of offering individualised psychological therapy tailored to the stage of adjustment either to 
their disease (149) or to an external chronic stress; all factors which need to be taken into account in 
future trials. Because of the difficulties inherent in undertaking appropriately targeted and blinded 
studies, large patient numbers are needed for multiple stratifications. 
 
Chapter 6: Hypnotherapy for the prevention of relapse in UC: A multi-centre, randomised, 
single-blind, controlled clinical trial. 
Gut-focussed hypnotherapy does not appear to have a major clinically useful effect in preventing 
relapse or altering psychological status in patients with ulcerative colitis who are withdrawing from 
treatment with thiopurines.  At week 52, there was no difference in relapse rates between those 
patients who had received gut-focussed hypnotherapy and the control education sessions treated 
patients.  At week 13, gut-focussed hypnotherapy did not alter psychological or quality of life scores in 
patients still in remission. 
Our failure to detect any effect of gut-focussed hypnotherapy on quality of life or the psychometric 
scores of these patients with UC could have been due a floor effect, since baseline scores indicated a 
low prevalence of psychological disturbance in the patients recruited.  Further studies would need to 
be designed to ensure recruitment of enough patients to provide sufficient statistical power to enable 
detection of change in disease activity and/or mood status.  Whether hypnotherapy would be valuable 
as an adjunctive therapy merits further investigation. 
 
SUMMARY 
There is now good evidence of an association between psychological stress and the course of IBD.  
Importantly, current investigations in both man and animals of the mechanisms by which stress 
induces relapse may open up new therapeutic targets acting at a range of specific points in the 
relevant psychoneuroimmunological pathway.  In animal models, for example, probiotics (256, 257), 
inhibitors of mast cell degranulation (99, 258) , beta-blockers (96) and a PPARγ agonist (93) have 
each been shown to reduce the adverse effects of stress on intestinal mucosal inflammation. 
 137 
 
Subsequent clinical trials will be needed to determine whether conclusions derived from relatively 
acute animal experiments are comparable and applicable to humans with IBD. 
Trials of psychotherapy and other ways of addressing psychological stress and mood disorders are 
fraught with difficulty.  Attempts to conduct further therapeutic studies in the future will need to take 
these into account if they are to provide results of clinical value.  Areas which are worthy of specific 
attention include:-  
 The need for careful and objective documentation of IBD activity, for example using 
colonoscopy, blood tests and/or faecal calprotectin (259) given that disease activity scores 
such as the CDAI may improve as a result of the direct effect of stress reduction on bowel 
frequency rather than through its effects on mucosal inflammation. 
 Stratification of patients with IBD by disease diagnosis, site, extent, activity, smoking habit 
and conventional treatment. There may be, for example, differences in the associations 
between stress and UC, on the one hand, and depression and Crohn’s disease on the other. 
 Stratification of patients by genotype, since patients with different genotypes may respond 
differently to different psychological interventions. 
 Stratification of patients with UC by pANCA status, in view of the apparently greater 
psychobiological responsiveness of pANCA-negative patients compared with their pANCA-
positive counterparts (116). 
 Stratification of patients by severity and type of psychological stress or mood disturbance. 
 Stratification of patients to take into account their personality, resilience and the coping 
strategies they employ (81, 127),  
 Design of trials with sufficient statistical power to enable detection of change in disease 
activity and/or mood status.  For example, having included a substantial proportion of subjects 
whose disease was inactive at recruitment, several trials to date have sought a beneficial 
effect of the test intervention on disease activity: equivocal or negative results were almost 
inevitable. 
 Individualization of therapy by stage of adjustment to IBD (149). 
 138 
 
 Differences in therapeutic approach and response for different age groups.  Adults, for 
example, may well respond to interventions ineffective or inappropriate in children or 
adolescents. 
 In future studies of antidepressants and other pharmacological approaches, avoidance, where 
possible, of drugs which themselves can directly influence IBD symptom scores, for example 
by reducing stool frequency (181).  If use of such agents is unavoidable, careful account of 
their intestinal effects needs to be taken in trial design and analysis. 
 Assessment of the value of training in the use of specific coping techniques (127) . 
 The impracticality, given current health cost restrictions in most countries, of certain potential 
therapeutic approaches.  Despite the likely importance of individualization of therapy, 
attention should be given to assessing the efficacy of group as opposed to single person-to-
person therapies. 
 
The evaluation of the effects of psychological stress and mood disorders on the course of IBD 
remains in its infancy, particularly as it relates to useful therapeutic applications.  The points listed 
above indicate that trial design needs to be improved if we are to gain a clearer idea of the possible 
benefit to the course of IBD of approaches aimed at modifying psychoneuroimmunological pathways 
(125, 126). 
Patients suffering with IBD vary dramatically in their psychological response to the illness: despite 
significant morbidity from their IBD, many appear heroically resilient. For those who develop or 
already have associated psychological stress or other mood disturbances, management should be 
holistic and, as far as possible, individualized.  
Nevertheless, it is clear that at the same time as optimizing conventional treatment of their IBD, 
physicians should look out, and even formally screen for psychological stress and mood disorders in 
their patients.  They should be ready and able to offer patients therapies directed at improving their 
psychological state, even if such approaches have not yet been shown to reduce IBD activity.  At the 
very least, physicians should ensure that they have in place routes for prompt referral of their patients 
to colleagues with expertise in the management of psychological disorders.  What remains unclear is 
which of the wide range of available interventions is most appropriate for individual patients with IBD 
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who have associated psychological illness. Further formal well-designed randomized controlled trials 
of psychological interventions are urgently needed, and should focus in particular on their effects on 
objectively assessed activity of the associated bowel disease. 
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APPENDIX 1: QUESTIONNAIRES 
 
The following questionnaires were used in the thesis: 
A1.1 Smoking study: Beliefs about smoking in patients with inflammatory bowel disease 
A1.2 Montreal Classification of IBD 
A1.3 Perceived Stress Questionnaire (General and Recent) 
A1.4 Hospital Anxiety & Depression Score 
A1.5 State Trait Anxiety Inventory 
A1.6 Multidimensional health locus of control (MHLC) scales (Form C) 
A1.7 Stanford Hypnotisability Susceptibility Score 
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A1.1: SMOKING STUDY 
BELIEFS ABOUT SMOKING IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE 
Please complete this form, if you have any problems with the questions we will help you if necessary. 
The information is strictly confidential.      
1) What condition do you suffer? 
Crohn’s Disease  Ulcerative Colitis  
2) Will smoking worsen your condition?  
Yes   No  
 3) Are you a smoker? 
Yes   No  
If yes, please complete the following questions: 
4) How many cigarettes do you smoke per day? 
    __________________per day 
5) Have you ever been advised to stop smoking 
    a) By you GP  
Yes   No  
     b) By your Gastroenterologist 
Yes   No  
6) Have you ever tried to stop smoking? 
Yes   No  
7) Have you been to a smoking cessation clinic 
Yes   No  
8) Are you aware there is a smoking cessation clinic in the hospital? 
Yes   No  
9) Would you consider attending the smoking cessation? 
Yes   No  
10) Do you smoke more when your disease is active? 
Yes   No  
11) Do you smoke more when you are stressed? 
Yes   No  
Please turn over 
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Thank you for completing this questionnaire 
 
How soon after you wake up do you smoke 
your first cigarette? 
Within 5 mins 3 
6-30 mins 2 
31-60 mins 1 
> 60mins 0 
Do you find it difficult to stop smoking in no 
smoking areas? 
Yes 1 
No 0 
Which cigarette would you hate most to give 
up? 
The first of the morning 1 
Any other 0 
How many cigarettes per day do you usually 
smoke? 
10 or less 0 
11-20 1 
21-30 2 
30 or more 3 
Do you smoke more frequently in the first 
hours after waking than during the rest of the 
day? 
No 0 
Yes 1 
Do you smoke if you are so ill that you are in 
bed most of the day? 
No 0 
Yes 1 
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A1.2: MONTREAL CLASSIFICATION OF IBD 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Crohn’s Disease   
Age at 
diagnosis 
A1: <16  
A2: 17-40  
A3: >40  
Location L1: Ileal  
L2: Colonic  
L3: Ileo-colonic  
L4: Upper GI  
Behaviour B1: Inflammatory  
B2: Stricturing  
B3: Penetrating   
P:   Perianal  
Ulcerative Colitis   
Age at 
diagnosis 
A1: <16  
A2: 17-40  
A3: >40  
Location Extensive  
Left sided  
Proctitis  
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A1.3: PERCEIVED STRESS QUESTIONNAIRE 
 
General PS Questionnaire 
Name:  ____________________________       Age:  _______        Date: _________________ 
Sex:  _____          Marital status:  _______________      Occupation:  ____________________ 
Instructions:  For each sentence, mark the number that describes  how often it applies to you in 
general, during the last two years.  Work quickly, without bothering to check your answers, and be 
careful to describe your life in the long run.  
                                                                                                                                                       Almost   Some-    Often  Usually 
                                                                                                                                                       never     times 
1.  You feel rested ------------------------------------------------------------------------------- 1        2          3          4 
 2.  You feel that too many demands are being made on you ------------------------ 1        2          3          4 
 3.  You are irritable or grouchy -------------------------------------------------------------- 1        2          3          4 
 4.  You have too many things to do -------------------------------------------------------- 1        2          3          4 
 5.  You feel lonely or isolated ---------------------------------------------------------------- 1        2          3          4 
 6.  You find yourself in situations of conflict ---------------------------------------------- 1        2          3          4 
 7.  You feel you're doing things you really like ------------------------------------------- 1        2          3          4 
 8.  You feel tired --------------------------------------------------------------------------------- 1        2          3          4 
 9.  You fear you may not manage to attain your goals -------------------------------- 1        2          3          4 
10. You feel calm -------------------------------------------------------------------------------- 1        2          3          4 
11. You have too many decisions to make ------------------------------------------------ 1        2          3          4 
12. You feel frustrated -------------------------------------------------------------------------- 1        2          3          4 
13. You are full of energy ---------------------------------------------------------------------- 1        2          3          4 
14. You feel tense ------------------------------------------------------------------------------- 1        2          3          4 
15. Your problems seem to be piling up --------------------------------------------------- 1        2          3          4 
16. You feel you're in a hurry ----------------------------------------------------------------- 1        2          3          4 
17. You feel safe and protected -------------------------------------------------------------- 1        2          3          4 
18. You have many worries ------------------------------------------------------------------- 1        2          3          4 
19. You are under pressure from other people ------------------------------------------- 1        2          3          4 
20. You feel discouraged ---------------------------------------------------------------------- 1        2          3          4 
21. You enjoy yourself -------------------------------------------------------------------------- 1        2          3          4 
22. You are afraid for the future -------------------------------------------------------------- 1        2          3          4 
23. You feel you're doing things because you have to,  
      not because you want to ------------------------------------------------------------------ 1        2          3          4 
24. You feel criticized or judged -------------------------------------------------------------- 1        2          3          4 
25. You are lighthearted ----------------------------------------------------------------------- 1        2          3          4 
26. You feel mentally exhausted ------------------------------------------------------------- 1        2          3          4 
27. You have trouble relaxing ---------------------------------------------------------------- 1        2          3          4 
28. You feel loaded down with responsibility --------------------------------------------- 1        2          3          4 
29. You have enough time for yourself ----------------------------------------------------- 1        2          3          4 
30. You feel under pressure from deadlines ---------------------------------------------- 1        2          3          4 
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Recent PS Questionnaire 
Name:  ____________________________       Age:  _______        Date: _________________ 
 
Sex:  _____          Marital status:  _______________      Occupation:  ____________________ 
 
Instructions:  For each sentence, mark the number that describes  how often it applies to you during 
the last month.  Work quickly, without bothering to check your answers, and be careful to consider 
only the last month.                                                                                                                                                                
                                                                                                                           Almost   Some-   Often Usually 
                                                                                                                                                           never     times 
1.  You feel rested ------------------------------------------------------------------------------- 1        2          3          4 
 2.  You feel that too many demands are being made on you ------------------------ 1        2          3          4 
 3.  You are irritable or grouchy -------------------------------------------------------------- 1        2          3          4 
 4.  You have too many things to do -------------------------------------------------------- 1        2          3          4 
 5.  You feel lonely or isolated ---------------------------------------------------------------- 1        2          3          4 
 6.  You find yourself in situations of conflict ---------------------------------------------- 1        2          3          4 
 7.  You feel you're doing things you really like ------------------------------------------- 1        2          3          4 
 8.  You feel tired --------------------------------------------------------------------------------- 1        2          3          4 
 9.  You fear you may not manage to attain your goals -------------------------------- 1        2          3          4 
10. You feel calm -------------------------------------------------------------------------------- 1        2          3          4 
11. You have too many decisions to make ------------------------------------------------ 1        2          3          4 
12. You feel frustrated -------------------------------------------------------------------------- 1        2          3          4 
13. You are full of energy ---------------------------------------------------------------------- 1        2          3          4 
14. You feel tense ------------------------------------------------------------------------------- 1        2          3          4 
15. Your problems seem to be piling up --------------------------------------------------- 1        2          3          4 
16. You feel you're in a hurry ----------------------------------------------------------------- 1        2          3          4 
17. You feel safe and protected -------------------------------------------------------------- 1        2          3          4 
18. You have many worries ------------------------------------------------------------------- 1        2          3          4 
19. You are under pressure from other people ------------------------------------------- 1        2          3          4 
20. You feel discouraged ---------------------------------------------------------------------- 1        2          3          4 
21. You enjoy yourself -------------------------------------------------------------------------- 1        2          3          4 
22. You are afraid for the future -------------------------------------------------------------- 1        2          3          4 
23. You feel you're doing things because you have to,  
      not because you want to ------------------------------------------------------------------ 1        2          3          4 
24. You feel criticized or judged -------------------------------------------------------------- 1        2          3          4 
25. You are lighthearted ----------------------------------------------------------------------- 1        2          3          4 
26. You feel mentally exhausted ------------------------------------------------------------- 1        2          3          4 
27. You have trouble relaxing ---------------------------------------------------------------- 1        2          3          4 
28. You feel loaded down with responsibility --------------------------------------------- 1        2          3          4 
29. You have enough time for yourself ----------------------------------------------------- 1        2          3          4 
30. You feel under pressure from deadlines ---------------------------------------------- 1        2          3          4 
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A1.4: HOSPITAL ANXIETY AND DEPRESSION SCALE (HADS) 
 
Name: __________________________________________                           Date: _______________ 
 
Clinicians are aware that emotions play an important part in most illnesses. If your clinician knows about these 
feelings he or she will be able to help you more. 
This questionnaire is designed to help your clinician to know how you feel. Read each item below and underline 
the reply which comes closest to how you have been feeling in the past week. Ignore the numbers printed at the 
edge of the questionnaire.  
Don’t take too long over your replies, your immediate reaction to each item will probably be more accurate than a 
long, thought-out response. 
 
 FO
L
D
 
H
E
R
E
 
   FO
L
D
 
H
E
R
E
 
 
A D   A D 
 
3 
2 
1 
0 
 I feel tense or .wound up. 
Most of the time 
A lot of the time 
 From time to time, occasionally 
Not at all 
I feel as if I am slowed down 
Nearly all the time  
Very often  
Sometimes  
Not at all  
  
3 
2 
1 
0 
  
0 
1 
2 
3 
I still enjoy the things I used to enjoy 
Definitely as much 
Not quite so much 
Only a little 
Hardly at all 
 
 I get a sort of frightened feeling like 
.butterflies. in the stomach 
Not at all  
Occasionally  
Quite often  
Very often  
 
 
0 
1 
2 
3 
 
 
 
3 
2 
1 
0 
 I get a sort of frightened feeling as if 
something awful is about to happen 
Very definitely and quite badly 
Yes, but not too badly 
A little, but it doesn’t worry me 
Not at all 
I have lost interest in my appearance 
Definitely  
I don’t take as much care as I should  
I may not take quite as much care  
I take just as much care as ever  
 
  
3 
2 
1 
0 
  
 
0 
1 
2 
3 
I can laugh and see the funny side of 
things 
As much as I always could 
Not quite so much now 
 Definitely not so much now 
Not at all 
I feel restless as if I have to be on 
the move 
Very much indeed  
Quite a lot  
Not very much  
Not at all  
  
 
3 
2 
1 
0 
 
 
3 
2 
1 
0 
 Worrying thoughts go through my 
mind 
A great deal of the time 
A lot of the time 
Not too often 
Very little 
 I look forward with enjoyment to 
things 
As much as I ever did  
Rather less than I used to  
Definitely less than I used to  
Hardly at all  
 
 
0 
1 
2 
3 
 
  
3 
2 
1 
0 
I feel cheerful 
Never 
 Not often 
Sometimes 
Most of the time 
I get sudden feelings of panic 
Very often indeed  
Quite often  
Not very often  
Not at all  
  
3 
2 
1 
0 
 
0 
1 
2 
3 
 I can sit at ease and feel relaxed 
Definitely 
Usually 
Not often 
Not at all 
I can enjoy a good book or radio or 
television programme 
Often  
Sometimes  
Not often  
Very seldom  
 
 
0 
1 
2 
3 
 
Now check that you have answered all the questions 
   
TOTAL 
A D 
    
 
This form may be reproduced for use within the purchasing institution only within the terms stated in the permission agreement from the publisher. 
HADS copyright © R.P. Snaith and A.S. Zigmond, 1983, 1992, 1994. Record form items originally published in Acta Psychiatrica Scandinavica, 
67, 361.70, copyright © Munksgaard International Publishers Ltd, Copenhagen, 1983.Published by nferNelson Publishing Company Ltd, The 
Chiswick Centre, 414 Chiswick High Road, London W4 5TF, UK. All rights reserved. nferNelson is a division of Granada Learning Limited. 
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A1.5: STATE-TRAIT ANXIETY INVENTORY FOR ADULTS 
 
(For use by Mahmood Wahed only. Received from Mind Garden, Inc. on December 13, 2007) 
 
To whom it may concern, 
 
This letter is to grant permission for the above named person to use the following copyright material; 
 
Instrument: State-Trait Anxiety Inventory for Adults;  
Authors: Charles D. Spielberger, in collaboration with R.L. Gorsuch, G.A. Jacobs, R. Lushene, and 
P.R. Vagg. Copyright: 1968, 1977 by Charles D. Spielberger 
 
for his/her thesis research. 
 
Five sample items from this instrument may be reproduced for inclusion in a proposal, thesis, or 
dissertation. The entire instrument may not be included or reproduced at any time in any other 
published material. 
 
Sincerely, 
Vicki Jaimez 
Mind Garden, Inc. 
www.mindgarden.com 
 
 
DIRECTIONS: 
A number of statements which people have used to describe themselves are given below. Read each 
statement and then blacken the appropriate circle to the right of the statement to indicate how you feel 
right now, that is, at this moment. There are no right or wrong answers. Do not spend too much time 
on any one statement but give the answer which seems to describe your present feelings best. 
SELF-EVALUATION QUESTIONNAIRE STAI Form Y-1 
Please provide the following information: 
Name    Date        S____ 
Age    Gender (Circle) M F      T____ 
    
N
O
T
 A
T
 A
L
L
 
S
O
M
E
W
H
A
T
 
M
O
D
E
R
A
T
E
L
Y
 S
O
 
V
E
R
Y
 M
U
C
H
 S
O
 
1. I feel calm ................................................................................................... 1 2 3 4 
2. I feel secure ................................................................................................... 1 2 3 4 
3. I am tense ................................................................................................... 1 2 3 4 
4. I feel strained ................................................................................................... 1 2 3 4 
5. I feel at ease ................................................................................................... 1 2 3 4 
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A1.6: MULTIDIMENSIONAL HEALTH LOCUS OF CONTROL (MHLC) SCALES (Form C)  
      
Instructions: Each item below is a belief statement about your medical condition with which you may 
agree or disagree. Beside each statement is a scale which ranges from strongly disagree (1) to 
strongly agree (6). For each item we would like you to circle the number that represents the extent to 
which you agree or disagree with that statement. The more you agree with a statement, the higher will 
be the number you circle. The more you disagree with a statement, the lower will be the number you 
circle. Please make sure that you answer EVERY ITEM and that you circle ONLY ONE number per 
item. This is a measure of your personal beliefs; obviously, there are no right or wrong answers. 
1=STRONGLY DISAGREE (SD) 
2=MODERATELY DISAGREE (MD) 
3=SLIGHTLY DISAGREE (D) 
4=SLIGHTLY AGREE (A) 
5=MODERATELY AGREE (MA) 
6=STRONGLY AGREE (SA) 
 
  SD MD D A MA SA 
1 
If my condition worsens, it is my own behaviour which determines how 
soon I will feel better again. 
1 2 3 4 5 6 
2 As to my condition, what will be will be. 1 2 3 4 5 6 
3 
If I see my doctor regularly, I am less likely to have problems with my 
condition. 
1 2 3 4 5 6 
4 Most things that affect my condition happen to me by chance. 1 2 3 4 5 6 
5 
Whenever my condition worsens, I should consult a medically trained 
professional. 
1 2 3 4 5 6 
6 I am directly responsible for my condition getting better or worse. 1 2 3 4 5 6 
7 
Other people play a big role in whether my condition improves, stays the 
same, or gets worse. 
1 2 3 4 5 6 
8 Whatever goes wrong with my condition is my own fault. 1 2 3 4 5 6 
9 Luck plays a big part in determining how my condition improves. 1 2 3 4 5 6 
10 
In order for my condition to improve, it is up to other people to see that 
the right things happen. 
1 2 3 4 5 6 
11 
Whatever improvement occurs with my condition is largely a matter of 
good fortune. 
1 2 3 4 5 6 
12 The main thing which affects my condition is what I myself do. 1 2 3 4 5 6 
13 
I deserve the credit when my condition improves and the blame when it 
gets worse. 
1 2 3 4 5 6 
14 
Following doctor's orders to the letter is the best way to keep my condition 
from getting any worse. 
1 2 3 4 5 6 
15 If my condition worsens, it's a matter of fate. 1 2 3 4 5 6 
16 If I am lucky, my condition will get better. 1 2 3 4 5 6 
17 
If my condition takes a turn for the worse, it is because I have not been 
taking proper care of myself. 
1 2 3 4 5 6 
18 
The type of help I receive from other people determines how soon my 
condition improves. 
1 2 3 4 5 6 
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A1.7 STANFORD HYPNOTIC SUSCEPTIBILITY SCALE, FORM C (Summary) 
 
Andre M. Weitzenhoffer & Ernest R. Hilgard 
Stanford University 
Modified by John F. Kihlstrom 
Original version © 1962 by Stanford University 
 
 
Summary of protocol:  
Establishing Rapport 
ITEM 0   INDUCTION BY EYE CLOSURE 
ITEM 1   HAND LOWERING. 
ITEM 2  MOVING HANDS APART. 
ITEM 3  MOSQUITO HALLUCINATION. 
ITEM 4  TASTE HALLUCINATION. 
ITEM 5  ARM RIGIDITY 
ITEM 6  DREAM 
ITEM 7  AGE REGRESSION 
ITEM 8  ARM IMMOBILIZATION 
ITEM 9  ANOSMIA 
ITEM 10  HALLUCINATED VOICE 
ITEM 11.  NEGATIVE VISUAL HALLUCINATION 
ITEMS 12/13  POSTHYPNOTIC SUGGESTION AND AMNESIA 
POST-EXPERIMENTAL INTERVIEW 
 
Note on the Modifications 
The various Stanford scales of hypnotic susceptibility have served the field of hypnosis extremely well 
for more than 30 years. Nonetheless, over the years certain modifications seemed desirable. Very 
quickly, for example, the original authors sanctioned a group version of the Stanford Hypnotic 
Susceptibility Scale, Form A, known as the Harvard Group Scale of Hypnotic Susceptibility, Form A (a 
Form B is also in existence, roughly paralleling the Stanford Form B); later, Arlene H. Morgan and 
Josephine R. Hilgard adapted the Stanford scales for clinical testing of adults and children, and E.R. 
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Hilgard proposed that the Stanford Hypnotic Susceptibility Scale, Form C be tailored for special 
purposes, so that some of the screening purposes of the Stanford Profile Scales of Hypnotic 
Susceptibility, Forms I and II, could be accomplished without additional testing. 
 
There are five principal modifications in the present version of SHSS:C. (1) The wording of the 
Induction by Eye Closure (Item #0) has been altered slightly to reduce unintended connotations of 
authoritarian control present in the original. (2) Age Regression (Item #7) permits the subject to 
choose between two target ages within each epoch. (3) Anosmia (Item #9) substitutes oil of 
peppermint for ammonia. (4) Posthypnotic Amnesia (Item #12) is assessed in terms of a joint criterion 
considering both initial amnesia and subsequent reversibility, and the instructions for the reversibility 
test now ask subjects to report all items they remember; in addition, an optional recognition test of 
amnesia has been included, following procedures developed by John J. Allen at the University of 
Minnesota (the recognition test does not compromise the standard amnesia test of SHSS: C). (5) 
Finally, a test of Posthypnotic Suggestion (Item #13) modified from SHSS:A has been added to reflect 
the special interests of the laboratory, although it does not enter into the scoring of the scale. John F. 
Kihlstrom 
 
Note: If a subject fails to respond to three consecutive suggestions, the experimenter should 
terminate the scale with Item #12 (Posthypnotic Amnesia), including Item #13 (Posthypnotic 
Suggestion). 
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APPENDIX 2: HYPNOTHERAPY STUDY - EDUCATION SESSIONS  
 
The following are the control education sessions in the randomised study of hypnotherapy for the 
prevention of relapse in ulcerative colitis study (written by MW). 
Education session 1: What is ulcerative colitis? 
 
Slide 1+2 
What is Ulcerative Colitis?
 
Overview
 What is ulcerative colitis?
 How common is it?
 Where is the inflammation?
 What are the symptoms?
 Are there any complications?
 Tests 
 What happens in the long term?
 
Slide 3+4 
Definition
Chronic inflammatory diseases of gastrointestinal tract
ULCERATIVE  COLITIS
(Colon and rectum only)
CROHN’S DISEASE
(Anywhere from mouth
to anus)
 
Ulcerative Colitis – How Common is it?
• Incidence 10/100,000/yr
(new cases)
• Prevalence 150/100,000
(patients)
• UK has 1 Wembley Stadium-full of patients 
with ulcerative colitis
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Slide 5+6 
Age of Onset
 2 age peaks
 20 – 40 years old
 60 – 80 years old
 Not much difference between men 
and women
 
Epidemiology
 Can affect up to 5% of immediate family 
(mum, dad, brother, sister)
 Related to 
– Non-smoking 
 
Slide 7+8 
Structure of the colon?
 
Which part of the colon is affected ?
 Rectum – Proctitis
 Left sided colitis
 Total colitis
 
Slide 9+10 
Endoscopic Appearances
normal ulcerative colitis
 
What are the symptoms ?
diarrhoea, often bloody
urgency to empty bowel
 abdominal pain
 weight loss
 feeling generally unwell
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Slide 11+12 
When do symptoms occur ?
 relapses & remissions
 onset any age
 life-long
 
Other symptoms – outside the bowel
– Skin
– Eyes
– Joints
– Liver 
 
Slide 13+14 
erythema nodosum  
(this is rare)
pyoderma gangrenosum
(this is very rare)
Skin
 
Eyes
Iritis
(rare)
 
Slide 15+16 
Ankylosing Spondylitis 
(again rare)
 
Sclerosing cholangitis
normal sclerosing cholangitis
Scarring of the bile 
ducts in the liver
Liver
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Slide 17+18 
Complications 
 In the bowel:
– Bleeding from ulceration
– Perforation
– Cancer
 
Colorectal Cancer
Other risk factors
• extent of disease
• sclerosing cholangitis
• other family members   
with bowel cancer
• poorly controlled 
disease       
Risk increases with time
 
Slide 19+20 
Tests
 To make the diagnosis of ulcerative colitis
 To find out how much of the colon is affected
 To assess current disease activity 
 To look for any complications
 
Investigations – Blood tests
 Diagnosis and disease activity
– Haemoglobin
– Inflammatory markers
 If anaemia present, check iron levels
 Complications
– Liver function tests
 
Slide 21+22 
Investigations – Exclude infection
 Infection complicates/initiates 10% UC relapses
 Hot fresh stool
– Microscopy for amoebae in travellers
– Clostridium difficile toxin
 
Investigation - Endoscopy
 Sigmoidoscopy with 
biopsies
 Colonoscopy with biopsies
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Slide 23+24 
Endoscopic Appearances
normal ulcerative colitis
 
Biopsies appearances (under the microscope)
ulcerative colitisnormal
Inflammatory cells
 
Slide 25+26 
Xray tests
 Abdominal X ray
 CT scan
 WBC Scan
 
Abdominal X ray in acute ulcerative colitis
 Transverse colon 
dilation, mucosal 
islands and “thumb-
printing”
 
Slide 27+28 
CT scan
 Inflammed colon
 
Assessing disease extent in ulcerative colitis 
with radiolabelled white cell scan
• This involves giving a blood 
sample. The white cells are then 
labelled with a small amount of a 
tracer and then blood is replaced 
back. The images taken with 
camera
• 99-Tc HMPAO scan
• UC extending to mid-transverse 
colon
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Slide 29 
How ulcerative colitis behaves in the longterm
 Life-long relapses and remissions
 Bowel resection - Colectomy  20%
 Mortality 
– Overall no difference to general population
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Education session 2: The aetiopathogenesis of ulcerative colitis. 
 
Slide 1+2 
Aetiopathogenesis of Ulcerative Colitis
 
Definitions
• aetiology – primary cause(s)
• pathogenesis – mechanism by                    
which cause produces disease
 
Slide 3+4 
Normal and inflamed gut mucosa 
Normal
How does 
this 
occur?
Active IBD  
Cause of inflammatory bowel disease
genes
mucosal immunity
mucosal inflammation
Ulcerative Colitis
foodbacteria
smoking
appendix
drugs
stress
 
Slide 5+6 
Genetic Risk – Ulcerative colitis
 Increased risk of IBD in
– Ethnic groups (eg Ashkenazi Jews)
– First degree relatives
 mum, dad, brother, sister - 5%
– Identical twins  - 10%
 
Genetic Abnormalities in UC
 Increased gut leakiness
 Defective colonic mucus
 Abnormal immune regulation
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Slide 7+8 
Intestinal bugs (bacteria)
 UC symptoms and pathology look like those caused 
by bacterial infection
 Onset and relapse of UC may be triggered by 
infections (C diff, salmonella, amoebae….)
 
Gut bugs (bacteria) in IBD
 More bugs in the colon than cells in the body!
 Resident gut bugs are likely to be a major 
environmental factor in IBD
 Balance of “good” and “bad” bugs changes
 Mucosal immunity influenced by gut bugs
 Some patients with IBD respond to antibiotics and 
probiotics
 
Slide 9+10 
Diet in UC
 Cows’ milk intolerance (Up to 5%)
 No other dietary factors are known
 
 What is this?
 
Slide 11+12 
Appendix in UC
 Risk of UC is reduced in people with 
appendicectomy at age less than 20
 The appendix is often in inflamed in patients 
with UC
 
Non smoking and UC
 UC commoner in non- and 
ex-smokers 
 Nicotine patches have 
some effect in treating 
active UC
 Why smoking is good for 
UC but bad for Crohn’s is 
unknown
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Slide 13+14 
 
Can drugs initiate relapse in UC
 NSAIDs - bad for all IBD
 Opioids (loperamide, codeine) – cause bowel 
distension in acute severe UC
 Antibiotics - unproven 
 Iron - unproven 
 
Slide 15+16 
Oral iron well tolerated and effective in UC
0
5
10
15
20
25
UC CD controls
Total
Intolerant
patients
• Ferrous sulphate also as effective in restoring Hb in IBD as in controls  
Psychological stress
Hockney 1962
 
Slide 17+18 
What is stress?
• A (real or perceived) threat to an organism’s 
homeostasis
– physical
– psychological
• Function of stress response is to maintain 
individual’s physical or psychological stability
 
Stress - UC
 Psychological stress is common in patients with 
IBD
 Stress may trigger flare of UC
 This may be mediated by
– Brain - Gut interactions
– Brain – Adrenal gland interactions
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Slide 19+20 
parasympathetic
Stress
autonomic nervous system
Enteric nervous system
sympathetic
glucocorticoids adrenaline,
noradrenaline
medulla
adrenal gland
higher cortical structures
hypothalamus
pituitary
CRF
ACTH
cortex
Gut immune cells
Brain-gut
axis
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Slide 21+22 
? How
 Altered immune regulation in the gut wall leads to 
inflammation
 Defective colonic mucus
 Abnormal intestinal leakiness
 
GUT LUMEN
EPITHELIUM
LAMINA PROPRIA
ENDOTHELIUM
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BACTERIA &/OR FOOD PRODUCTS
IL-8
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IL-1, TNF, etc
PLATELETS
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LEUCOCYTES
ADHESION MOLECULES
 
Slide 23 
Aetiopathogenesis – Summary
 Aetiopathogenesis gradually emerging
– Genetics, mucosal bacteria, mucosal immunity
 Implications for treatment
– Understanding how current drugs work
– Devising new targeted drugs …. 
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Education session 3: Ulcerative colitis – implications for family life 
 
Slide 1+2 
Ulcerative colitis – Family Life
 
Overview
 Inheritance risk
 Sexual function
 Fertility
 Pregnancy and childbirth
 
Slide 3+4 
Inheritance risk
 The risk for children developing inflammatory 
bowel disease is 5% if one parent is affected 
with ulcerative colitis
 Even with genetic predisposition other 
additional factors are required to trigger 
inflammatory bowel disease
 
Sexual relationships
 Coping with fears
 Physical difficulties
 Difficult feelings
 Who can you talk to?
– Friends/family
– Specialist Nurse
– NACC in contact
– RELATE
 
Slide 5+6 
Fertility
 Most men and women with Ulcerative colitis do 
not have have decreased fertility compared to 
general population
 Most patients with IBD have normal 
reproductive function and normal healthy 
babies
 
Fertility – male patients
 In male patients taking sulphasalazine, fertility 
is reduced; this is temporary and returns back 
to normal within 2 – 3 months of stopping 
 Very rarely male patients who have undergone 
extensive surgery involving removal of their 
colon including rectum may have sexual 
difficulties
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Slide 7+8 
Fertility – female patients
 Females who have undergone pouch surgery 
for UC have a risk of reduced fertility
 Oral contraceptive pill
– Important to remember that severe diarrhoea may 
reduce the protective effect of the pill
 
Pregnancy
 Does pregnancy affect the activity of the 
disease?
 Does ulcerative colitis affect the outcome of 
pregnancy?
 
Slide 9+10 
Does pregnancy affect the activity 
of the disease?
 Pregnancy itself has no consistent effect on the 
activity of ulcerative colitis
 
Does ulcerative colitis affect the 
outcome of pregnancy?
 If disease is inactive at the time of conception, 
the chances of having a healthy baby are the 
same as the general population
 If disease is active at the time of conception 
there is an increased risk to baby (premature 
delivery, abortion) and other pregnancy 
complications are increased
 
Slide 11+12 
Does medication for ulcerative colitis 
taken in pregnancy affect the foetus?
 Important to keep disease under control
 Most of the drugs including azathioprine are 
safe during conception and pregnancy
 Methotrexate should NOT be taken by either 
partner as there is a risk of congenital birth 
defects
 
Pregnancy - Diet
 Patients do not require a special diet
 Balanced diet with adequate intake of calories, 
vitamins and minerals
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Slide 13+14 
Pregnancy – What sort of delivery?
 In most cases normal vaginal delivery is fine
 
Can I breast feed?
 Breast feeding is important to develop baby’s immune 
system
 5 ASA and steroids considered safe. They are 
transferred into breast milk but in very low 
concentrations
 Azathioprine – very little of active drug is secreted in 
breast milk. There is no evidence of harm in children of 
mothers who have breastfeed on the drug
 Breast feeding NOT ADVISED with methotrexate, 
antibiotics and loperamide
 
Slide 15 
Summary
 Most men and women do not have have 
decreased fertility compared to general 
population
 Most patients with ulcerative colitis have 
uneventful pregnancies
 Most drugs used to treat ulcerative colitis in 
pregnancy are safe
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Education session 4: Management of Ulcerative Colitis 
 
Slide 1+2 
Management of Ulcerative Colitis
 
Overview
 Principles of treatment
 Medical therapy
– Relapse of disease (“attack”)
– Remission
 Surgical therapy
 
Slide 3+4 
Principles of treatment
 General measures
– Explanation, psychosocial support
 Physicians, specialist nurses
 Patient support groups (NACC)
– Specialist Multidisciplinary hospital care
 Monitoring disease activity, nutrition, therapy
 Checking for complications
 Colonoscopic cancer surveillance
 
Principles of therapy
 Supportive treatment
– Dietary and nutritional advice
– Drugs
 Iron tablets
 Osteoporosis prevention and treatment
– Drugs to avoid
 Anti diarrheal – loperamide
 NSAIDS, Antibiotics
 
Slide 5+6 
Principles of treatment
 Specific treatment
– Drugs
 Aminosalicylates – Asacol, Pentasa, Balsalazide
 Steroids
 Immunomodulatory – azathioprine, 6-mercaptopurine, 
ciclosporin, methotrexate
 Antibiotic
 Biological - Infliximab
 Surgery
 
Treatment of Active UC
 Determined by
– The extent of disease
– The severity of the relapse
 Who to admit to hospital
– Severe attack of UC
– 6 or more bloody stools daily
– Unwell – fever, increased pulse rate
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Slide 7+8 
Mild attack
 5 ASA orally 
(asacol/pentasa/balsalazide/sulphasalazine)
 Dose up to 4.8g daily (12 tablets/sachets)
 Topically (directly into rectum)
– Proctitis – suppositories 
 Asacol,pentasa
 Predsol
– Left sided disease – foam or retention enema 
 Asacol, pentasa
 predfoam
 
Moderate attack
 As mild plus
 Oral Prednisolone (steroids)
– 40mg daily – weekly reduction of dose
 Calcium supplements (Calcichew D3 Forte) to 
protect bones
 
Slide 9+10 
Severe attack
 Intravenous (hydrocortisone or methylprednisolone) 
then oral prednisolone
 Continue with 5 ASA 
(asacol/pentasa/sulphasalazine/balsalazide)
 Antibiotics if infection is suspected
 If no response to steroids at 3-7 days consider
– Ciclosporin
– Infliximab
 Surgery for non responders at 5-7 days, dilated colon, 
perforation or major haemorrhage
 
Keeping UC inactive (in remission)
 5 ASA drugs 
(asacol/pentasa/suphasalazine/balsalazide)
– 2g-2.4g daily
– Reduces risk of bowel cancer
– Blood test every 6 months – 1year
 Azathioprine, mercatopurine 
– Patients who have repeated attacks
– Careful monitoring required – blood tests every 3 
months
 
Slide 11+12 
Medical treatment - summary
 Depends on disease extent and severity
 Active UC is treated primarily with steroids and 
5 ASA
 Maintenance of remission achieved with 5ASA, 
although azathioprine/mercaptopurine required 
for patients in whom 5ASA 
(asacol/pentasa/suphasalazine/balsalazide) 
are ineffective
 
Surgery for ulcerative colitis
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Slide 13+14 
Surgery for Ulcerative Colitis
 Who is involved in the decision?
 Reasons for surgery
 Types of operation
 
Surgery – who is involved?
 The patient will be closely involved in the 
decision
 Requires close liaison with physicians and 
surgeons
 Specialist nursing care
 Stoma therapist
 Dietician
 Counsellor
 
Slide 15+16 
Reasons for surgery
 Emergency
 Colonic perforation
 Major colonic bleeding
 Urgent
 Non response to medical treatment of bad attack of 
ulcerative colitis in 5-8 days
 Dilating colon
 Elective
 Chronic active UC despite medical treatment
 Dysplasia (abnormal cells) on colon biopsy / Cancer 
 
Types of operation
 Restorative protocolectomy 
with ileoanal pouch
– Most people
 Protocolectomy with 
ileostomy
– Older people
 Colectomy with ileorectal 
anastomosis
– Young people
 
Slide 17 
Surgery - summary
 Surgery offers a cure for ulcerative colitis
 The patient should be closely involved in the 
decision to have surgery
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